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ABSTRACT 
   
 A history and detailed account of the applications of β-lactones towards natural 
products and bioactive compounds in the last ten years is discussed as these small 
heterocycles are becoming more widely recognized for their reactivity, numerous 
methods of construct, and high degree of functionalization.  
 An improvement to the nucleophile catalyzed aldol-β-lactonization of keto-acids is 
reported employing commodity reagents delivering gram quantities of bicyclic β-
lactone.  
 The first total synthesis of caulolactone A is reported employing a highly 
diastereoselective biscyclization to a key carvone–derived β-lactone. The natural product 
was completed from chiral pool (R)-carvone in 10 total steps.  
 Towards rapidly generating complex cyclopentanes an organocatalyzed tandem 
Michael aldol-lactonization process is reported. Subsequently revealing conditions for an 
enantioselective variant generating two C-C bonds, one C-O bond, two rings, and up to 
three contiguous stereocenters from simple starting materials.  
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From the end is where we begin…. 
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CHAPTER I                                                                                           
INTRODUCTION: β-LACTONES IN NATURAL PRODUCT SYNTHESIS 
1.1. Introduction 
1.1.1. Brief History of β-Lactones 
Since the account of the 1st isolated β-lactone by Einhorn in 18831 (Eq. 1) these 
small-oxygenated heterocycles largely remain underutilized intermediates in the 
synthesis of natural products and bioactive compounds. In the last 20 years, the field of 
synthetic organic chemistry has seen an exponential growth in the development of 
methodology for synthesizing β-lactones and their application as advantageous 
intermediates in natural product synthesis. They are being increasingly targeted due  
NO2 Br
CO2H
NO2
O
O
Na2CO3, H2O
(40%)
(1)
 
to their presence in natural products, potential as enzyme inhibitors, and versatility as 
synthetic intermediates. It was almost 85 years after Einhorn’s reported isolation that 
Borrman and Wegler disclosed the first enantioenriched β-lactone synthesis from the 
reaction of an acid chloride with chloral in the presence of (-)-brucine (Eq. 2a).2 
Wynberg continued this work and reported the first catalytic, asymmetric synthesis of β-
lactones using 1-2 mol% of the cinchona alkaloid quinidine (Eq. 2b).3 This discovery 
opened the door for the propagation of the use and exploration of β-lactones in synthesis. 
While Wynberg’s work has also had a profound impact on modern organocatalysis, it 
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serves as the foundation for enantioselective β-lactone synthesis.  
•
O
HH
Cl3C
O
H
+
(>95%, 98% ee)
quinidine (1-2 mol%)
 PhMe
O
O
CCl3
H (2b)
Cl3C H
O
Cl
O
R1
R2
+
(-)-brucine
CCl4
45-69%
up to 72% ee
O
O
R2
R1
H
Cl3C
R1 = H or Cl, R2 = H, Cl or OAr
** (2a)
 
 The present review will focus on the use of β-lactones as intermediates in total 
synthesis and the synthesis of β-lactone containing natural products. Providing detailed 
information for evaluating the broad synthetic utility of this motif as well as the reaction 
tolerance of β-lactones. Emphasis will be placed on highlighting the robust nature of β-
lactones in the realm of natural product synthesis. Focus will be on the application to 
natural products and bioactive compounds since 2003. Examples prior to 2003 can be 
seen in the 2004 Heterocycles review by Romo et al.4 This review is not meant to 
convey every use of β-lactones in synthesis since 2003 alternatively it serves to depict 
the applications in recent years and serve as admission to the literature for those 
interested.  
1.1.2. Four-Membered Oxygenated Heterocycles 
β-Lactones, as they are more commonly referred to, are 3 carbon 2 oxygen 
containing cyclic esters. Formally referred to as oxetan-2-ones, or 2-oxetanones, with the 
simplest of them being β-propiolactone (Figure 1). As a functional group, β-lactones 
have often been thought of as unstable, highly reactive, and difficult to handle stemming 
from their potential votalitity5 and tendency towards decarboxylation.6 They are a 
   3 
functional derivative of oxetane, the core of the 4-membered oxygenated heterocyclic 
family (Figure 1). In 1995, it was reported that “the importance of four-membered 
heterocycles for organic synthesis is limited.”7 While the ‘importance’ has been explored 
in the realm of medicinal chemistry being highlighted by Carreira. Oxetane and 3-
oxetanone have been referred to as neglected synthetic intermediates for synthesis and 
drug discovery with several citations of the prevalence of these small heterocycles on the 
rise.8,9 
O
O
O
O
O
oxetan-2-one
2-oxetanone
!"propiolactone
!-lactone
4-methyleneoxetan-2-one
or 4-alkylidene oxetanone
diketene
2-methyleneoxetane
O
O
O
oxetane3-oxetanone
oxetane-3-one
O
O
O
malonic anhydride
 
Figure 1. Four-Membered Oxygenated Heterocycles 
 
 
Another functional derivative of oxetane, 4-alkylidene oxetanone, or commonly called 
diketene, has found widespread synthetic and industrial use as a highly reactive acylating 
agent,7,10 being extensively utilized for generating 1,3-diketones11 or β-ketoesters (Eq. 
3).12 Calter’s homo ketene dimerization was the first report of a catalytic, asymmetric  
O
O
ROH
OR
OO
(3)RLi
H2OR
O O
 
route to this oxetane functional derivative. Drawing from Wynberg’s work of using 
cinchona alkaloids to generate an optically active ammonium enolate, variously 
   4 
substituted ketene dimers can be readily accessed with high levels of enantioinduction 
(Eq. 4).13  
Cl
O
R
TMSQn 
(cat.)
TMSQn
O
R O
O
R Racylammonium
enolate
•R
O
base
(4)
 
Malonic anhydride, the most obscure of this class of heterocycles has been 
synthesized by ozonolysis of diketene, however upon warming quickly decomposes to 
carbon dioxide and ethenone.14 Other structures that have garnered interest in the class 
include 2-methyleneoxetane which can be accessed by methylenation of the 
corresponding β-lactone.15 Howell and co-workers have extensively studied further 
functionalization16 and applications of 2-methyleneoxetanes in the synthesis of bioactive 
compounds with examples shown herein.17 
1.1.3. Structure and Physical Organic Properties 
Often referred to as the smallest lactone rings that are synthetically viable,18 the 
structural and spectroscopic properties of β-lactones have been extensively reviewed by 
Searles.19 Mulzer20 established  vicinal coupling constants from 1H NMR for 
differentiating cis and trans β-lactones21 (J = 4-4.5 and 6.5 Hz respectively) and 17O 
NMR has been used to distinguish the two oxygen atoms.22 Numerous computational 
and experimental studies have been conducted on β-lactones including β-propiolactone, 
herein only applicable data will be addressed.23,24 The most diagnostic feature that has 
aided in the characterization of β-lactones is the intense IR absorption at ν = 1840-1810 
cm-1, attributed to the carbonyl stretching.25 Both bond lengths26 and angles23a,24c,27 have 
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been experimentally and computationally28 determined for β-propiolactone (Eq. 5)  
 
 
 
which attest to the angle strain. The deviation from standard bond angles reveal the sp2-
hydridized C2 atom has an endocyclic bond angle of 94°, determined by electron  
diffraction,24c diverging from the more typical 120° at sp2 centers. It should be noted 
when assessing the exocyclic bond angles (O1C2O5 and C3C2O5) they are enhanced to 
compensate for the O1C2O3 angle of 94°. Interestingly, there is a difference of ~20° 
between the O1C2O5 and C3C2O5 angles indicating the carbonyl group is tilted towards 
the ether-like oxygen in the ring. The deformed bond angle investigated by Bürgi, was 
determined to be in agreement with an anomeric effect through analysis of the relevant 
molecular orbitals (MO).23a Given that the p-type lone pair of the carbonyl oxygen 
governs the highest occupied molecular orbital (HOMO), and the C-C bonding orbital is 
higher in energy than the C-O bonding orbital the tilt minimizes the interaction of the 
HOMO with the C-C bonding orbital, a destabilizing interaction (I, Eq. 6).  
O
O
O
O
p to !*
(6)
I II  
Deformation in bond angle too enhances the stabilizing interaction of the HOMO by 
maximizing the overlap with the empty antibonding σ*(C-O) orbital (II, Eq. 6).23a,29 In 
small rings, such is the case of β-lactones, the σ(C-C) bonding orbital is higher in energy 
O
O
1
4 3
2
5
89°
94° 83°
94°
123°
143° (5)
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than the σ*(C-O) and in accordance with ‘Walsh Rules’ this geometry leads to the 
greatest stabilization of the HOMO.30 The negative hyperconjugation23a,31 stemming 
from the tilted carbonyl serves as a two electron stabilizing interaction. Though most 
prominent in β-lactones it is observed to lesser degree in γ-lactones.29,31 
As opposed to the oxetane ring which can adopt a puckered conformation to 
eliminate Pitzer strain from eclipsing interactions of the C-H bonds,7 β-lactones assume 
a strictly planar conformation which has been corroborated by X-ray and MM2 
calculations of several structures.23a,25 The ester type resonance stabilization is cited as 
the primary attribute resulting in planarity according to Allinger (Eq. 7).24a To adopt a 
puckered conformation, would cause the ester linkage to twist out of plane, a barrier of 
10 kcal/mol. The presumed resonance coupled with the stabilizing interactions attribute 
to the planar conformation.24a 
(7)O
O
O
O
 
Analysis of the reported 102 solved β-lactone crystal structures from the Cambridge 
Structural Database (CSD, update May 2013, 658,047 structures) reveals the average 
O1C2O5 angle to be 126.12°±1.61°, while monocyclic β-lactones have an angle of 
126.52° ± 0.75° in accordance with that of β-propiolactone (Table 1). In light of this the 
C3C2O5 has a bond angle of 138.89°± 1.58 and 138.27°± 0.81° for all β-lactone 
structures and monocyclic ones respectively confirming the significant angle 
deformation. 
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Table 1. Average bond and dihedral angles of β-lactones from CSD. 
Angle Mean Min. Max 
A-O1C2O5 126.12°± 1.61° 116.18° 129.83° 
B-O1C2O5 126.52°± 0.87° 124.51° 128.56° 
A-C3C2O5 138.89°± 1.58° 134.97° 148.51° 
B-C3C2O5 138.27°± 0.81° 136.79° 140.41° 
φ A*     3.15°± 2.38° 0.06° 9.29° 
φ B*     2.90°± 4.87° 0.22° 9.12° 
A refers to values from all reported -lactone X-rays from CSD, B refers monocyclic -
lactones from CSD. *Values were obtained from averaging all four dihedral angles in the 
lactone ring. 32 Scrutiny of the structures shows an average absolute dihedral angle (φ) of 
3.15°± 2.38°, statistically 0° from further analysis of the CSD.32  
 
 
The dihedral angle of 0.22°, determined by X-ray of monocyclic tri-aryl β-
lactone  (I, Figure 2) places the O1, C2, C3, C4, and O5, atoms in the same place. 
However, the β-lactone fused γ-lactam (II, Figure 2) deviates from planarity by 9.29° 
stemming from stereoelectronic effects for structural stabilization. Despite the fact that 
β-lactones are cyclic esters they behave quite differently than larger cyclic and acyclic 
esters, in that they are significantly more reactive,33  attributing to the cis-conformation 
of the ester. 
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O
O
NO2
I  
                           II
H
N
O
H Me
O
O
OHCl
 
Figure 2. Crystal structures of mono- and bicyclic β-lactones. 
 
 
The compulsory restriction of bond angles inhibits the stabilizing interaction of the n to 
π* (Eq. 8) that is present in the S-trans-conformation of the corresponding ester. The 
overall ring stain of 22.8 kcal/mol34 is a testament to the inherent reactivity of β-
lactones, reminiscent of epoxides (27.2 kcal/mol)35 in that they elicit more electrophillic 
character than corresponding acyclic esters or larger lactones.36 
 
 
 
 
 
Prompted by the work that protonated β-lactones in solution lead to alkyl bond 
scission37 LeBlanc and cowokers preformed ab initio molecular orbital calculations 
disclosing protonation in the gas phase delivers  two stable structures (Eq. 9).29 Unlike 
higher lactones (i.e. γ-,δ-lactones, etc.), β-lactones are known to undergo acyl (I) or alkyl 
HO ORn to !* OO
O
O
OR
O
(8)
n to !*
   9 
bond cleavage (II).25,38 That these two carbocations are relatively similar in energy, 
attests to the fact that the mode of bond fission cannot be predicted solely on the reactive 
intermediate as is true with higher lactones.  
O
OH
HO
O
I II
(9)
 
 Abbound and coworkers, elaborated ab initio calculations, posing protonation at the 
ether-like oxygen preferentially cleaved the C-Oacyl bond, a peculiarity exclusively 
observed in β-lactones (Eq. 10). 39 Stabilized by the C=O and C-Oalkyl bonds shortening, 
the acylium ion was documented as the preferred intermediate for acyl bond cleavage 
under mildly acidic conditions.39 Whereas protonation of γ-butyrolactone revealed stable 
cyclic oxonium ion, devoid of cleavage in the absence of a nucleophile (Eq. 11).39 
Protonation at the carbonyl oxygen of both lactones produces stable cis intermediates, 
stabilized by the ether-like oxygen (vida supra).29 Striking is that protonation at the 
carbonyl oxygen of β-butyrolactone consequently leads to C-Oalkyl bond fission observed 
by NMR studies, indicative of intermediate II (Eq. 9).37 
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1.1.4. Reactivity 
The paucity of crossed aldol reactions employing asymmetric catalysis devoid of 
pre-enolization40 or functionalization has elicited considerable interest for methodology 
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development in recent years.41 While elegant examples have been reported, the scarcity 
sparked interest in viewing β-lactones as ‘activated aldol products’,42 permitting an 
alternative approach to classical examples of asymmetric cross aldol reactions (Eq. 
12).13a,43 Alcoholysis of a β-lactone reveals a β-hydroxy ester, the equivalent of an ester 
enolate cross aldol reaction (Eq. 12). This motif has been realized as an appropriate aldol 
surrogate. 
O
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R' OR
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Another testament to the strain present in β-lactones is the bifunctional 
electrophillic character that permits C-Oalkyl or C-Oacyl bond fission, with the former only 
being exhibited by β-lactones.37,44 Two different pathways, whose selectivity has been 
explained thus far through Hard Soft Acid Base (HSAB) theory,45 operate to open the β-
lactone ring.45a,46 The two sites of reactivity for nucleophiles have been categorized as 
the ‘soft’ sp3 carbon (C4) and the ‘hard’ sp2 carbon (C2)(Eq. 13).47,48 Addition to the C4 
atom follows a nucleophilic substitution mechanism (SN2) with scission of the Calkyl-O 
bond, and is precedented to proceed with complete inversion of configuration, to a β-
substituted carboxylic acid (Eq. 13).49 Whereas nucleophilic attack at the C2 carbon  
O
HO
Nuc O
Nuc
OHO
O
34
21
5
hard site
soft site
(13)
 
follows an addition/elimination pathway to  β-hydroxy ketones, esters, or amides with 
retention of configuration. The Hard Soft Acid Base theory (HSAB)45a,46 has been 
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applicable to an extent at predicting the reactive site for various nucleophiles. Hard 
nucleophiles (alkoxides,50 alkyllithiums, thiolates, Grignards,51 etc.) and hydride 
reducing agents (DIBAlH (diisobutylaluminium hydride), LiAlH4, and BH3•DMS) 
predominately result in cleavage of the C-Oacyl bond to carbonyls or 1,3-diols 
respectively. 25,51-52 The C2 has a higher degree of s-character and the larger HOMO-
LUMO (lowest unoccupied molecular orbital) gap is amenable for hard nucleophiles, 
dictated principally by electrostatic interactions.53 Soft nucleophiles (halides,52f 
benzethiol,54 thiourea,52c azide,55 organocuprates,49a,56 etc.),36,57 classified as larger and 
relatively polarizable, react at the C4 position as can be expected due to achieving better 
electronic matching with the electrophilic β-carbon.47b,45b  
The product distribution while sensitive to the nucleophile is often times dictated 
by the solvent and reaction conditions. Selectivity of alcohols,58 phenols,52b ammonia, 1° 
and 2° amines,59 along with nitrates and cyanides,60  are dominated by solvent and pH as 
was described in an early series of publications by Gresham et al.48,50 Polar protic 
solvents have tended to favor C2-O1 bond cleavage, yielding the amide with ammonia, 
while aprotic solvents lend themselves to C4-O1 cleavage delivering amino acids (Eq. 
14).59 One assumption for this regioselectivity is the stabilization garnered by charge 
separation in polar aprotic solvents, desirable for SN2 type reactions.61 Early rate studies 
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to discern nucleophilic preferences by Gresham revealed chloride, bromide, iodide, 
acetate, thiocyanate, thiosulfate, and hydroxyl groups to exhibit second order kinetics as 
nucleophiles both strong and weak (hard or soft) have the potential for a SN2 type 
reaction.48,50,62  
In addition to the aforementioned dual modes of reactivity for nucleophilic 
addition via acyl or alkyl bond scission (a and b, Figure 3), β-lactones have been 
reported to undergo a plethora of transformations to a wide array of functional groups.26a 
Reactions of β-lactones have been divided into four main categories: 1) ring opening via 
nucleophilic attack 2) Lewis acid catalyzed rearrangements 3) decarboxylation and 4) 
addition to an electrophile through an enolate intermediate.  
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Figure 3. General transformations of the β-lactone motif. 
 
 
Stereoselective decarboxylation to E or Z olefins (c) is carried out through thermal, 
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photolytic or radical cleavage mechanisms, while some have been reported to undergo 
spontaneous decarboxylation. Thermal decarboxylation of β-lactones is unique 
mechanistically acting as a rare example of a reverse [2+2] cyclization process.63 β-
Lactones are amenable to a variety of rearrangements to generate ring expansion 
products,64 dyotropic rearrangements to γ-lactones (d, n = 1),65 intramolecular allysilane 
addition to δ-lactones (d, n = 2),66 or reaction with hydrazone anions to form 2,3-
dihydro-4H-pyrones (e).67 Direct conversion to a β-lactam (f) can be accomplished by a 
one-pot Miller-Mitsunobu reaction as Romo showed.68 While Namy and Machrouhi 
showed that β-lactones could be coupled with aldimines or Schiff bases via a dual 
catalyst system to provide facile access to γ-lactams (g).69 The Nelson group has worked 
at exploiting the usefulness of this motif as building blocks for creating enantioenriched 
β-amino acids (b),70 allenes (h),71 and β-β-disubstituted carboxylic acids.36 As a gateway 
to another class of heterocycles Romo et al showed facile conversion to tetrahydrofurans 
(i) employing a Mead reductive cyclization.72 Electrophilic addition through enolate 
formation has been recognized to further substitute the β-lactone core, subsequently the 
enolate proceeds to react with aldehydes in a highly diastereoselective aldol reaction 
(j).73 Howell pioneered conversion of the carbonyl to a methylene moiety (k),16,17 while 
Danheiser exhibited thermal decomposition of spirocyclic cyclopropane-β-lactones to 
generate alkylidenecyclopropanes (l).74 While reduction with LiAlH4 has been 
extensively reported to give rise to stereodefined 1,3-diols for further manipulations.  
Aside from the aforementioned synthetic transformations these small 
heterocycles have found use in industrial settings for polymer synthesis and chain 
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polymerization reactions.75 The polymerization of β-propiolactone forming polyester 
acids76 applied in plastics and clothing (Eq. 15).77  
(15)O
O O
O
n
catalyst
 
β-propiolactone was previously responsible for more than 85% of the production of 
manufactured acrylic acid and esters in the United States.78 
1.1.5 Biological Relevance 
Often coined as ‘privileged’ structures, β-lactones biological importance should 
not be understated as many exhibit a high degree of binding specificity, for varied 
enzyme classes, eliciting various modes of biological activity. β-Propiolactone long 
functioned as a key toxoiding agent inactivating polio and rabies viruses79 for the 
preparation of human and animal vaccines.78,80 Sterilization of blood plasma, tissue 
grafts, surgical equipment, enzymes, etc attest to the disinfectant properties of this 
simple β-lactone,81  while it has also taken on the role as a sporicide, providing 
protection from vegetative bacteria and pathogenic fungi.82 The more functionalized 
disubstituted trans-β-lactones including the belactosins83 ebelactones,84 panclicin,85 and 
tetrahydrolipstatin,86 have often been considered pivotal structural motifs functioning as 
pancreatic lipase inhibitors (Figure 4).87 By means of irreversible acylation by the serine 
protease88 the aforementioned natural products permit the absorption of fat. A 
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Figure 4. Trans-disubstituted β-lactone natural products. 
 
 
 simplified schematic, figure 5, illustrates acylation by the hydroxyl or thiol group of 
cysteine, serine or threonine amino acids in enzyme active sites facilitating selective and 
irreversible inhibition under mildly acidic media.89 Covalent reactions with active sites 
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Figure 5. β-Lactones as bioactive acylating agents. 
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of enzymes, permit β-lactone containing natural products to have promising and varied 
biological activity.90 A number of β-lactone containing natural products have been 
studied as anti-obesity treatments,87 with tetrahydrolipstatin being the first FDA 
approved anti-obesity drug (Figure 4). Ebelectone A, has become an attractive 
antimicrobial agent by way of irreversible acylation of the β-lactone with Ser143 in the 
active site of homoserine transacetylase (HTA). Modifications of the natural product’s 
scaffold stemming from structure activity relationships (SAR) has permitted the design 
of new antimicrobial agents which is a never-ending need for due to the evolving 
antibiotic resistance of pathogens.91 Similarly, the β-lactone moieties of omuralide and 
salinosporamide A have shown to be an essential feature in retaining bioactivity for 
selective inhibition of the 20S proteasome (Eq. 16).86b,92  
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As a result of their covalent interactions with enzymes, β-lactones have proven to be 
advantageous for developing activity-based protein profiling (ABPP) for the 
identification of dedicated target enzymes93 and developing activity-based probes.94,95 
Sieber recently reported the use of  β-lactone containing natural product, vibralactone, as 
a tool to further study biological activity.96 
1.1.6. Synthetic Design 
 The β-lactone motif can be thought of as a synthon for adding two oxygen’s and 
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three carbons rapidly. As mentioned in the reactivity section it is a precursor to all the 
functional groups in figure 3. Often times β-lactones are employed as a protecting group, 
for masking oxygen functionality, or to differentiate oxygen substutients.97 They can be 
selectively cleaved in the presence of acyclic esters, and chemoselectively reacted with 
regards to nucleophilic additions or reductions compared to other carbonyls. β-Lactones 
have found widespread use as synthon for acylation or β-functionalization (Eq. 17). 
(17)
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They have garnered interest in the realm of total synthesis due to the varied ways in 
which they can be constructed (Figure 6). Diverse intramolecular and intermolecular 
methods providing convenient templates to β-lactones have been disclosed, here only 
reviewing those falling within the bounds of the review. Intramolecular halolactonization 
of α,β- or β-γ-unsaturated acids (a), β-hydroxy acid cyclization (b), intramolecular 
nucleophile-catalyzed aldol-lactonization from keto- or aldehyde-acid substrates (c), and 
NHC (N-heterocyclic carbene) promoted aldol-lactonization of α,β-unsaturated 
aldehydes (d) have been well studied and applied to natural product synthesis. Of the 
intermolecular methods formal [2+2] cycloadditions have been the most prevalent, 
employing in situ generated ketenes from an acyl halide reacting with a ketone or 
aldehyde (e), or reaction of a ketene directly (f). The Mukaiyama-aldol-lactonization 
serves as a robust method for delivering β-lactones from thiopyridal acetals and 
aldehydes or ketones (g) an intermolecular variant of the aldol process for C-C bond 
construction. Carbonylation of epoxides with CO is distinctive in that it is the only 
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method used herein that does not require a preexisting carbonyl for β-lactone formation.  
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Figure 6. Templates to β-lactones. 
 
 
A plethora of reviews exist on numerous topics relating to β-lactones, dealing with 
their general synthesis,98 specifically from ketenes98 or ammonium enolates,99 as well as 
asymmetric design.100 Transformations of β-lactones have been documented4,25 and 
advancements in functionalization was reviewed by Romo et al in 2008.101 Specialized 
reviews, as in the applications and stability of spiro-epoxy β-lactones too have been 
reported.102 Structural features and reactivity of β-lactones103 as well as biological 
aspects including use of activity based probes94 have been addressed in the literature. 
The bioactivity of β-lactone containing natural products104 and the synthesis of natural 2-
oxetanones57 specifically lactacystin/omuralide105, and salinosporamide106 and 
derivates107 have appeared in the literature. However, the exponential growth in 
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methodology and applications in recent years as a synthetic intermediate has warranted a 
review on the role this small heterocyclic has had in the realm of natural product and 
bioactive compound construction. The following sections of the review will highlight the 
use of β-lactones in the synthesis of natural products and bioactive compounds, being 
arranged by the method in which the β-lactone was constructed. Figure 5 stands to 
highlight the methods for construction of β-lactones that have been applied in the 
synthesis of natural products and bioactive compounds in the last ten years, thus each 
method will be the heading of the remaining sections. In each section various 
applications in addition to the construction methods of the β-lactone will be assessed. 
While some use β-lactones as synthetic intermediates or protecting groups others are 
towards accessing a core of a natural product or class or natural products, or in a formal 
synthesis. Shown highlighted in red of each natural product or bioactive compound are 
the carbon’s and oxygen’s stemming from β-lactone chemistry. Each containing varying 
degrees of β-lactone incorporation in the final target, for some the β-lactone is fully 
incorporated in the final structure, whereas others maintain the hydroxy or carboxylic 
acid moiety (or both), or no trace whatsoever.  
1.2. β-Hydroxy Acid Cyclization 
1.2.1. Introduction and Mechanism 
One of the oldest and most precedent methods for the formation of β-lactones has 
been the cyclization of β-hydroxy acids. Lactonization from β-hydroxy acids is 
   20 
documented to occur through either carboxylic group activation (CGA) or hydroxy 
group activation (HGA) (Figure 7).108  
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Figure 7.  General approaches for β-hydroxy acid cyclization. 
 
 
The CGA method occurs by way of an intramolecular 4-exo-tet cyclization, and the 
HGA method employs a 4-exo-trig cyclization, both favorable according to Baldwin’s 
rules.109 The mechanism of the complementary modes of activation are shown in figure 
8, in subsequent schemes the carbon and oxygen functionality resulting from the β-
lactone motif of natural products synthesized by both methods is highlighted in red. 
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Figure 8. Cyclization of β-hydroxy acids and applications. 
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 1.2.2. Carboxylic Group Activation (CGA) 
During carboxylic group activation the β-hydroxy group syn to the carboxylic acid 
moiety attacks the activated acid delivering a cis-β-lactone (Figure 8). The relative 
configuration of the carboxylic acid and hydroxy group dictate the resulting 
configuration of the β-lactone formed. Conversely if the acid and hydroxy is initially 
anti after cyclization it will yield a trans-β-lactone. A surfeit of methods and reagents 
have been employed for carboxylic acid activation including but not limited to the 
following: Adams cyclization (PhSO2Cl and py (pyridine)),110 Yamaguchi conditions 
(2,4,6-trichlorobenzoyl chloride and DMAP),111 Mukaiyama’s reagent,112 Staab’s 
reagent (CDI), PyBOP,113 BOP, BOPCl, HATU, MNBA,114 Vederas method,115,116  
DCC, CIP117 EDC, DEAD, and DIAD (Figure 9). A plethora of other reagents 
historically used for macrolactonizations or peptide couplings have frequently been 
employed for carboxylic acid activation. Traditionally preference has been for 
carboxylic group activation (CGA) methods of lactonization as the resulting ring closure 
proceeds with retention of configuration. The vast range of conditions for establishing 
the syn stereochemistry required for the β-hydroxy acid has also promoted the CGA 
method as most favorable for β-lactone formation.  
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Figure 9. Activating Agents. 
 
 
1.2.2.1. Vibralactone and Vibralactone C  
The pancreatic lipase inhibitors, vibralactone and vibralactone C, both β-lactone 
containing natural products87,118 were synthesized by way of carboxylic group activation 
of a the appropriate β-hydroxy carboxylic acid. Vibralactone recently elucidated in 2006 
by Liu and co-workers119 was synthesized racemically120 and enantioselectively by 
Snider,121 with the latter employing Schultz’s asymmetric Birch reductive alkylation122 
to establish absolute stereochemistry. Zinc mediated retro-iodolactonization of the 
diastereomeric mixture of iodo-γ-lactones 1 converged to a single diastereomer of β-
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hydroxy acid 2 (proceeding in 27% yield for the α-substituted diastereomer and 56% for 
the β-diastereomer) (Scheme 1.1). Lactonization was accomplished using conditions 
developed by Adam et al.,110 TsCl activation of the acid (3), in the presence of py 
(pyridine), with concomitant cyclization by the hydroxyl group delivered (-)-
vibralactone C. Subsequent chemoselective reduction of the aldehyde in the presence of 
the β-lactone delivered (-)-vibralactone. 
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1.2.2.2. Vittatalactone and Norvittatalactone  
The polydeoxypropionate vittatalactone (R = Me) also a β-lactone containing 
natural product has been synthesized enantioselectively123 several times along with one 
known synthesis of the analogue, norvittatalactone (R = H, Scheme 1.2).124 These 
molecules have attracted attention due to their potential applications for developing an 
environmentally benign plant protection strategy.125 The absolute configuration was first 
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determined by Breit and Schmidt as they synthesized the enantiomer of vittatalactone, 
confirming the relative stereochemistry as possessing a trans–configured β-lactone with 
an all syn-tetramethyl side chain.123b Each synthesis has relied on various strategies for 
installing the polyproprionate fragments while all reported syntheses have employed a 
late stage lactonization to install the β-lactone using Adam’s conditions110 and in cases 
the assistance of DMAP aided in improving cyclization yields.124,126 All reported 
syntheses of vittatalactone (supra vide) constructed the β-lactone as one of or the final 
synthetic steps, retrosynthetically implying that it was a labile functional group.  
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1.2.2.3. Ebelactones A and B 
 Since the first synthesis of the ebelactones A and B in 1995 by Paterson and 
Hulme127 two additional syntheses have emerged in 2002 by Mandal128 and 2012 by 
Pons and co-workers129 all using a modified procedure of Adam et al (vide supra),110 
opting for benzenesulfonyl chloride vs. TsCl, to install the β-lactone from a β-hydroxy 
acid (Scheme 1.3). The Pons synthesis highlighted the robustness of β-lactone (6), while 
experimenting with the protecting group strategy, concluding SEM (2-
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trimethylsilylethyoxymethyl) could be removed under refluxing conditions with the 
buffered acid, PPTS (pyridinium p-toluenesulfonate) and alcohol, in good yields. With 
such buffered conditions there was no reported nucleophilic opening of the β-lactones. 
All attempts at using a fluorine source (Bu4NF•3H2O or TASF [(Me2N)3S+Me3SiF2]130 
refluxing in THF, HF or HF•py) for deprotection however perturbed the β-lactone. The 
resulting secondary alcohol (7) was oxidized using Dess-Martin periodinane (DMP), and 
PMB (p-methoxybenzyl) deprotection with DDQ (2,3-dichloro-5,6-dicyano-1,4-
benzoquinone) gave both ebelactone A and B in 2.9% and 3.7% overall yields 
respectively, displaying compatibility with oxidizing conditions. 
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1.2.2.4. Siomycin A and Largamide H
  
While planning the synthesis of the complex antibiotic siomycin A Hashimoto 
and Nakata131 dissected the molecule into five ‘practical’ segments, three of which relied 
on β-lactone chemistry to complete. Segment B began with chemistry developed by 
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Vederas for obtaining optically pure β-lactone salts of L-threonine (12, Scheme 
1.4).115,116 N-Acylation of L-threonine with 2-nitrobenzenesulfenyl chloride, followed by 
carboxylate activation with 4-bromobenzenesulfonyl chloride revealed α-amino-β-
lactone in 56% yield (11). Acid catalyzed cleavage of the S-N bond to the amine salt was 
accomplished without disrupting the optical purity of the β-lactone. The amine salt 12 
was then coupled to carboxylic acid (13) using PyBOP under basic conditions to activate 
the acid.113 A critical step for the synthesis was the opening of β-lactone 14 by 
phenylselenylation stemming from attack at the β-position. Exploration of a variety of 
conditions meet with failure (Shirahama’s conditions,132 PhSeNa, etc.), however 
benzeneselenol (PhSeH) in DMF provided nearly quantitative conversion to β-selenide 
15. This was the first reported example using PhSeH to open a β-substituted β-
lactone.133 In this instance the β-lactone motif served as both a protecting group for the 
carboxylic acid during the amide coupling and as a hydroxy activating group assisting in 
phenylselenation. Highlighted in red of segment B are the carbons stemming from β-
lactone 12. 
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Segments D and E began with optically active α-amino β-hydroxy acid 16 that 
lactonized under standard Mitsunobu conditions (DEAD/PPh3) via hydroxyl group 
activation yielding known Boc-L-serine β-lactone (17, Scheme 1.5).134 Using the 
previously discussed ring-opening tactic with PhSeH133 the authors then diverged to 
make segments D and E. Towards segment D the resultant carboxylic acid was 
converted to Fm-ester 18a by treatment with 9-flourenylmethanol135  and DCC. 
Deprotection of the Boc (di-tert-butyl dicarbonate) group and condensation, with the 
aforementioned Boc-L-serine β-lactone (17), assisted by CPI 117 delivered amide 19a (R 
= OFm). Dipeptide segment D was completed by hydrolysis of the Fm ester for late 
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stage coupling (not pictured). β-phenylselenide 18b was transformed to an amide by way 
of an anhydride intermediate and treatment with aqueous ammonia, similarly Boc 
deprotection and CIP assisted condensation with β-lactone 17, generated amide 19b (R = 
NH2). Subsequent treatment with TFA (trifluoroacetic acid) completed segment E from 
17 in 68% yield over five steps. Hashimoto and Nakata’s experimentally efficient design 
and synthesis of siomycin A is evident by the incorporation of intermediate 17 on four 
separate occasions installing differential functionalities of fragments D and E while 
transferring chirality from the same β-lactone.  
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Siomycin A, shown in figure 10 tracks segments B, D, and E with inclusion of the 
carbon and oxygen’s stemming from the corresponding β-lactones highlighted in red. 
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Figure 10. Siomycin A and β-lactone incorporation. 
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Correspondingly, the synthesis of largamide H (Figure 11) employed the same β-
lactone from the segment D and E constructs of siomycin A (Scheme 1.5) for accessing 
the enone systems in red, functionalizing intermediate 19b through a selenium promoted 
syn elimination (Figure 11).136 
1.2.2.5. Belactosin’s A and C  
Belactosin C, as with the aforementioned β-lactone containing natural products has 
also garnered the interest of synthetic groups as an inhibitor of the 20S proteasome, a 
target for controlling auto-immune diseases and cancer.137 Of the reported syntheses 
there have only been two different modes of cyclization for installing the β-lactone, here 
reviewing the hydroxy acid method for lactonization89,138 a subsequent section will 
address the alternative approach.139 The first synthesis by Kumaraswamy and 
coworkers89 cited lactonization as only being achievable by BOBCl activation, in the 
process confirming the trans-configuration of (-)-belactosin C (Scheme 1.6). After 
installing β-lactone hydrogenolysis and oxidation to carboxylic acid 22 was completed. 
Subsequent coupling of β-lactone 22 with Cbz (carboxybenzyl)-protected amine salt 23 
and deprotection gave rise to the natural product. 
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 A late report by Kumaraswamy and co-workers established the appropriate trans 
stereochemistry of the β-lactone motif at a earlier stage of the synthesis.138a 
Commencing from β-hydroxy aldehyde 25 Pinnick oxidation and BOPCl mediated β-
lactonization produced the acetonide-protected β-lactone 26 (Scheme 1.7). Deprotection 
with HCl and concomitant oxidative cleavage provided access to 22, a common 
intermediate in the aforementioned synthesis (Scheme 1.6).89 In this later synthesis the 
authors were able to generate the trans-configured β-lactone in an efficient manner 
showing reaction tolerance to both acidic and highly oxidizing conditions. 
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 Meijer and Larionov138b serendipitously discovered a tandem acylation-β-
lactonization sequence as an alternative to the belactosin core. Amine 28 and acid-
thioester 29 underwent direct coupling using EDC, TMP (2,2,6,6-tetramethylpiperidine), 
and HOAt (1-hydroxy-7-azabenzotriazole) (Scheme 1.8). The hydroxyl group cyclized 
with the thioester to β-lactone 30 and subsequent hydrogenolysis delivered belactosin A 
in 52% yield over two steps. Thioester 29 too was coupled with amine salt 23 and 
deprotection outlined in scheme 6 provided access to belactosin C (2 steps, 80%). This 
was the first reported literature example of a domino-type acylation-β-lactonization 
process, permitting a general approach to belactosin derivatives. 
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 The bioactivity of the belactosin’s prompted Armstrong and coworkers140 to 
expanded the scope of the  precedented stereoselective chlorination of a monosubstituted 
succinate141 employing a chlorination-β-lactonization sequence to belactosin A. 
Monosubstituted succinate 31, prepared from L-isoleucine, was deprotonated with 
LiHMDS (lithium bis(trimethylsilyl)amide) participating in a stereoselective 
chlorination with carbon tetrachloride (CCl4) in situ forming chloro-carboxylate 32 
(Scheme 9). Lactonization occurred upon exposure to the biphasic mixture of 
ether/NaHCO3 (aq), as previously reported by Barlaam.141b Care was taken to avoid 
reported SN2 ring opening at the C2 position142 by removing chloride from the ether 
phase. Conventionally not a HGA method, as chloride serves as an analogous ‘activated 
hydroxyl group’, nevertheless resulting in inversion of intermediate 33.  Transformation 
to the known carboxylic acid 22 (vide supra) was facile under acidic conditions, while 
the natural product was achieved by EDC coupling with amine 28 (R = H, Scheme 1.9) 
proceeding in moderate yield.143 This was the first report of a biphasic strategy for 
peptide coupling in the presence of a β-lactone; additionally the chlorination-
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lactonization sequence negated a formal activation step for cyclization minimizing use of 
protecting groups through selective activation of carboxylic acid 22. 
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1) i. LiHMDS 
(2 equiv.) O
O
Li
t-BuO
H
O
Cl3C-Cl
HO O
Me
t-BuO2C
H
-O O
Me
t-BuO2C
H
Cl
ii. then NaHCO3(aq)
Et2O, (55%)
O
O
O
HO
MeHH
CCl4
2) TFA, CH2Cl2
    (90%)
1) i. 28 (R = H), EDC,
    HOBT, H2O, CH2Cl2  
ii. DIPEA, DMF (50%)
22
2) Pd/C, H2, THF
    HCO2H (90%)
H
N
O
H2N
CO2H
Me O
O
O
H
N
MeHH
(+)-belactosin AR = H
31 32
33
 
 
 Shuto and co-workers144 followed a strategy similar to Armstrongs140 
approach for forming β-lactone 22 (Scheme 1.10). Activation of carboxylic acid in 22 
with pivaloyl chloride (PivCl) to the mixed anhydride 34 followed by amine acylation 
delivered tripeptide 35 in excellent yield. Here opting to install the carboxylic acid of the 
natural product at the final stage of the synthesis avoiding a protection/deprotection 
sequence or selective activation for β-hydroxy cyclization. Surprisingly, the β-lactone 
moiety was unaffected during oxidative cleavage of the terminal olefin in 35 with NaIO4 
and KMnO4. Lastly deprotection of the Cbz group, in which all syntheses to date employ 
as the final step, delivered belactosin A.  
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1.2.2.6. Nocardiolactone 
 Kumaraswamy and coworkers in continuing their interests of making trans- 
substituted β-lactones89,138a,145 completed the synthesis of nocardiolactone,146 a 
simplified structural motif of the ebelactone’s, belactosin’s, and tetrahydrolipstatin. 
BOPCl-Mediated cyclization of hydroxy acid 36, which in turn was obtained from a (S)-
proline-catalyzed cross-aldol, gave way to the natural product in good yield as the final 
step (Scheme 1.11). 
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1.2.2.7. Oxazolomycin A  
Oxazolomycin A has drawn considerable attention because of its unique 
spirocyclic-β-lactone-γ-lactam core and structural similarities to known 20S proteasome 
inhibitors salinosporamide and omuralide. It has a wide array of biological activities 
including in vivo antitumor activity147 with Hatakeyama and coworkers reporting the 
first synthesis of oxazolomycin A in 2011.148 Donohoe and coworkers subsequently 
disclosed the only reported asymmetric route to the pyrrolidinone core.149 Both tactics 
made use of HATU activation of the carboxylic acid moiety for generating the 
spirocyclic β-lactone-γ-lactam core of the natural product (Scheme 1.12). Hatakeyama’s 
synthesis reported installation of the spirocyclic core as the final step delivering the 
natural product in 72% yield.  
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1.2.2.8. Epi-Oxetin  
The Howell group has pioneered the synthetic utility of 2-methyleneoxetanes 
(vide supra)16 in 2008 reporting a methenylation-epoxidation sequence while completing 
epi-oxetin (Scheme 1.13).150 Access to optically active β-lactone 39 was achieved with 
Liskamp’s procedure,151 by treatment of N-tritylserine (obtained from L-serine) with 
   37 
BOP and NEt3. Methylenation with the Petasis reagent (Cp2TiMe2) delivered substituted 
2-methyleneoxetane 40 in 80% yield15 which was transformed to dioxaspirohexane 41 
with DMDO (dimethyldioxirane).152 When treated with DIBAlH, the epoxide could be 
selectively cleaved to a primary alcohol153 yielding the anti bis-substituted oxetane 42. 
Stereoselectivity from the reduction favored the undesired diastereomer, presumably 
from complexation of the nitrogen lone pair with DIBAlH. Howell and Blauvelt used the 
β-lactone 39 as a as a gateway to various 4-membered oxygen containing heterocycles as 
is evident in this synthesis from the transformation of the β-lactone to 2-
methyleneoxetane and then to a substituted oxetane ring.  
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1.2.2.9. Tetrahydrolipstatin  
Due to the potent and irreversible inhibition of pancreatic lipase86 
tetrahydrolipstatin, currently marketed as the anti-obesity drug Xenical®/Alli®, has 
been targeted by numerous groups in the last 17 years.73c,154,155 Of the syntheses since 
2003 (Yadav156 Kumaraswamy145,157 Raghavan158 Ghosh,159 Hanson,160 and Shiina161) 
that involve hydroxy-acid cyclization all have followed the general sequence outlined in 
scheme 1.14. By protecting the δ-hydroxy group in 43 (as a silyl group, benzyl ether, 
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methyl ether, etc.) the β-alcohol has been cyclized under a variety of conditions 
(Yamaguchi cyclization, BOPCl, Adams et al110 cyclization and modifications thereof, 
MNBA, etc.). Following cyclization, deprotection of the secondary alcohol and coupling 
with either (S)-N-formyl leucine or a protected analogue thereof has established the ester 
side-chain. Coupling has employed both carboxyl group activation (CGA) and hydroxy 
group activation (HGA) methods. Beginning with syn-β,δ-alcohols, CGA strategies used 
DCC and DMAP for installing the ester side chain whereas HGA methods utilized anti-
β,δ-alcohols with Mitsunobu conditions (DEAD/PPh3 or DIAD/ PPh3). The increase of 
methodology and activation methods for forming β-lactones has lead to a variety of 
methods to access tetrahydrolipstatin, allowing greater synthetic versatility for 
constructing β-hydroxy acid 43. 
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1.2.2.10 Salinosporamide A and Analogues  
The potent inhibitor of the 20S proteasome, salinsporamide A, which is currently 
in testing as a drug candidate for multiple myeloma106 has been synthesized by several 
synthetic groups106,162 focusing largely on the route to hydroxy acid 46 (Scheme 1.15).163 
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Corey163a first reported the enantioselective synthesis and final two steps, which several 
other syntheses utilized as their end game strategy.163a-c Reporting a β-lactonization 
chlorination sequence to salinsporamide A with BOPCl in py and triphenylphosphine 
dichloride proceeding in good yield (>60%) over two steps, similar yields were seen 
with others following this strategy.163a-c 
 
Scheme 1.15 
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Corey reported an improved end strategy in the clasto-lactacystin-
salinosporamide hybrid synthesis utilizing (MeTeAlMe2)2, a demethylating reagent 
developed to specifically hydrolyze  the ‘unusually’ difficult methyl ester of 47 (Scheme 
1.16).164 The propensity for retro-aldol, and susceptibility to decomposition under 
various conditions, complicated the seemingly simple transformation however the 
tellurium derived reagent prompted efficient demethylation. While ensuing lactonization 
with phosphine derived chlorinating agent, presumably through in situ acid chloride 
formation both cyclized the tertiary alcohol, and chlorinated the primary alcohol. Lastly 
acid-mediated silyl deprotection furnished the natural product analogue.  Pattenden163e 
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and Omura165 also employed this tellurium-mediated transformation, chlorination-β-
lactonization sequence to racemic and optically active salinosporamide A, respectively.  
Scheme 1.16. Salino-omuralide hybrid synthesis. 
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Potts et al. of Nereus Pharmaceuticals166 after following the β-lactonization 
chlorination sequence with BOPCl and Ph3PCl2 (vide supra)163a took a biological 
approach, relying on an enantioselective enzymatic reduction to establish the secondary 
alcohol’s stereochemistry (Scheme 1.17). Benzyl deprotection, β-lactonization, and 
chlorination preceded in moderate yield over three steps affording the hydroxy epimer of 
salinsporamide (49). Dess-Martin oxidation produced keto-salinosporamide (50) 
permitting excellent stereocontrol in the ketoreductase enzyme-mediated reduction to (-
)-salinosporamide.166 To the best of our knowledge this is the first time an enzymatic 
reduction was used in the end game approach for a β-lactone containing compound, 
eluding to the highly specific nature of enzymes.  
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1.2.2.11. Omuralide and Lactacystin  
As with salinosporamide A, the structurally related natural products lactacystin 
and omuralide (also referred to as clasto-lactacystin) are known to be selective and 
potent inhibitors of the 20S proteasome and too have elicited attention105,162b (synthesis 
since 2007 review)167 from the synthetic community. Omuralide and salinosporamide A 
bear structural similarities in that the cyclohexene of salinosporamide A is replaced with 
a sec-butyl group and the ethyl chloride by a methyl, while lactacystin is the cysteine 
thioester derivative of omuralide. As with the majority of the salinosporamide A 
syntheses (vide supra) β-lactonization of β-hydroxy acid 51 to omuralide was 
accomplished by carboxylic acid activation with BOPCl (Scheme 1.18). Direct 
introduction of the cysteine moiety to lactacystin, followed the initial procedure by 
Corey with N-acetyl L-cysteine mediated ring opening.168  
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Scheme 1.18 
H
NO
Me
OH
CO2H
OH
BOPCl, NEt3
CH2Cl2
(81%)
H
NO
Me
OH
O
O
H
omuralide
N-acetyl L-cysteine
NEt3, CH2Cl2
H
N
OH
O
S
O
OH
CO2HAcHN
lactacystin
51
 
1.2.2.12. Obafluorin  
Demonstrating the utility for functionalizing unactivated C(sp3)-H bonds He and 
Chen completed a formal  synthesis of the antibiotic (+)-obafluorin. 169,170 Aryl threonine 
derived hydroxy ester 52 was hydrolyzed and cyclized with BOP to β-lactone 53, a 
known intermediate from a synthesis previously reported by Vederas (Scheme 
1.19).116,171  
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1.2.2.13. Fluticasone Propionate  
In the pursuit of readily accessible intermediates for synthesizing glucocorticoid 
antedrugs, specifically fluticasone propionate which is currently marketed as 
Flovent/Flonase by GlaxoSmithKline as a potent anti-inflammatory asthma treatment,172 
Bain and Procopiou et al173 came across an unprecedented rearrangement to β-lactone 56 
(Scheme 1.20). Exposure of epoxy-thioester 54 to a chloroform/methanol mixture or 
triflic acid, invoked epoxide opening and intramolecular cyclization to spirocyclic α-
thiolactone intermediate 55. Opening of the α-thiolactone by the liberated hydroxyl 
group provided the thermodynamically favored thiol-substituted β-lactone 56. 
Subsequent applications involved late stage intermediates of synthetic trifluorinated 
glucocorticoid fluticasone propionate and derivatives thereof.174 
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1.2.2.14. Sclerophytin A and B  
Molander and Jeffrey took a unique approach employing β-lactone chemistry for 
synthesizing macrocyclic intermediate 60 (Scheme 1.21).175 Carboxylic group activated 
lactone formation with Tf2O (trifluoromethanesulfonic anhydride) in the presence of 
DTBP (2,6-di-tert-butylpyridine) and direct thermolysis to tetrasubstituted olefin 59 
created a platform for ring-expansion of the cyclopentene. Oxidative cleavage with 
ozone to cyclodecane diketone 60 was carried on to late stage intermediate 61, which is 
the core structure towards the synthesis of sclerophytin A and B.  
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1.2.2.15. Anisatin  
One of the most densely congested and compact β-lactone containing natural 
products (-)-anisatin, has proven to be a challenging structure synthetically bearing 8 
contiguous stereogenic centers, and four rings, one of which is a spirocyclic β-lactone 
moiety (Scheme 1.22). The structural complexity and biological activity as a strong 
GABAA antagonist176 has elicited attention from the synthetic community177 however 
there are only two total syntheses to date. Originally completed by Niwa178 and co-
workers in 1990, forming the β-lactone as the second to last step via Adam’s cyclization 
conditions,110 Fukuyama and co-workers179 recently disclosed a different approach of 
increasing the oxidation state of anisatin through the synthesis with minimal protecting 
groups. Ozonolysis of olefin 62 with ensuing Kraus oxidation180 (NaClO2, NaH2PO4, 2-
methyl-2-butene, t-BuOH-H2O), followed by Pearlman’s catalyst aided hydrogenolysis 
provided hydroxy acid 63. The crucial spiro-lactonization, proceeded in 90% yield with 
MNBA181 and DMAP as a nucleophilic promoter. Selective deprotection of the tertiary 
methyl ether with HCl, Os-mediated dihydroxylation of the tri-substituted olefin, and 
deprotection of the secondary methyl ether finalized the second (-)-anisatin synthesis. 
Noteworthy is the necessity to protect the tertiary alcohol prior to β-lactonization; 
ozonolysis of 64 in the presence of the unprotected tertiary alcohol gave a complex 
mixture presumably due to retro-aldol of the resulting β-hydroxy aldehyde. Additionally 
the free-tertiary alcohol of 64 was reported to preferentially cyclize to cis-fused β-
lactone-cyclohexane system (not shown). The spiro-cylcic β-lactone proved to be rather 
robust surviving HCl/MeOH at elevated temperatures.  
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1.2.2.16. Cephalotaxus Esters  
Capitalizing on the strained bond angles and acylating potential of β-lactones, 
Djaballah and Gin were able to successfully append the hindered side chain of several 
cephalotaxus esters through a common late stage intermediate as an efficient and 
convergent tactic to these bioactive compounds (Scheme 1.23 and 1.24).182 The most 
challenging part of synthesizing cephalotaxus esters, a treatment component for chronic 
myeloid leukemia,183 is the installation of acyl side chain, which is often inefficient or 
prohibited.184,185 This challenge arises from the secondary alcohol of cephalotaxine (68) 
being ‘buried’ within the concave face, as well the α-quaternary carbon of the acyl side 
chain in (-)-deoxyharringtonine further inhibits the coupling of these two fragments 
(Scheme 1.23). Not to mention the lack of direct routes to the optically active acyl 
fragments. To hurdle through this challenge of coupling the two ‘handicapped’ pieces 
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Djaballah and Gin synthesized β-lactone 66 from lactonization of (R)-malic acid derived 
hydroxy acid 65 with Yamaguchi conditions.111,182 A second treatment of Yamaguchi 
condition’s was employed for acylating cephalotaxine (68) with β-lactone 67 following a 
Pd-catalyzed hydrogenolysis of 66. The coupling of fragments 67 and 68 was achieved 
in 81% yield, which is impressive considering the difficulties of previous syntheses for 
installing the acyl side chain end game approach.185 Lastly ring opening with methanol 
gave way to (-)-deoxyharringtonine.  
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In efforts to explore a more direct route and understand the necessity of the β-
lactone, coupling was attempted with identical conditions employing linear derivative 70 
finding that only traces of protected (-)-deoxyharringtonine were observed. The authors 
were attracted to the β-lactone moiety as a useful intermediate for several of the reasons 
that most shy from using them in synthesis, the strain energy from bond angle 
compression, and enhanced electrophillicity. Rationalizing the carbonyl (C2) of 67 
would be more electrophilic as a result of increased s-character of the exocyclic bonds 
via induction thereby enhancing p-character for the endocyclic bonds (those contained in 
the β-lactone) an ‘C2’-acylium like intermediate’ once the free acid is activated to ester 
derivatives of (69) from vicinal π-delocalization. 
The development of a successful late stage acylation tactic facilitated the 
synthesis of (-)-homoharringtonine and (-)-homodeoxyharringtonine (Scheme 1.24). β-
Hydroxy acid 71, derived from (R)-malic acid, followed the previously utilized 
lactonization conditions (scheme 1.23) and direct cross metathesis to deliver 
disubstituted alkenyl-β-lactone 73 and the dimeric bis-β-lactone 74. Re-subjecting 
dimeric lactone 74 to Grubbs II, provided enhanced quantities of the desired cross 
metastasis product 73. Selective benzyl ester cleavage, esterification with cephalotaine 
(68, vide supra), and ring-opening proceeded in 65% yield over three steps to methyl 
ester 75. The β-lactone moiety was unperturbed by this sequence of events involving 
metathesis, hydrosilylation, and coupling, to a degree surprising as β-lactones 
themselves are rather electrophilic and prone to solvolysis. This could be attributed to 
the sterically congested environment of the secondary alcohol of cephalotaine preventing 
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β-lactone ring opening. Following lactone opening, Pd-mediated hydrogenolysis and 
hydrogenation in methanol afforded (-)-homoharringtonine (conditions A), while the 
absence of methanol gave way to (-)-homodeoxyharringtonine (conditions B). Djaballah 
and Gin highlighted the use of β-lactones for difficult acylation reactions of sterically 
encumbered alcohols. 
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1.2.2.17. Ravuconazole 
 Zhu and coworkers186 published an improved synthesis of the antifungal 
triazole,187 ravuconazole, currently in phase II clinical trials188 with kilogram processes 
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being developed for phase III clinical trials189 employing an enzymatic lipase AK for 
establishing absolute stereochemistry. β-Hydroxy acid 76 activated by CDI lactonization 
proceeding in 92% yield; ensuing ring opening with aqueous ammonia resulted in 
hydroxy amide 78 (Scheme 1.25). Benzylic β-lactone 77 was unexpectedly stable, 
considering benzylic β-lactones are prone to spontaneous decarboxylation.190 Is this 
instance the β-lactone was employed for facile conversion of the carboxylic acid to 
amide 78 devoid of formally protecting the secondary alcohol.  
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1.2.3. Hydroxyl Group Activation (HGA) 
The latter method for cyclization of β-hydroxy esters, hydroxyl group activation 
(HGA), proceeds with inversion of configuration at the hydroxy position (Figure 8). 
Activation of the β-hydroxyl group followed by an intramolecular nucleophilic 
displacement by the carboxylate anion provides the β-lactone motif.191 The overall 
transformation follows an SN2 pathway resulting in net inversion at the alcohol 
stereocenter. If the β-hydroxyl and carboxylic acid groups are initially in a syn–
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configuration the resultant β-lactone will bear a trans-configuration. Mitsunobu type 
conditions are typically employed for this type of cyclization (DEAD/PPh3 or DIAD/ 
PPh3),192 activation of the alcohol with MsCl (methanesulfonyl chloride),56a, TsCl (p-
toluenesulfonyl chloride),108a,193 etc. have also proven fruitful. The HGA method is less 
common for the synthesis of β-lactones for several reasons; it is often necessary to mask 
the carboxylic acid in order to selectively activate the β-hydroxy group, which can 
require additional protection/deprotection steps, or intricate planning of the synthesis. 
Secondly, after the β-hydroxyl is converted into a good leaving group it makes the 
selective deprotection of the carboxylic acid rather difficult, as the activated alcohol is 
vulnerable under basic/nucleophilic conditions. Although methods have been developed 
to compensate for the shortcomings of this strategy (Lenz194 and Giannessi191,195 having 
reported esterification of the acid and mesylation of the alcohol followed by 
hydrogenolysis or hydrolysis, respectively to provide the carboxylic acid and activated 
alcohol) it has nevertheless been employed less frequently for lactonizing β-hydroxy 
acids. 
1.2.3.1.6-Deoxyerythronolide B  
In hopes of employing β-lactone chemistry for effective acylation, Krische and 
coworkers reported the most concise route to any erythromycin in their synthesis of 6-
deoxyerythronolide B (Scheme 1.26).196 The approach for synthesizing cis-β-lactone 79 
relied on a hydroxy acid activation strategy for inverting the stereochemistry β to the 
carboxylic acid during lactone formation. Initial attempts with Mitsunobu conditions 
lead to decarboxylative-Grob-type elimination forming an analogous cis-olefin in >70% 
   52 
yield (not pictured).197 Successful β-lactonization resulted from treating the dianion of 
79 with methanesulfonyl chloride (MsCl),193 albeit in low yields, 15-20%, along with 
recovered starting material. The recovery of starting material indicated the need for a 
more electrophilic reagent to selectively and completely acylate the β-hydroxy group. 
Certainly, using chloromethanesulfonyl chloride delivered β-lactone 80 in 72% yield. 
Though the goal was to exploit the β-lactone in hopes of directly acylating another 
fragment of the natural product this approach was meet with failure. Finding in the 
course of their studies that cis-disubstituted β-lactones are obstinate acylating agents,198 
therefore hydrolysis with LiOH to the carboxylic acid 81 permitting coupling providing 
access to the natural product. To this end the β-lactone essentially functions to invert the 
β-hydroxy group of acid 79, acting as an alternative method to a Mitsunobu reaction and 
ether hydrolysis.  
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1.2.3.2. Nocardiolactone and Valilactone 
 Synthesizing the trans α,β-disubstituted β-lactone, nocardiolactone Wu and Sun 
developed a DBU (1,8-diazabicyclo[5.4.0]undec-7-ene)-mediated lactonization 
procedure carried out in a homogenous media (Scheme 1.27).108a At the time of initial 
publication this was the first alternative to the biphasic protocols for hydroxyl group 
activation (HGA) in the presence of the carboxylic acid.108b Prior attempts at lactonizing 
82 with Na2CO3 in H2O-Et2O,193 or a dianion derivative thereof (proved successful in 
scheme 28), delivered no desired β-lactone product. The long hydrophobic substutients 
and relatively unfunctionalized nature of substrate 82 lead to solubility issues with 
typical biphasic conditions (H2O-Et2O or H2O-CH3Cl).199 Discovering cyclization of the 
β-mesylate with DBU delivered nocardiolactone in 70% yield, while 30% trans-olefin 
was isolated (boxed in scheme 2). The authors reported this HGA method, ‘more 
convenient’ than standard Mitsunobu conditions; though the necessity for differentiating 
the hydroxy and carboxylic acid moieties was not completely negated with this 
procedure. It was however strategically planned into their route as the carboxylic acid 
underwent hydrogenolysis to give the ‘unmasked’ carboxylic acid 82 prior to the 
lactonization event. Regardless, offering alternative conditions for cyclizing β-hydroxy 
acids with such non-polar substrates.  
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Sun and Wu used the same approach to synthesize valilactone, structurally 
similar to tetrahydrolipstatin (R= C10H21) which is another potent lipase inhibitor.200 In 
this instance their previously developed conditions of DBU in THF for cyclizing 83, 
however delivered predominately the elimination-decarboxylation pathway product 
observed as in nocardiolactone and traces of starting material (Scheme 1.28). Finding 
that K2CO3 was sufficient for permitting β-lactonization, with subsequent steps 
following those similarly noted for tetrahydrolipstatin (Scheme 1.14), deprotection, and 
esterification with (S)-N-formylvaline.201  
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1.3. Intermolecular Lewis Acid Catalyzed [2+2] Cycloaddition 
1.3.1. Introduction and Mechanism 
Convergent access to β-lactones in the last 100 years has been realized from the 
[2+2] cycloaddition of ketenes and carbonyl compounds first reported by 
Staudinger.202,203 Since this report the use of ketenes or in situ generated ketenes204 with 
aldehydes has been the forefront for synthesizing enantiomerically pure β-lactones.98,203 
These thermally allowed205 [2+2] cycloadditions have involved Lewis acid, Lewis base, 
or a combination of both for catalysis. The generally accepted Lewis acid catalyzed 
mechanism involves carbonyl activation, invoking asynchronous bond formation with 
the C3-C4 bond advancing to zwitterionic transition states with concomitant lactonization 
via C2-O1 bond formation (Figure 12).206 
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Figure 12. Lewis acid mediated net [2+2] cycloaddition. 206 
 
 
The Lewis acid promoted cycloaddition proceeds by effectively lowering the LUMO 
(lowest unoccupied molecular orbital) of the aldehyde, which reacts with the ketene 
HOMO (highest occupied molecular orbital)207 In many cases Lewis acid catalysis is 
necessary for the cycloaddition to occur and unless the carbonyl coupling partner is 
activated by having electron-withdrawing substutients.208 In 1975 Zaitseva brought new 
life to this transformation employing silylketenes209 though selectivity was an issue, in 
that various Lewis acids including BF3•Et2O, as reported by Brady, delivered mixtures 
of cis and trans β-lactones.210 Yamamoto developed conditions for the stereoselective 
formation of cis-β-lactones by employing the bulky aluminum based Lewis acid MABR 
(methylaluminum bis(4-bromo-2,6-di-t-butylphenoxide)).207b This Lewis acid mediated 
mechanism211 was determined to favor the arrangement of intermediate I having a 
smaller steric interaction with R2 than R3 solely delivering the cis-β-lactone A (Figure 
13). Whereas significantly smaller Lewis acids, e.g. BF3•Et2O, have minimal 
interactions with the R groups of the ketene thus selectivity is dictated by interactions of 
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the approaching aldehyde with the ketene, II and IV. If R2 and R3 are relatively similar a 
mixture of cis and trans will be observed from II and IV, respectively. However when 
R2 = H and R3 = t-butylMe2Si arrangement IV is favored over II delivering only the 
trans-β-lactone B.207b 
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Figure 13. Selectivity for Lewis acid catalyzed cycloadditions. 
 
 
1.3.1.1.(±)-Prelactone B, (±)-Goniothalaminm, and (-)-Massoialactone 
 Pons and coworkers have showed the synthetic potential of β-siloxy-β-lactones 
transforming them to δ-lactones trough an intramolecular HF-mediated transacylation 
reaction, providing access to (±)-prelactone B, goniothalamin, and massoialactone.212,213 
The key β-lactone intermediates were formed using an Al-mediated [2+2] cycloaddition 
with the appropriately substituted aldehydes and trimethylsilyl ketene214 (Scheme 1.29). 
Commencing with trans-α-methyl-β-siloxy aldehyde 84, as a 85:15 mixture of 
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diastereomers, delivered cycloadduct bis-silyl-cis-β-lactone 86 that was carried on to a 
two-step approach mediated by fluorine. Firstly, C-Si cleavage then a second fluorine 
source (HF) revealed an alkoxide intermediate with concomitant transacylation to the δ-
lactone, prelactone B as a 5.7:1 mixture of diastereomers.  
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 The tandem deprotection-lactonization approach was also applied to the α,β-
unsaturated dihydropyrone, (±)-goniothalamin (Scheme 1.30).213,215 The EtAlCl2 
promoted [2+2] cycloaddition provided a mixture of four diastereomers (81:10:7:2 
cis/cis/trans/trans) of the resultant β-lactone (not pictured), presumably due to the lack 
of significant steric interactions, the diastereoselectivity was inconsequential and the 
mixture was directly subjected to excess HF. At this juncture, HF facilitated a one-pot 
bis-desilylation domino transacylation, β-hydroxy elimination to deliver the 
dihydropyranone natural product in 61% yield over two steps.  
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A third application of the lactone ring expansion made use of optically active β-siloxy 
aldehyde 89, readily available from (-)-dimethyl malonate212 for the enantioselective 
synthesis of (-)-massoialactone (Scheme 1.31).212,213,215 Using the same reaction 
conditions (supra vida) delivered the lactone in 61% yield from the corresponding 
aldehyde (89) devoid of stereochemical erosion. The six-step total synthesis proceeded 
in 34% overall yield and >99% ee, as Pons very elegantly highlighted the creativity for 
developing reactions with β-lactones as a robust method providing rapid access to δ-
lactones.  
Scheme 1.31 
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1.3.1.2. Amphidinolide P  
Whilst revising the route to amphidinolide P, Trost and co-workers turned to β-lactone 
intermediate 92 as a gateway to the eight-membered lactone 97 (Scheme 1.32).97 
Seeking to exploit the β-lactone as both an activated acyl group for translactonization, 
concurrently functioning as a protecting group for minimizing chemoselectivity issues in 
the end-game, [2+2] Me2AlCl-mediated cycloaddition205,209a of enantioenriched 
aldehyde 91 and trimethylsilylketene216 provided a 1.6:1 mixture of diastereomers. This 
mixture, though separable was carried on due to the inconsequential nature of the 
resultant stereocenter (being oxidized at a later stage of the synthesis). Cleavage of both 
the C-Si and O-Si bonds without perturbing the lactone proved fruitful employing 
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conditions reported by Romo and Zemibro.217 Mono-substituted terminal olefin 93 
underwent selective Ru-catalyzed alkene-alkyne coupling developed in the Trost 
laboratory218 followed by Katsuki-Sharpless asymmetric epoxidation furnishing a 1:1 
mixture of diastereomers 95 (again resulting from the mixture at the β-lactone 
stereocenter). Finally, the β-lactone was functionalized using Otera’s catalyst219 to 
prompt formation of the eight-membered lactone 97 in 93% yield. Subsequent oxidation, 
deprotection, and lactonization yielded amphidinolide P. This synthesis demonstrated 
usefulness of a β-lactone intermediate in the formation of a medium-sized ring and its 
efficacy in minimizing unnecessary protection/deprotection sequences for differentiating 
the two secondary alcohols. Additionally, highlighting the chemo- and regioselectivity 
of the Ru-catalyzed alkene-alkyne coupling and capability with an array of functional 
groups (β-lactone, silyl ethers, and free alcohols).  
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1.3.2. Chiral Lewis Acid [2+2] Overview 
 Moving away from substrate control Miyano,220 building on Yamamato’s 
approach, reported the first chiral aluminum-BINOL (1,1′-bi-2-naphthol) Lewis acid 
complex to deliver β-lactones of moderate optical purity, with iterations by Pons,221 
Romo,222 Nelson,223 Evans,205 and Corey204 following suit.203,224 Herein discussing 
Nelson’s recently developed chiral Al-based Lewis acid’s as the applications fall within 
the bounds of this review being utilized in natural product synthesis. The chiral Lewis 
acid catalyzed [2+2] cycloaddition follows the aforementioned mechanistic pathway 
however this transformation has shown itself to be a more practical procedure employing 
acid halides (X = Cl or Br), transformed to ketenes by a hindered tertiary base (DIPEA) 
in situ, negating the need for silyl- or preformed ketenes (Figure 14).225 Elimination of  
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Figure 14. Catalytic enantioselective Lewis acid catalyzed [2+2]. 
 
 
 HX, promoted by the amine base provides the ketene intermediate, with the aldehyde 
component serving as the appropriate electrophile permitting C-C bond formation, 
catalyzed by the Lewis acid as lactone formation was retarded in the absence of Lewis 
acid.211,226 Moreover, the combination of Al(III) with amine ligands enhanced the Lewis 
acidity permitting effective cross coupling on non-activated aldehydes, expanding the 
synthetic utility of amenable coupling partners.226 The Nelson group has coined the 
acronym AAC referring to this transformation as an acyl halide-aldehyde 
cyclocondensation reaction. 
1.3.2.1. Amphidinolide B 
 The Nelson laboratory utilized their developed methodology for dictating several 
stereocenters of the polyketide amphidinolide B by way of a chiral Lewis acid catalyzed 
[2+2] cycloaddition (Scheme 1.33 and 1.34).227 The synthetic route instigated by β-
siloxy aldehyde 98 and acetyl bromide catalyzed by the chiral Al(III) complex 100 
furnished the TBS-protected β-lactone in good yield and enantioselectivity223a The 
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methylketene intermediate (not pictured) formed in situ highlights the progression of this 
chemistry diverging from silyl or unsubstituted ketene substrates. Transformation of the 
lactone was accomplished using a stereoselective Cu-mediated SN2 reaction with 
MeMgBr36 cleaving the C-O acyl bond to β-methyl carboxylic acid 102. This fragment 
was eventually converted to the boronic ester 103, preserving the methyl stereocenter for 
incorporation into the natural product. 
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As part of a convergent approach a second β-lactone intermediate was recruited, 
exhibiting the participation of a significantly more complex aldehyde 104, bearing a β-
quaternary carbon and alkynal substutient (Scheme 1.34). Acetyl bromide coupled with 
chiral aldehyde 104 through the Al-mediated [2+2] cycloaddition delivered the 1,3 syn-
β-lactone in both excellent yield and diastereoselectivity.223a N-Methoxylmethyl ring 
opening and silyl protection of the resultant secondary alcohol perturbed the lactone ring 
to linear Weinreb amide 107. The remnants of the two β-lactones can be seen in 108 
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highlighted in red, with incorporation of the β-hydroxy carbonyl and establishment of 
the methyl-bearing stereocenter from 107 and 103 respectively in hopes of this late stage 
intermediate giving access to amphidinolide B.  
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1.3.2.2. Iromoteolide 3a  
In efforts to evaluate the biological activity of iriomoteolide 3a and analogues thereof 
Nevado and co workers split the natural product into four fragments utilizing a catalytic, 
asymmetric cyclocondensation reaction to engender enantioenriched β-methyl hydroxy 
acid 111 (Scheme 1.35).228 Modifications of the AAC conditions developed by 
Nelson,223a with Al(II) catalyst 105 (formed in situ),229 produced the cross aldol-
lactonization of aldehyde 109 and acetyl bromide 99 in excellent yield. (The authors 
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make no note of the enantioselectivity in their SI or original manuscript). 
Dimethylcuprate addition facilitated C-Oalkyl bond cleavage providing rapid access to the 
optically active building block 111 for completion of the synthesis, establishing the β-
methyl stereocenter of the macrolactone further exhibiting the usefulness of 
methylketene equivalents.  
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1.3.2.3. Leustroducsin B 
 A novel application of enantioenriched β-lactones from the AAC reaction was 
reported by Johnson and coworkers in the formal synthesis of leustroducsin B instituting 
a tandem multi-component reaction sequence (Scheme 1.36).230,231 Reformatsky reaction 
of (2-ethoxy-2-oxoethyl)zinc(II) bromide and silyl glyoxylate 114 followed by a [1,2]-
Brook rearrangement delivered intermediate enolate 116. Ensuing Claisen reaction with 
β-lactone 113 serving as an electrophilic trap and incipient C-O acyl bond cleavage 
generated the complex linear fragment 117 as a single diastereomer through 1,4-
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induction from the optically active β-lactone. Subsequent transformations delivered 
known intermediate 118 previously reported in the completed synthesis the Imanishi 
group.232 The disparate nature of the β-lactone annulled the requirement for sequential 
addition of reagents as with previous endeavors employing ketones233 due to the 
indiscriminate nature of the Reformatsky reagent. Additionally, the strain associated 
with the β-lactone ring elicited reactivity similar to an aldehyde serving as a suitable 
carbonyl motif, diminishing competitive reaction with the Reformatsky reagent.230  
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Diastereoselectivity is premised on a closed transition state, with the in situ formed zinc-
enolate adopting the appropriate geometry through 7-membered ring chelate I and II 
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(Figure 15). Approach of the enolate is postulated to be from the less hindered 
diastereotopic face of the β-lactone through 1,4-stereoinduction exclusively delivering 
117. The multicomponent sequence stands as a testament to the utility of β-lactones for 
transferring chirality to the newly generated quaternary center, as all carbon quaternary 
centers in the realm of asymmetric synthesis are difficult to construct especially in 
acyclic settings.234,223a,235  
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Figure 15. Johnson’s proposed transition states for diastereoselectivity.230 
 
 
1.4. Intermolecular Lewis Base Nucleophile Catalyzed Aldol-Lactonization 
1.4.1. Introduction and Mechanism 
Lewis base catalyzed net [2+2] cycloadditions have also been well documented 
in the literature as reliable methods for the synthesis of versatile optically active β-
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lactones. Wynberg’s pioneering research developing a catalytic asymmetric β-lactone 
synthesis with cinchona alkaloid catalysts TMSQd or TMSQn (Eq. 18) served as the 
standard for preparing optically active β-lactones under Lewis base catalysis.3,236 
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The generally accepted mechanism for the Wynberg Lewis base catalyzed net [2+2] 
employs a chiral tertiary amine nucleophile (*NR3, historically TMSQd or TMSQn) 
adding to the electrophilic ketene creating an ammonium enolate intermediate (Figure 
16). Intermolecular aldol with an activated, non-enolizable aldehyde (here chloral) and 
ensuing β-lactonization regenerates the catalyst and delivers the optically active β-
lactone. The Lewis base catalyzed variant involves a stepwise mechanism and can 
generally be coined as a nucleophile catalyzed aldol-lactonization (NCAL) process. 
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Figure 16. Lewis base catalyzed net [2+2] cycloaddition. 237 
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 Cinchona alkaloids have proven to be predictable and robust catalysts for the 
synthesis of optically active β-lactones with Wynberg proposing ketene activation.3 
Chiral ammonium enolates, obtained by nucleophilic attack of cinchona alkaloids have 
been suggested to explain asymmetric induction by Wynberg,236b,238 Romo,239 
Nelson,235a and Armstrong.240 Preferential nucleophilic attack by the Nsp3 quinuclidine 
nitrogen permits catalytic asymmetric induction from the more stable quinculidinium ion 
than corresponding attack of the N sp2 delivering the quinolinium ion. Enantioselectivity 
arises from approach of the aldehyde from the β-face of TMSQd-ammoninium enolate 
(Eq. 19). 236b,241 
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1.4.1.1. Schulzeine B and C  
Romo and Liu employed Wynberg’s (R)-trichloromethyl-β-lactone (121),3 which is now 
commercially available, as a versatile and readily accessible chiral starting material to in 
the first reported synthesis of schulzeine B and C (Scheme 1.37).242 Silyl protection 
following alcoholysis, and DIBAlH reduction delivered enantioenriched aldehyde 122243 
serving to effectively install three carbons and one stereocenter into the nanomolar α-
glucosidase inhibitors244 schulzeine B and C. 242 
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Wynberg’s (S)-β-lactone prepared using the pseudoenantiomeric catalyst 
TMSQd,3 provided expedient delivery to the nanomolar ceramide transfer protein 
inhibitor HPA-12 in five steps (Scheme 1.38).245 Friedel-Crafts acylation followed by 
tetramethylammonium triacetoxyborohydride reduction246 furnished the anti-diol 123 via 
1,3-direction in 71% and high diastereoselectivity. Wynberg’s β-lactone (both R and S 
enantiomers) have found widespread application as commercially available chiral pool, 
being increasingly utilized as commodity chemicals for various synthetic endeavors. 
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1.4.1.2. Fatty Acid Synthase Inhibitors  
Calter’s Lewis base catalyzed procedure for the synthesis of enantiomerically pure 
ketene dimers proved fruitful while developing a one-pot ketene dimerization-
hydrogenation sequence to fatty acid synthase (FAS) inhibitors (Scheme 1.39).13c,203 
Employing chiral Lewis base TMSQd for dimerization of acid halide 124, direct 
filtration after cyclization for removal of quaternary ammonium salts and immediate 
hydrogenation delivered cis-β-lactone 126. When employing a one-pot procedure the 
fatty acid synthase inhibitor 126 (Ki = 23 ± 4 µM, apparent inhibition constant against 
FAS thioesterase domain) suffered from diminished yield (75% to 40 %) and 
enantioselectivity (ee 96% to 74%) compared to purification of the dimmer prior to 
hydrogenation.247 Nevertheless offering a facile procedure to accessing optically active 
cis-β-lactone derivatives of 126.The resulting product from the one-pot or two-step 
procedure was functionalized to the more potent inhibitor 127 through enolate acylation 
generating a new quaternary center. Trans-substituted β-lactone core 128 too employed 
LiHMDS for epimerization of the α-stereocenter. A plethora of derivatives employing 
the sequences outlined in scheme 1.39 were synthesized for biological screening 
comparing efficacy to known FAS inhibitor tetrahydrolipstatin. 
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1.4.1.3. (+) Maculalactone A  
Expanding the applications of Wynberg’s β-lactone synthesis and Calter’s ketene 
dimerization, Romo described a novel and concise route to the γ-lactone derived natural 
product (+)-maculalactone employing an unusually stable spiroepoxy-β-lactone as the 
key intermediate (Scheme 1.40).248 Optically active β-lactone 130 was easily accessed 
implementing Calter’s organocatalytic ketene dimerization13c of 3-phenylpropanoyl 
chloride with TMSQd in 60% yield, with z-olefin geometry.247 Epoxidation mediated by 
DMDO (dimethyldioxirane) generated the dibenzyl spiroepoxy-β-lactone 131, in 57% 
yield, which was isolated and purified by chromatography with silica gel. Romo reported 
this and derivatives of 1,4-dioxaspiro[2.3]-hexan-5-ones249 as a new class of 
heterocycles whose prior existence was unknown, and revealed their relative stability, ~7 
days when stored purified at -20°. Lewis acid mediated rearrangement established the γ-
lactone core presumably through coordination of the epoxide facilitating the cleavage to 
oxocarbenium 133. Acyllium intermediate 129, fostered by lactone ring-opening, 
followed corollary cyclization with the Lewis acid stabilized alkoxide delivering to the 
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γ-lactone core. Recrystallization afforded tetronic acid 135 in 86% yield. To confirm the 
enantiopurity at this stage, Mosher ester 136 revealed no stereochemical erosion during 
cyclization.  The final feat to the natural product involved triflate formation and Negishi 
cross coupling with benzyl cuprate facilitated by oxazoline ligand (137).250 The β-
lactone 130 not only served to establish absolute stereochemistry and incorporate three 
carbons and one oxygen directly but also expanded the confines of β-lactones exuding a 
new heterocycle in the process.  
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In addition to the aforementioned Lewis acid/Lewis base mediated cyclization, 
preliminary studies by the Romo group revealed the unique reactivity of spiroepoxy β-
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lactones.249 One can envision four major modes of functionalization stemming from the 
three reactive centers in the highly strained spirocycle 138. Functionalization to enone 
139, albeit in low yield, was accomplished with TMSOTf (Trimethylsilyl 
trifluoromethanesulfonate) and DIPEA (Scheme 1.41). Tetrabutylammonium chloride 
(Bu4NCl) and sodium azide delivered α-substituted ketones 140 and 141, respectively 
presumably via invertive epoxide cleavage followed by lactone ring opening and 
decarboxylation. This pathway was confirmed by the incorporation of 18O, through the 
addition of neutral water (142). As an alternative method to generate a tertiary amide 
restricting the α-center from epimerization, N,N-diisopropylethylamine was added to the 
spiroepoxy-β-lactone 138 delivering the 1,3-dicarbonyl as a 1:1 mixture of 
diastereomers, while diethylamine provided a single diastereomer of 144. Interestingly, 
the non-nucleophilic base DBU produced butenolide 145, similarly to butenolide 135 
(Scheme 40). Triol 146 was obtained by reduction with LiAlH4 as expected in good 
yield.  
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1.5. Intermolecular Lewis Acid Lewis Base Nucleophile Catalyzed Aldol-
Lactonization 
1.5.1. Introduction and Mechanism 
The synergistic combination of Lewis acid and base catalysis has found 
widespread success in the synthesis of complex optically active β-lactones (Figure 17). 
Cinchona alkaloid-Lewis acid catalyst systems are marked by the exceptional enantio- 
and diastereoselectivity observed bestowing more flexible and general routes to highly 
substituted β-lactone motifs.223b Advantages of this cooperative catalyst combination, 
TMSQd/TMSQn and LiClO4 include participation of sterically hindered aldehydes, 
notably the addition of α-branching, having previously been inert with Al(III) Lewis 
acid variant and extensions to substituted in situ ketenes previously not permitted.223b 
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While Calter’s cinchona alkaloid and scandium triflate catalyst system is prominent for 
accessing disubstituted β-lactones.251 In 2008 the first report of cooperative catalysis, 
employing dual activation through Lewis acid and ammonium salt (Lewis base) 
catalysis, was shown by Peters for generating selective trans-β-lactones. 252  
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Figure 17. Proposed mechanism by Nelson of cooperative catalysis.235a 
 
 
 Whereas Lewis acid activation permits more electrophilic aldehydes 
compensating for the weakly nucleophilic ketene, Lewis base promoted ammonium 
enolate formation augments nucleophilicity to the ketene eliciting a mode of dual 
activation for both reaction partners (Figure 17). The co-catalyst system is a hybrid of 
each individual catalyst, ketene generation aided by Bronstead base sanctions 
ammonium enolate formation while Lewis acid activation of the aldehyde is postulated 
to invoke a closed transition state serving also to stabilize the enolate from a bidendate 
metal. A significant draw of employing Nelson’s acyl halide-aldehyde 
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cyclocondensation (AAC) reaction is it is a catalytic, asymmetric aldol addition reaction. 
This in of itself eliminates the necessity for stochiometric chiral auxiliaries and 
improving synthetic efficiency, as there are no additional steps required for installing 
and destroying/recycling/or removing the auxiliary after the reaction. Exhibiting the 
magnitude of asymmetric aldol-based reactions for synthesizing repeating propionates in 
an iterative fashion.  
1.5.1.1. Apoptolidin C Aglycon 
 Nelson and coworkers exploited the utility of the AAC reaction as a catalytic 
asymmetric aldol equivalent for assembling propionate linkages in the synthesis of 
apoptolidin C aglycon.253 An approach of iterative assembly was employed whereby 
stereodefined polyketide units could be repetitively created using the AAC methodology 
(Scheme 1.42).223a,235d,254 Commencing with β-lactone formation from acetyl bromide 
(99) and methoxyacetaldehyde (147), catalyzed by the chiral Al(III) complex 148 β-
lactone 149 was provided in excellent yield and enantioselectivity.223a,235d,254 To elongate 
the chain and allow for a second application of the AAC, the resulting β-lactone was 
converted to the Weinreb amide, followed by silyl protection, and DIBAlH-mediated 
reduction to chiral aldehyde 150. The cinchona alkaloid O-trimethylsilylquinidine 
(TMSQd) catalyzed the second cyclocondensation of 150 with propionyl chloride set the 
syn relationship of the propionate aldol β-lactone. Conversion of the β-lactone to another 
aldehyde equivalent (152) followed the same tactic, ring opening, protection, and 
reduction while the third AAC iteration employed O-trimethylsilylquinine (TMSQn) to 
established the syn,anti,syn relationship of the alcohol functionality in  β-lactone 154 in 
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77% as a single diastereomer. Completion of this fragment involved refunctionalization 
to methyl ketone 155 through amide formation, protection of the emergent alcohol, and 
addition of MeMgBr.  
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Repetition of the aforementioned sequence yielded enantioenriched β-lactone 157 from 
cyclocondensation of 5-heptynal255 and acetyl bromide (99) catalyzed by the enantiomer 
of 148 (Scheme 1.43). Recurring transformation to an aldehyde was prompted by amine 
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opening of the lactone, PMP protection of the incipient alcohol and DIBAlH reduction in 
58% yield over the three steps. 
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Assembly of the tetraene fragment 161 commenced with TMSQd catalyzed AAC of 3-
trimethylsilylpropynal  (112) and propionyl chloride, producing β-lactone 159 with high 
levels of absolute and relative stereocontrol (Scheme 1.44). Here, Nelson and coworkers 
employed a condensed refunctionalization of the β-lactone moiety to an aldehyde with a 
two-step approach. A one-pot thioester formation and silyl protection of the incipient 
alcohol allowed for DIBAlH reduction directly to the aldehyde. The syn propionate aldol 
equivalent was then carried on to generate tetraene 161. 
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The end-game strategy to apoptolidin C aglycone stitched together all three 
fragments using classical transformations while highlighting utility of the AAC approach 
for generating aldol equivalents. Of the ten asymmetric centers, 8 were instituted from 
catalytic asymmetric Lewis acid or base catalyzed net [2+2] reactions using a diverse 
array of functionalized aldehydes for coupling with acid halides (Figure 18).223a,235d,254 
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Figure 18. β-Lactone incorporation of apoptolidin C aglycone. 
 
 
1.5.1.2. (-)-Pironetin  
To test whether the catalyst would be able to override the stereochemical bias 
stemming from the alpha stereocenter of the aldehyde-coupling partner was explored in 
the synthesis of (-)-pironetin (Scheme 1.45 and 1.46). This was the first example of a 
matched/mismatched situation; during model studies for the iterative AAC reaction it 
was experimentally determined that there was a degree of double diastereoselection. 
These model studies uncovered the conditions for matched/mismatched between the 
substrate’s and the catalyst’s chirality. Synthesis of the polyketide commenced with 
AAC catalyzed by TMSQd delivering syn β-lactone 163 from reaction of propionyl 
chloride and the PMB-protected aldehyde 162 with excellent enantioselectivity (99% ee) 
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and high diastereoselectivity (89:11, cis:trans)(Scheme 1.45). It was next carried onto a 
two-step procedure, ring opening to the Weinreb amide, protection of the resultant 
secondary alcohol as a silyl ether, and reduction to aldehyde 164 setting the stage for a 
second AAC reaction. This time being catalyzed by the pseudoenantiomeric catalyst 
TMSQn to deliver the syn:anti:syn β-lactone 165 as a single diastereomer presumably 
through a matched catalyst/substrate system. Both AAC reactions established all four 
contiguous stereogenic centers in a catalytic asymmetric fashion. Reduction of 165 to the 
1,3-diol and tosylation of the primary alcohol provided access to the highly oxygenated 
fragment 166. 
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 The synthesis of (-)-pironetin was complete by caring on fragment 166 to 
aldehyde 167 for a four carbon homologation with butyryl chloride (Scheme 46).230 The 
third AAC reaction could not be catalyzed by a cinchona alkaloid therefore Nelson and 
coworkers moved to Al(III) based Lewis acid 168. While substantial increase in catalyst 
loading (50 mol%) produced a diminished yield, 65%, it exhibited flexibility in the 
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methodology that the Lewis acid mediated AAC is an alternative approach to the Lewis 
base or cinchona alkaloid catalyzed variant. The selectivity and predictably should 
exemplify the usefulness of this as an alternative to traditional aldol reactions employing 
chiral auxiliaries as six stereocenters were established with the AAC methodology 
serving as a potential solution to asymmetric aldol addition reactions, delivering syn 
propionate aldol equivalents.235d Subsequently β-lactone 169 was converted to β-keto 
ester 170 by the enolate of t-BuOAC mediated by MgBr2 permitting selective ring 
opening and C-O acyl bond scission. 
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1.5.1.3. (-)-Rhazinilam 
 One of the most direct routes to optically active allenes for subsequent 
functionalization is realized through the appropriate opening of chiral β-lactones 
(Scheme 1.47). 2-Pentynal (171) and propionyl chloride (151) provided the allene 
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precursor in excellent yield as well as enantio- and diastereoselectivity, performing the 
net [2+2] catalyzed by TMSQd.223,235a Cu-Mediated SN2’ ring opening of the optically 
active β-lactone 172 by the pyrrole based Gringard gave way to the chiral β-allenic acid 
173. The remote alkyne of 172 was predicted to be the site of addition due to the 
stereoelectronic effects of both reactant and reagent (supra vida), serving to dictate the 
selectivity and deliver a single diastereomer of the optically active allene. This transfer 
of chirality between the β-lactone and allene was further propagated by serving to 
establish the absolute stereochemistry of the resulting quaternary carbon in (-)-
rhazinilam after metal-catalyzed cyclization (not shown). Although none of the oxygen 
functionality resulting from the β-lactone was incorporated into the final natural product 
structure, the necessary quaternary carbon center could not have been established 
without the chiral allene intermediate. Synthetically the β-lactone moiety served as a 
means to replace chiral ligands for the metal–catalyzed cyclization that ensued. In this 
regard the alkyne substutient of β-lactone 172 functioned as an activated propargylic 
ether.71  
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1.5.1.4. (-)-Exiguolide 
 Scheidt and co workers reported an extraordinary example of repurposing the β-
lactone skeleton for completing the 3rd reported synthesis of the structurally intriguing 
16-membered macrolactone (-)-exiguolide (Scheme 1.48).256 Enlisting the efficient and 
well-established methods for catalytic asymmetric formation of β-lactone’s, 159 
(reported in Scheme 1.44) was directly converted to Weinreb amide 174. Though using 
aforementioned methodology for forming the β-lactone and functionalizing it, the 
synthesis highlighted the β-lactone for establishing the absolute stereochemistry of the 
methyl and the hydroxy group of 174, which were pivotal in key steps of the synthesis. 
The hydroxy group later underwent an Eschenmoser-Claisen rearrangement 
diastereoselectively, establishing the stereocenter in exiguolide denoted with a red 
asterisk. While the C2 position of the β-lactone is incorporated in the tetrahydropyran 
ring from a stereoselective dioxinone-directed Prins cyclization. In this elegant synthetic 
design Scheidt showed the incorporate of the β-lactone in a novel way, cleaving first the 
C2-O1 bond by amide formation and subsequently the C2-C3 bond while maintaining the 
stereochemical integrity at both asymmetric centers. This exemplified the notion that the 
carbons and oxygen incorporated form β-lactone intermediates don’t necessarily have to 
remain as a consecutive 3-carbon chain or as a 1,3-oxgyen functionality.223 
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1.5.1.5. (+)-Trans-Whisky Lactone  
A drastically different approach for repurposing intermediate 159 was through 
allene 175 to a chiral γ-butyrolactone core (Scheme 1.49). Attention has been paid to 
chiral γ-butyrolactones due to both their bioactivity257 and application as building blocks 
in the synthesis of more complex molecules.258 Ma and coworkers made use of 
Nelson’s71 two step route to chiral allenes from aldehyde and acyl halide precursors in 
their synthesis of (+) and (-)-trans-whisky lactones.259 Cis-alkynl β-lactone 159, 
generated using the AAC235a,260 reaction (vida supra) between 3-
(trimethylsilyl)propynal261 and propionyl chloride with the appropriately selected chiral 
catalyst, TMSQn proceeded in both high yield and enantioselectivity. Subsequent TBAF 
(tetra-n-butylammonium fluoride) removal of the silyl group and SN2’-type ring opening 
with EtMgBr, mediated by CuBr-DMS, delivered chiral 3,4-allenoic acid 175. Ma and 
coworkers took advantage of the chiral allene to perform a diastereoselective 
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halolactonization to deliver (+)-trans-whisky lactone. The (-) enantiomer was 
synthesized similarly employing TMSQn to catalyze the AAC reaction.  
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1.5.1.6. (-)-Inthomycins A-C and Oxazolomycin A  
In order to provide convenient templates to various members of oxazolo-triene 
antibiotics Hatakeyama reported a convergent tactic to the olefin isomers, inthomycins 
of A-C (Scheme 1.50 and 1.51), with inthomycin A (Scheme 1.50, boxed, amide = NH2) 
being the left handed segment of oxazolomycin A (vida supra).148 The potent and varied 
biological activities include but are not limited to antitumor, antibacterial, and 
antiviral,147 with inthomycin A acting as a strong inhibitor of prostate cancer cell growth 
and has prompted alternative approaches for their rapid assembly.262 148 263 The general 
route to the triene fragment was reported with Nelson’s catalytic enantioselective acyl-
halide aldehyde cyclocondensation reaction building on the work from their previously 
reported synthesis of neooxazolomycin.264 Though many ynal’s have been used with this 
cinchona alkaloid-catalyzed reaction (supra vida) conjugated ones as 176 and 179 have 
been infrequently employed.235d,265 Previously attempting the net [2+2] of aldehyde 176 
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with TMSQd and isobutyryl chloride, or dimethylketene with Fu’s catalyst266 delivered 
no desired β-lactone. Thus showing some limitations of the methodology in that the all 
carbon quaternary center α- to the lactone is now amenable with conjugated aldehydes 
such as 176.  
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Commencing the synthesis with known Z-eneyne aldehyde 176267 and E-eneyne (179) 
organocatalytic asymmetric [2+2] cycloaddition developed by Nelson delivered β-
lactones 177 and 180 respectively in 85-92% yield with excellent enantio- and 
diastereoselectivity (Scheme 1.51). The β-lactone 177 was opened to the methyl ester 
with sodium methoxide, methylated and desilylated giving β-hydroxy esters 178, with β-
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lactone 180 following suit. To distinguish between oxazolomycin A/inthomycin A and 
inthomycin B later transformations involved stereoselective iodination diimide reduction 
or hydrozirconation iodination. While inthomycin C’s E,E olefin geometry was 
established from a stanyl-cuprate addition. The success of these investigations put forth 
the growing applications and power of cyclocondensation methods for generating 
increasingly complex optically active β-lactone intermediates. 
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1.5.1.7. Fludelone  
Nelson’s AAC methodology has proven to be powerful in its application to total 
synthesis, as Leighton and coworkers made use of it for a fragment towards the synthesis 
of fludelone (Scheme 1.52).268 Alkynl-aldehyde 181 and propionyl chloride revealed β-
lactone 182 in 56%, and insipient alcoholysis delivered the t-butylester 183. 
Extraordinarily, the alkynyl-α-quaternary substituted aldehyde did not hamper the 
transformation under the generally utilized reaction conditions.  
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1.5.1.8. Xanthane-Type Sesquiterpenoids  
Expanding on the first reported rearrangement of β-lactones to γ-butryloactones 
by Mulzer and Bruntrup65,269 Tang and coworkers developed a controllable Wanger-
Meerwein-type dyotropic rearrangement of cis-β-lactones to γ-butryloactones.270 The 
necessary enantioenriched β-lactones were synthesized using the organocatalyzed 
reaction pioneered by Nelson235a propionyl chloride and aldehyde 186 with cinchona 
alkaloid catalysis (Scheme 1.53). Oxazolidinone 185 went through a consecutive 
reduction, oxidation, and organocatalytic asymmetric [2+2] cycloaddition to cis-
substituted β-lactone 187 in 55% yield over the three steps on a 2 g scale. Aimed at 
expanding the scope a EtAlCl2-mediated dyotropic rearrangement of the cis-β-lactone 
delivered trans-fused γ-butryloactone-cycloheptene 189, in 67-75% yield (100-500mg 
respectively), a known intermediate. Having a robust scaleable route to the trans-5-7 
   90 
ring system permitted a formal synthesis of xanthatin271 along with various xanthane-
type sesquiterpenoids, and the first completed synthesis of sundiversifolide.  
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1.5.1.9. Pederin and Theopederin. Exploiting the use of β-lactones as effective 
acylating agents Floreancig272 and coworkers set out to develop a catalytic asymmetric 
method for construct of the acyl subunit 192, a common intermediate toward 
synthesizing pederin and theopederin (Scheme 1.54). Asymmetric induction in previous 
syntheses arose from chiral pool, stochiometric chiral auxiliaries or reagents, therefore in 
developing a more practical protocol Floreancig turned to a catalytic asymmetric 
synthesis of β-lactone 191. Here the volatile β-lactone 191, serving an effective aldol 
surrogate, was synthesized enantio- and diastereoselectively via TMSQn-catalyzed 
cyclocondensation of acetaldehyde with propionyl chloride.235a This was immediately 
reacted with the lithium enolate of t-BuOAc to afford the β-hydroxy-1,3-dicarbonyl 192. 
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Subsequent transformations were in accordance with Nakata’s route273 to des-methylene 
pederic acid derivative 193.  Late stage synthesis of pederin and theopederin involved 
amide coupling of the des-methylene pederic acid derivative 194.  
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1.5.1.9. Epoxyisoprostaines  
Understanding or testing of biological function(s) of natural products for their 
potential as therapeutic agents is often the driving force for developing more efficient 
and practical synthetic routes, as is the case with the epoxyisoprostanes. Carriera and 
coworkers chose commercially available (Z)-decenal 195 and acetyl chloride, 
commencing the synthesis with a cinchona alkaloid catalyzed AAC reaction to deliver β-
lactone 196 (Scheme 1.55).274 Following lactonization, ring opening mediated by the 
lithium enolate of methyl acetate generated the acyclic (Z)-alkenyl-dicarbonyl 197, with 
the β-lactonization event serving to establish the absolute stereochemistry of the β-
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hydroxy group whose chirality was transferred to the alkenyl substituted carbon in later 
transformations to EI and PEIPC, as well as the dihydro derivatives EC and PECPC.  
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1.5.1.10. Erythronolide B  
To truly exemplify the power of iterative acyl-halide aldehyde cyclocondensation 
reactions for generating stereodefined polypropionate fragments,254 and the ease with 
which they can be employed in complex natural product synthesis Nelson and coworkers 
completed erythronolide B (Figure 19 and Schemes 1.56 and 1.56).275 Since β-lactones 
are well known to be aldol surrogates the natural product can be retrosynthetically 
dissected to several fragments for stereoselectively installing 5 of the 7 oxygens (Figure 
19). Disconnection to propionate triene fragments A and B permits subsequent 
breakdown to several readily accessible ketene and aldehyde precursors. This highly 
convergent approach allows for simple iterations as each fragment can be employed with 
different catalyst systems for defining absolute configuration when retrosynthetically 
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dissecting molecule Nelson synthesized erythronolide B.275 The retrosynthetic design 
employs a methyl ketene on three separate occasions times, which is readily accessed 
from in situ reaction with propionyl chloride and base for defining the C2, C3, C8, C10, 
and C11 centers of erythronolide B. 
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Figure 19. Deconstruction of erythronolide B. 
 
 
 The C9-C13 portion initiated by a propionate homologation cycloaddtion 
sequence of propionaldehyde and propionyl chloride with TMSQd rendered cis-β-
lactone 199, whose direct conversion to the aldehyde for an iteration of the AAC 
reaction was achieved by addition of ethylthiolate (Scheme 1.56). Pre-generation of the 
anion with KHMDS (potassium bis(trimethylsilyl)amide) ensured C-O acyl bond 
scission, and quenching with TBSOTf (tert-Butyldimethylsilyl 
trifluoromethanesulfonate) delivered the β-siloxy thioester 200. DIBAlH- mediated 
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reduction to aldehyde 201 permitted a second AAC employing the same conditions as 
the first iteration providing the syn, anti, syn β-lactone trimer 202 with high 
diastereoselectivity (>95% de).  Functionalization of the second lactone with N,O-
dimethylhydroxylamine to the Weinreb amide fostered subsequent carbon homologation 
to 203.  
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Introduction of the C3-C5 centers by the cinchona-alkaloid-catalyzed cyclocondensation 
engaging methacrolein 204 and propionyl chloride with TMSQd to syn-β-lactone 
intermediate 205 (Scheme 1.57). This lactone was then transformed to the β-siloxy 
aldehyde 206 by way of ethylthiolate ring opening and TBS protection of the liberated 
alcohol and reduction by DIBAlH. 
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 The power of this Lewis base catalyzed net [2+2] is assessed in the direct 
formation of six of the ten stereocenters in erythronolide B, with the remaining instituted 
from diastereoselective transformations of the AAC established centers (Figure 19).  
1.6. Intramolecular Nucleophile Catalyzed Aldol-Lactonization 
1.6.1. Introduction and Mechanism 
While investigating an intramolecular variant of the Wynberg synthesis Romo 
and coworkers developed a method for generating novel β-lactone scaffolds from 
unactivated carbonyl’s through a tandem nucleophile catalyzed aldol-lactonization 
(NCAL).239a,239b,239c,276,277 The pioneering NCAL process of carboxylic acids tethered to 
carbonyl electrophiles (aldehydes or ketones) serves as a general method for accessing 
optically active substituted β-lactones rapidly.204,278,279,280 The Lewis base or 
nucleophilic catalysts makes use of acylammonium and ammonium enolate 
intermediates that Wynberg so classically forged with cinchona alkaloids for his 
enantioselective process.3 Employing an intramolecular aldol-lactonization permits the 
use of ‘unactivated’ ketones or aldehydes as it minimizes entropic barriers that can be 
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problematic intermolecularly.281 Therefore it is not necessary to have a highly 
electrophilic coupling partner, moving away from the requirement for a ketene generator 
or activated aldehyde (i.e. α-dihalogenated aldehydes or Lewis acid activation) as is the 
drawback of the Wynberg procedure (Figure 20).282 The intramolecular NCAL has been 
proposed once283 and documented284 however, Romo and coworkers reported the first 
catalytic, enantioselective, aldol-lactonization involving non-activated aldehydes 
providing absolute regio- and stereochemical control of the resultant bicyclic-β-
lactone.239c  
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Figure 20. Proposed mechanism for NCAL process. 
 
 
The generally accepted mechanism involves deprotonated of the carboxylic acid 
with a tertiary amine base, typically DIPEA, followed by carboxylic acid activation (Act, 
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as seen in the CGA and HGA modes of cyclization) to activated acid I (Figure 20). 
Transacylation by an highly nucleophilic tertiary amine,285,286 (DMAP, 4-PPY, cinchona 
alkaloids, etc.,) with ensuing deprotonation generates ammonium enolate II. 
Intramolecular aldol, and β-lactonization by an ‘SN2’ process287 (II to III) facilitates 
catalyst turnover delivering the bicyclic β-lactone.235c,239c,247,278,288 While an 
intramolecular thermal [2+2] cycloaddtion,284b,289 via ketene V has not been ruled out, 
high levels of enantioinduction from chiral tertiary amine nucleophiles suggest 
involvement of the nucleophile. 239c,288b,290 Early studies employing activating agent 
Mukaiyama’s reagent,291 and DMAP/4-PPy revealed no product was observed in the 
absence of base, serving as indirect evident for the transient ammonium enolate 
intermediate II.288b Thus far only cis-cyclopentyl fused β-lactones have been accessed 
presumably due to the ring constraints imposed by the pendant cyclopentane preventing 
the trans-β-lactone. The robust nature of the methodology is exemplified by the various 
natural products accessed and the ease of the protocol for gram scale preparation of 
bicyclic β-lactones. 290,280,277 
1.6.1.1 (+)-Dihydroplakevulin  
Romo and coworkers circumvented the necessity of a highly electrophilic 
carbonyl for β-lactone formation in their synthesis of the DNA polymerase inhibitor 
dihydroplakevulin A (Scheme 1.58).288b Optically active keto-acid 207, nucleophilic 
promoter 4-PPY, and the carboxylic acid activating agent, modified Mukaiyama’s 
reagent 208 (2-bromo-N-propylpyridinium triflate)292 with DIPEA lead to bis-cyclization 
providing bicyclic β-lactone 209 in moderate yield as a single diastereomer (dr > 19:1). 
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Methanolysis and silyl deprotection delivered (+)-dihydroplakevulin A. The nucleophile-
catalyzed aldol lactonization effectively served to construction the cyclopentane core 
with the β-siloxy group relaying stereochemical bias for the aldol-lactonization in turn 
establishing the β-hydroxy ester’s relative and absolute stereochemistry. 
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1.6.1.2. (±)-Cinnabaramide A, (-)-Salinosporamide A, and (-)-Homo-
salinosporamide  
The Romo group also has shown significant interest in the γ-lactam fused β-
lactone-containing proteasome inhibitors salinosporamide A, homosalinosporamide, and 
cinnabaramide A putting forth racemic and enantioselective syntheses using the NCAL 
for the key cyclization of the bicyclic core (Schemes 1.59-61).276,293 Inspired by the 
NCAL process and applications to keto-acid substrates288b and expanding the work from 
carbocycle-fused β-lactones, a strategy to the core of these proteasome inhibitors was 
realized by simultaneous C-C and C-O bond formation from keto-acid precursor 213.276 
The racemic synthesis of cinnabaramide A involved acylation of PMB-glycine benzyl 
ester 210 following Calter’s procedure13c with unsymmetrical ketene dimer 211294 
providing a 1:1 mixture of diastereomers of linear NCAL precursor 212 (Scheme 1.59). 
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Cleavage of the methyl ester with trimethyltin hydroxide295 delivered keto-acid 213 
which was subjected to the NCAL conditions similar to those reported for 
carbocycles288b with Mukaiyama’s reagent (208) and 4-PPY delivering β-lactone 214 as 
a 3.3:1 mixture of diastereomers. During the course of the bis-cycliztion the ammonium 
enolate of 213 destroyed the C4 stereocenter delivering a racemate of diastereomers in 
modest yield with the desired diastereomer being favored. The diastereoselectivity after 
hydrogenolysis, was enhanced (dr >19:1) owing to separation at this stage. Subsequent 
Parikh-Doering oxidation,296 addition of zincate 216 following Corey’s procedure163a 
(zincate was prepared immediately prior to addition using n-butyllithium, cyclohexenyl 
tributyltin, and ZnCl2) and oxidative cleavage of the PMP group delivered 
cinnabaramide A as a single diastereomer. The onset studies demonstrated the tolerance 
of the labile β-lactone during zincate addition and oxidative deprotection, as being 
unaffected. 
With the goal of ultimately developing an enantioselective synthesis it was 
essential to develop reaction conditions for the NCAL that minimized by-products and 
inhibited epimerization of the C2 stereocenter in 213 and correspondingly 218. After 
carboxylic acid activation and nucleophilic displacement acy1 ammonium 220 could be 
deprotonated to reveal three conformations of the ammonium enolate 221 (Scheme 60). 
Having realized that 221 and 221’ were unproductive intermediates for the biscyclization 
as the ketone and ammonium enolate were not proximal to permit cyclization, they 
would ultimately equilibrate to the reactive conformation 221’’ permitting preservation 
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of enantiopurity as the α-proton is in plane with the carbonyl of the amide stemming 
from A1,3-strain.297 Interestingly was the effect that the absolute stereochemistry of the 
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C4 position, derived from (S) or (R)-serine, had on the diastereoselectivity. Discovering 
that (R)-serine derived keto-acid 221’’ favored an 8:1 mixture with β-lactone 223 being 
the major diastereomer (Scheme 1.60), whereas (S)-serine keto-acid 224 provided a 1:2 
mixture of diastereomers with β-lactone 226 favored. The diastereoselectivity arises 
from steric interactions in the initial aldol reaction, presumably the torsional strain that 
occurs with the methyl ketone and the substutient at C2 in 225 is void in 221 while the 
modestly favored intermediate dictates the relative stereochemistry for the ensuing 
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lactonization.298 Romo and coworkers reported the possibility of a chiral memory effect 
whereby the absolute stereochemistry of C4 presumably from the required conformation 
for deprotonation stemming from the N-C4 rotamer of acyl ammoniums 220 and the 
diastereomeric 224 lead to ammonium enolates 221 and 225 respectively. In this case the 
(R)-serine derived acyl ammonium 220 delivers the N-C4 rotamer 221’’ ultimately 
providing β-lactone 223 as the major diastereomer conversely (S)-serine derived acyl 
ammonium 224 provides access to 226 as the major diastereomer.  
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Having worked out conditions for the key cyclization Romo and coworkers 
completed the synthesis of (-)-salinosporamide A. Microwave-assisted acylation of 
PMB-protected amine 227, derived from (R)-serine, and ketene dimer 228 delivered a 
1:1 mixture of diastereomers 229A and 229B (Scheme 1.61). The diastereomers were 
separated by MPLC on gram scale (dr 30:1, 98% ee, 46% yield isolated for desired 
diastereomer) while the undesired diastereomer 229B was epimerized at the C2 center 
(devoid of the C4) with p-TsOH permitting an effective resolution of ketene dimer 228. 
The C4 carboxylic acid was then revealed by Pd(0)-mediated deprotection, which 
proved to be the best conditions for minimizing epimerization at C2, providing keto-acid 
230 as a single diastereomer for biscyclization. Optimization of the NCAL conditions 
revealed MsCl and 4-PPy in less polar solvents produced the highest dr of 7:1 with ~3% 
epimerization being observed. Longer reaction time (1.5 to 3.5 hours) enhanced the yield 
from 35% to 60% (over two steps) albeit at the cost of diminished diastereoselectivity 
(7:1 to 4:1) and enantioselectivity (92% ee to 88% ee). Subsequent hydrogenolysis and 
separation of the minor diastereomer followed by a modified Pfitzner-Moffatt oxidation 
provided the necessary aldehyde.299 Zincate addition with activated zinc following 
Knochel’s procedure,300 significantly improved the reaction output with minimal 
byproducts and improved the yield and diastereoselectivity293b. Lastly, PMP-
deprotection delivered the natural product as a 15:1 mixture of diastereomers. Romo and 
coworkers made effective use of the ketene dimer strategy for accessing the keto-acid 
231 in what still stands as the shortest total synthesis of (-)-salinosporamide A. (-)-
Homosalinosporamide A was achieved following similar reaction conditions with the 
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one carbon homologue of ketene dimer of 228 while the NCAL proceeded in 60% yield 
(dr 3.5:1) subsequent transformations to (-)-homosalinosporamide A were carried out 
using identical conditions. 
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1.6.1.3. (±)-Alstilobanine A and E, (±)-Angustilodine  
Syntheses of alkaloid natural products have typically shied from β-lactone 
intermediates, potentially due to the possibility of the N-heteroatom intercepting β-
lactone formation. Nevertheless, Weinreb employed intramolecular cyclization 
conditions by Romo et al235c,278,288b,290,293 as a key step for constructing the requisite cis-
2-azadecal in his synthesis of the indole alkaloids, (±)-alstilobanine A and E as well as 
(±)-angustilodine (Scheme 1.62-64).301, 302 Cyclization of the cyclohexane-fused β-
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lactone was accomplished in excellent yield using NCAL conditions (vide supra), with 
the addition of acetic acid to avoid epimerization of the methyl ester of 235, delivering 
the desired cis-fused ring system 237 along with trans-fused 236 (cis:trans 97:3) in 94% 
yield (Scheme 1.62). The mixture of β-lactone diastereomers were carried on to 
hydrogenolysis, after which the N-H indole diastereomers were separated using 
chromatography, the cis-fused ring system 238 was isolated in 94% over the two steps 
along with 3% of the Cbz-free intermediate of 235.302 Previous work proved it was 
necessary to remove the Cbz, due to conformational constraints, to successfully generate 
enolate 239. Stereoselective hydroxymethylation of 239 on the α-face with monomeric 
formaldehyde303 delivered a single diastereomer at the newly formed quaternary carbon 
center. However the free hydroxy group of 240 proved to be problematic under basic 
conditions causing acyl migration to 241, in addition to retro-aldol process. 
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To circumvent the tranesterification event, and prevent retro-aldol processes, the 
hydroxymethyl was protected as silyl ether 242, with concomitant reduction of the β-
lactone to 1,3-diol 243 by LiBH4 (Scheme 1.63). The β-lactone served to 
stereoselectively install the cis-2-azadecalin moiety, establishing two new stereocenters, 
one being a quaternary center en route to alstilobanine.  
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It was realized that monoterpene indole alkaloids, alstilobanine E and angustilodine, 
could be derived from a common β-lactone intermediate 242 (Scheme 1.64). Protection 
of the indole proved necessary to attenuate reactivity at the C3 indole position 
(observing cyclopropane formation while attempting to cyclized the ether ring of the 
natural products when the indole was unprotected) and reduction proceeded in good 
yield to diol 245 which was used to complete the first total synthesis of (±)-alstilobanine 
E and (±)-angustilodine. The stereoselective NCAL to delivered the requisite cis-2-
azadecalin. Weinreb elegantly employed a common β-lactone intermediate for the cis-2-
azadecalin and establishing the relative stereochemistry of three centers which directed 
stereoselective hydroxymethylation for the three natural products. 
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1.6.1.4. (+)-Omphadiol  
Demonstrating the synthetic utility of β-lactones Romo and Liu took an 
interesting approach to the sesquiterpene omphadiol, developing a robust and practical 
route to carvone-derived bicyclic β-lactone 249 as a general intermediate to several 
bioactive natural products (Scheme 1.65).304 (R)-Carvone was used as chiral pool 
providing rapid access to optically active keto-acid 246 by way of a formal hydration 
and oxidative cleavage (not shown). Facile aldol-β-lactonization delivered carvone-
derived bicyclic β-lactone 249.247 Optimization of NCAL reaction conditions277 
employed K2CO3 as a shuttle base305 for diminishing the reaction time (from 24 to 2 h) 
along with commercially available TsCl (as the acid activating agent) delivering a 
practical and reliable procedure proceeding in excellent yield and diastereoselectivity 
(83%, >19:1 dr) on larger than a 10 g scale. The diastereoselectivity is rationalized from 
the chair-like transition states of the two possible ammonium enolates 247 and 248, 
wherein the latter the isopropenyl moiety adopts a pseudo-axial position thereby causing 
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a pseudo 1,3-diaxial interactions as well as 1,3-allylic strain. These unfavorable 
interactions are devoid in 247, which is believed to undergo a facile aldol and 
subsequent lactonization to 249. Quantitative reduction with DIBAlH generated 1,3-diol 
250 which was taken on to the natural product. A highlight of this approach is the use of 
(R)-carvone, which severed to establish the absolute stereochemistry generating two 
additional stereocenters, with each additional center was established from highly 
diastereoselective transformations from (R)-carvone.  Absolute stereochemistry with all 
remaining 5 being established through highly diastereoselective transformations.304  
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1.6.1.5. Merck Investigational New Drug  
Capitalizing on the selective and inherent reactivity of β-lactones Romo and coworkers 
reported an expedient synthesis to the Merck investigational new drug (IND) 
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intermediate (Scheme 1.66).306 Catalytic enantioselective nucleophile-catalyzed aldol-
lactonization (NCAL), of aldehyde acid 251 with AcQn rendered optically active 
tricyclic β-lactone 253.235c,239b,c Functionalization by way of 1,4-cuprate addition, 
proceeding in an SN2 fashion for invertive ring opening exclusively delivering 
stereodefined cyclohexyl carboxylic acid. Succeeding boron-mediated reduction and 
cleavage of the dioxolane delivered the Merck IND in 3 steps from the known β-lactone 
253.235c,239c 
Scheme 1.66. 
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Stereochemical rational of the catalytic asymmetric NCAL drew from previous models 
with cinchona alkaloids (supra vida). Approach of the aldehyde from the si face of the 
(Z)-(O)-ammonium enolate, minimizes interactions with the quinoline ring, delivering 
the cis-aldolate (Figure 21). 
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Figure 21. Proposed transition states for AcQn-catalyzed NCAL.239c 
 
 
1.6.1.6. Fluoroquinolone Antibiotic Derivatives 
Dikshit and Sikriwal pursued a catalytic intramolecular NCAL variant using 
nearly identical conditions to those reported by Romo239c for piperidine and pyrrolidine 
cores (Scheme 1.67).307 The pseudoenantiomeric catalysts AcQn and AcQd paralleled in 
efficiency delivering 66% yield and 83% ee to β-lactone 258 and 65% yield and 92% ee 
for the enantiomer, ent-258 to pyrrolidine-fused β-lactones. The formal synthesis of 
several fluoroquinolone antibiotic derivatives308 have been reported using known aza-
sugars 259, specifically pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid (260) 
currently under investigations for clinical trials due to the potent antibacterial activity 
rivaling current treatments clinafloxacin and levofloxacin (levaquin ®).308 
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1.6.1.7. (-)-Curcumanolide A and (-)-Curcumalactone  
Having developed an efficient catalytic desymmetrization of dione keto-acids278 
it was applied to the synthesis of (-)-curcumanolide A and (-)-curcumalactone (Scheme 
1.68).309 Starting with dione keto-acid 261 optimization revealed that the isothiourea 
catalyst HBTM (homobenzotetranisole), developed by the Birman group,310 in 
conjunction with Lewis acid LiCl, gave tricyclic β-lactone 262 in 65% yield on a gram 
scale with excellent levels of diastereo- and enantioselectivity (Scheme 1.68).290 
Showing what could be done in the presence of a β-lactone, Baeyer-Villiger oxidation 
was conducted, converting the β-lactone 262 to δ-lactone 263 in 45% yield under 
buffered conditions, while starting material ~6% of starting material was recovered and 
resubjected to the reaction conditions. An unprecedented dyotropic rearrangement via 
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1,2-acyl migration to spirocyclic bis-γ-lactone 265 provided a rapid route to the core of 
(-)-curcumalactone and (-)-curcumanolide A.  
Scheme 1. 68 
m-CPBA,Na2HPO4
CH2Cl2
(45% + 6% rec. 262)
O
O
CO2H
Me O
O
O
Me
O
O
O
Me
O
TsCl, LiCl, DIPEA
 CH2Cl2, 23 °C, 24 h
(65%, dr >19:1, 98% ee)
(R)-HBTM (20 mol%)
N
SNPh
3
(73%, dr >19:1)
TMSOTf
C6H6
O
O
O
Me
O
O
O
O
Me
O
(-)-curcumanolide A
O
O
Me
(-)-curcumalactone
O
O
Me
261 262
263
264 265
 
The model for enantioinduction, in agreement with that initially proposed by Birmann311 
supports an S-O nonbonding interaction (ηO →σ*C-S) of the isothiourea catalyst and 
ammonium enolate (A, Figure 22). The omission of LiCl delivered β-lactone 262 with 
diminished yield (59%) and identical enantiomeric excess. In the presence of LiCl this 
interaction is replaced by a Li-S both activating the ketone and enhancing the chair-like 
transition state (267).251 The cooperative catalysis of LiCl267 and HBTM was provoked 
to involve a chelation of lithium stabilizing the ammonium enolate and coordination to 
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the chiral nucleophile tightening the transitions state. (B, Figure 22).  Investigation of the 
potential achiral pathways (B, Figure 22) revealed 18% yield of β-lactone 262 when the 
reaction was run devoid of (S)-HBTM revealing the achiral pathway is operational to 
deliver racemic product. Whereby ketene intermediate 270 is possible from 268 or 
269.284b,289 
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Figure 22. Desymmetrization NCAL proposed transition states. 
 
 
1.6.1.7.1. NHC-Catalyzed Introduction and Overview  
Leaps and bounds have been made in the realm of N-heterocyclic carbene (NHC) 
chemistry in the last 9 years312,313,314 with its applications to natural product synthesis 
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standing as an emerging area, however it has been largely untapped for the use of β-
lactone synthesized by NHC methodology. In 2006 Nair reported the first cyclopentene 
from NHC catalysis of unsaturated aldehydes and chalcones denoting a transient β-
lactone intermediate.315,316 Scheidt and coworkers early work aimed to develop new 
NHC-catalyzed reactions perusing homoenolate and enol/enolate reactivity stemming 
from the same substrates. Discovering NHC-catalysis employing achiral IMes (bis(1,3-
(2,4,6-trimethylphenyl)imidazol-2-ylidene)) lead to dimerization of cinnamaldehyde 
proceeding through a Michael  aldol-lactonization delivering the bicyclic β-lactone, as 
was confirmed by X-ray analysis (Eq. 20).190  
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Expanding the breadth to chiral carbene catalysts, Scheidt and others had developed a 
new variant for catalytic, enantioselective aldol reactions. Further development of the 
reaction permitted the desymmetrization of achiral substrates providing rapid access to 
quaternary carbon centers and complex scaffolds. The proposed mechanism involves 
conjugate addition of the NHC catalyst to the enal substrate delivering 
homoenol/homoenolate I while ensuing protonation (HNR3+) generates enol II (Figure 
23). Intramolecular aldol of enol II with either ketone (R1) provides the stereodefined 
cyclopentane core, delivering chiral acyl azolium intermediate III. The activated acyl 
group, analogous to acyl ammoniums seen with Lewis base catalysis is poised for an 
intramolecular β-lactonization with the tertiary alcohol providing the optically active 
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cyclopentane fused β-lactone IV. When R1 is aliphatic β-lactone IV is stable and 
isolable, however when R1 is an aryl moiety spontaneous liberation of carbon dioxide (-
CO2) is observed providing optically active cyclopentene V.190,315  
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Figure 23. Proposed mechanism of NHC-catalyzed β-lactone formation.190 
 
 
Triazolium salt 274 was identified as the optimal carbene catalyst for desymmetrization 
of 1,3-diketone substrates tethered to an α,β-unsaturated aldehyde (273) (Figure 24). 
Formation of Z(O)-enol intermediate 276 involves hydrogen bonding through a six-
membered transition state dictating the absolute stereochemistry of the ensuing aldol 
reaction. As depicted this array minimizes the non-bonding interactions among the 
phenyl’s of the catalyst and the R group from the ketone electrophile. While the relative 
stereochemistry between R1 and the lactone ring is dictated by the flexibility of the 
diketone moiety, either being linear or in a locked cyclic array.190 
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Figure 24. Desymmetrization by NHC catalysis 
1.6.1.7.1.1. (-)-Bakkenolides I, J, and S  
This desymmetrization approach was utilized for the synthesis of the 
bakkenolides I, J and S as a powerful strategy for constructing the angular quaternary 
methyl group present in these challenging natural products (Scheme 1.69).317,318 The 
authors foresaw employing methodology they previously disclosed to access the 6-5-
bicyclic ring system through a desymmetrization of 1,3-diketone 278 with chiral 
triazolium salt ent-275.190 During cyclization the achiral aldehyde underwent a tandem 
homoenolate protonation, intramolecular aldol acylcation delivering the tricyclic β-
lactone 279 in 69% yield. This robust method was applied on a 5g scale with excellent 
enantio- and diastereocontrol (98% ee,  >20:1 dr). With tricyclic β-lactone tricycle in 
hand, it was functionalized by a silica gel-mediated decarboxylation,43a,319 and ketal 
formation in 98% over the two steps. The desymmetrization to β-lactones highlights a 
unique alternative for the synthesis of optically active quaternary carbons centers, a 
challenge in organic chemistry.  
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1.7. Intermolecular Tandem Mukaiyama Aldol-Lactonization 
1.7.1. Introduction and Mechanism  
In 1994, Hirai and co-workers reported a single example of a cis-β-lactone 283 
produced in low yield from p-nitrobenzaldehyde 281 and thiopyridyl ketene acetal 282 
(Eq. 21).320 Although the yield was not optimal, this constituted the first example of β-
lactone formation via the Mukaiyama aldol lactonization reaction.321 
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Me
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CHO
+
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Building on the work of Hirai, Romo and coworkers extensively developed the tandem 
Mukaiyama aldol- lactonization (TMAL) providing access to both cis- and trans-β-
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lactones 286 from aldehydes 284 and thiopyridyl ketene acetals 285 (Scheme 1.70).322 
Employing ZnCl2 trans-β-lactone could be synthesized in good to moderate yields with 
high diastereoselectivity (dr >19:1).43b,323Conversely, complete reversal in selectivity can 
be achieved with Lewis acid SnCl4 at low temperatures (dr > 19:1) favoring the cis-β-
lactone.322 Based upon initial experimental results and corroborated by calculations 
(B3LYP/BSI), asynchronous, concerted transition states between aldehydes and 
thiopyridyl ketene acetals were proposed324 that account for several unique features of 
this reaction including the superior reactivity of alphatic aldehydes, and the 
stereoconvergence of (E) and (Z).  
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Both computational and experimental evidence proposed an initial pre-coordination of 
the thiopyridyl ketene acetal 285 with ZnCl2 forming chelate complexes (E)- or (Z)-
287·ZnCl2 (Figure 25).324 Upon addition of the aldehyde 285, coordination to ZnCl2 
affords the precursors (E)- or (Z)-288 to asynchronous, concerted transition states (E)- or 
(Z)-289. The newly formed 4-6 ring systems (E)- or (Z)-290 subsequently collapse into 
silylated-β-lactones (E)- or (Z)-291. Capture of this intermediate with chloride from 
complex 293 delivers trans-β-lactone 286.  
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Figure 25. Transition states and mechanism of the TMAL reaction.324 
 
 
 1.7.1.1.Tetrahydrolipstatin. This method was applied to fatty acid synthase 
(FAS) inhibitor, (-)-panclicin D, in the first reported example of a substrate controlled 
diastereoselective TMAL.323 Subsequently Zhang and coworkers exhibited the utility of 
the TMAL reaction to 296 in their total synthesis of tetrahydrolipstatin, while the end 
game approach followed aforementioned conditions (Scheme 1.71).325  
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1.7.1.1. Valilactone  
Romo and coworkers extended this diastereoselective TMAL process toward a 
“second generation” strategy providing divergent access to tetrahydrolipstatin, 
valilactone, and several other derivatives (Scheme 1.72).326 Several β-lactone containing 
derivatives were subjected to inhibition studies of the thioesterase domain of FAS which 
demonstrated the viability of particular congeners of tetrahydrolipstatin with increased 
potency as potential preclinical drug candidates.327 
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1.7.1.2. (-)-Belactosin C  
Whereas substituted aldehydes provided good diastereoselectivity, substituted 
ketene acetals were less effective. However, a unique application of the TMAL in the 
total synthesis of (-)-belactosin C was demonstrated by two related strategies toward this 
bioactive natural product. Synthesis of the substituted thiopyridyl ketene acetal 302 and 
a chiral auxiliary-based aldehyde 303 gave the substrates necessary for a proximal 
double diastereoselective TMAL, which proved to afford the best results (Scheme 
1.73).139 This advanced β-lactone intermediate 304 was hydrogenated to remove the 
chiral auxiliary and the resulting acid 305 was subjected to peptide coupling en route to 
(-)-belactosin C.139 
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In the course of studying the TMAL, several intriguing by-products were observed that 
were dependent on the silyl group of the thiopyridyl ketene acetal. One such by-product 
was β-chlorosilyl ester 308, which is derived from intermolecular chloride attack of the 
silylated β-lactone 309 (Scheme 1.74). As opposed to cases with less bulky silyl groups 
in which mixtures of products were observed, no β-lactone was detected due to the very 
bulky TBDPS (tert-butyldiphenylsilyl) protecting group on the thiopyridyl ketene acetal.  
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 These results and others led Romo and coworkers to explore the utility of the β-
lactone as either an isolable or transient intermediate toward more complex ring systems. 
Toward the total synthesis of  (+)-brefeldin A, the TMAL reaction was utilized with β-
silyloxy aldehyde 311 and thiopyridyl ketene acetal (Z)-312 (Scheme 1.75).328 Although 
longer reaction time was required, syn-β-lactone 313 was isolated in good yield and 
moderate diastereoselectivity. After Grubbs cross metathesis329 with allyltrimethylsilane, 
TiCl4-promoted cyclization proceeded smoothly to deliver the crucial cyclopentane acid 
315 as a single diastereomer (>19:1) for completing the synthesis of (+)-brefeldin A. 
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1.7.1.3. Colopsinol B  
In an effort to combine the TMAL with the reductive cyclization of keto-β-
lactones developed by Mead and coworkers,330 Romo and coworkers envisioned the 
capture of a transient silylated-β-lactone with a pendant ketone in a single reaction 
(Scheme 1.76).72,331 Upon treatment α-benzyloxy aldehyde 316 with thiopyridyl ketene 
acetal 317, Et3SiH, and ZnCl2 in THF 321 was obtained as a single diastereomer. 
Chelation-controlled TMAL likely gives rise to silylated β-lactone 319, which undergoes 
ring-opening via the pendant ketone to deliver oxocarbenium 320. This oxocarbenium 
adopts the favored envelope with the benzyloxy substutient oriented in the pseudoaxial 
position and Et3SiH approaches through the preferred “inside attack” model as set forth 
by Woerpel.332 
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The THF fragment of colopsinol B333 was deemed an adequate target to demonstrate 
application of this three-component TMAL-based process in which two new 
stereocenters and two new bonds (one C-C and one C-O) are constructed (Scheme 
1.77).331 Treatment of α-benzyloxy-γ-ketoaldehyde 322 with ketene acetal 333 followed 
by reduction of the silyl ester with DIBAlH delivered the substituted tetrahydrofuran 
portion (327) of  colopsinol B in moderate yield.  
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1.8. Epoxide Carbonylation 
1.8.1. Introduction and Mechanism 
The last ten years has seen an expansion in the development of methodology for 
carbonylation of epoxides to β-lactones however few examples have been applied to the 
synthesis of natural products (A, Figure 26).334,335,336,337 The proposed mechanism 
invokes metal-activation of the epoxide and subsequent oxidative addition of CO 
followed by CO insertion and lactonization to reductively eliminate the metal catalyst 
(B, Figure 26). With the substutients of the epoxide dictating the relative stereochemistry 
or absolute (in the case of employing a chiral ligand)338 of the resulting β-lactone. 
Preferential epoxide opening and C-O bond formation occurs on the side with the 
smallest R group, as a result of minimizing steric interactions.  
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Figure 26. Carbonylation of epoxides to β-lactones. 
 
 
1.8.1.1. Fridamycin E  
Coates and O’Doherty reported in 2011 one of the first applications for the 
insertion of CO to optically active epoxides delivering substituted β-lactones with a Al-
Co bimetallic catalyst.339 Carbonylation of epoxide 329 was utilized to deliver the active 
tertiary β-hydroxyl carboxylic acid, highlighted in red, of the natural fridamycin E by 
way of β-lactone intermediate 330 (Scheme 1.78).339 Sharpless asymmetric 
dihydroxylation established the absolute stereochemistry of the tosylated anthraquinone 
alcohol (328) while base induced cyclization smoothly delivered the anthraquinone 
epoxide. Using methodology developed in their laboratory 10 mol% of the 
[CITPPAl][Co(CO)4] (CITTP = meso-tetra(4-Clphenyl)porphyrinato) catalyst system 
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facilitated CO insertion generating β-lactone 330 in 70%. Despite concerns of the 
catalyst being oxidized by the anthraquinone, or Lewis acid promoted conversion of the 
epoxide to the allylic alcohol, the insertion of CO proved to be the dominant pathway 
under the reaction conditions. No signs of decarboxylation were observed using the 
relatively low temperature of 40 °C, however at temperatures of up to 60 °C 
decarboxylation of the β-lactone occurred yielding a disubstituted-olefin derivative of 
330 in ~20% yield. The synthesis was complete by aqueous hydrolysis of the lactone 
ring and Pd-mediated hydrogenolysis, providing a 9 step 16% overall yield de novo 
synthesis to both enantiomers of fridamycin E. The unprecedented end game 
carbonylation and lactone functionalization exhibit a unique platform for generating 
optically active β-hydroxy acids. 
Scheme 1.78 
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1.8.1.2. 1’-Fluoromethyl-OXT-A. I 
A collaborative between Howell and Coates was reported a concise route to the 
HIV-1 inhibitor, 1’-fluoromethyl-OXT-A through CO insertion methodology.340 Silyl 
protection of (Z)-but-2-ene-1,4-diol with concomitant epoxidation by DMDO provided 
the carbonylation precursor 333 in high yield (Scheme 1.79). Catalyst 334 proved to be 
both active and selective delivering β-lactone 335 in 81% yield as a single 
diastereomer.341 Subsequently methylenation with Petasis reagent16a(vide supra) 
functionalized the β-lactone to 336. Further manipulations inevitability transformed the 
β-lactone to the oxetane core of 1’-fluoromethyl-OXT-A.342  
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1.9. Halolactonization 
1.9.1. α,β-Unsaturated Halolactonization Mechanism and Overview 
 Halolactonization of α,β-unsaturated carboxylic acids to form β-lactones was 
first confirmed in 1937 by Bartlet and Tarbell has since been slow to progress the 
applications in synthesis.343 Deprotonation of α,β-unsaturated carboxylic acid permits 
cyclization opening the bromonium intermediate to the more stable β-lactone (B, Figure 
27).  
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Figure 27. Mechanism of α,β-unsaturated halolactonization. 
 
 
The labile nature of the resultant cis-β-lactone often makes purification difficult by 
chromatography, and when an aryl group occupies the β position spontaneous 
decarboxylation predominately occurs inhibiting isolation of the β-lactone intermediate. 
Owing to the elimination of an eclipsing interaction, the decarboxylative rates of trans-
β-lactones is higher than that of cis-products.344 Therefore most applications of the 
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methodology propose or allude to a transient β-lactone intermediate. While coupling the 
halolactonization to decarboxylation conditions (heat, microwave, acid-catalysis, etc.) 
has been frequently employed in the literature for synthesizing alkyl-substituted bromo-
styrenes,345 often relying on Kuang’s ‘halodecarboxylation’ procedure345a to access 
bromo-styrene products for Suzuki or Heck cross couplings.346  
1.9.1.1. P38 MAP Kinase Inhibitor  
While developing an industrial scale, practical, synthesis of the 
pyrazolopyridinone-based p38 MAP kinsase inhibitor at Amgen, Milburn and co-
workers performed a kilogram scale decarboxylative-bromination.347 In order to install 
the necessary vinylic bromide for future Suzuki cross coupling, an NBS (N-
bromosuccinimide)-mediated Hunsdiecker-type reaction348,349 was carried out, 
presumably with the unsaturated carboxylic acid 336 undergoing bromination to form 
brominium intermediate 338 with insipid β-lactonization of the carboxylate (Scheme 
1.80). Subsequent decarboxylation ensued upon heating at 50 °C. While the authors 
speculated the mechanism proceeded as shown, they were unable to confirm (via react-
IR or LC/MS) evidence of the β-lactone intermediate. However, Kuang and coworkers 
previously confirmed (by NMR) such an intermediate during mechanistic studies on the 
decarboxylative-bromination of cinnamic acid.350 
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1.9.2. β-γ-Unsaturated Halolactonization Mechanism and Overview  
 In the 1970’s Barnett and McKenna, broadened the applications and the range of 
amenable substrates disclosing the first halolactonization of β-γ-unsaturated carboxylic 
acids to γ-bromo-β-lactones.351 Amazing is the observed selectivity of the transformation 
with β-lactones being exclusively achieved under kinetic control, while prolonged 
exposure to the reaction conditions provided the thermodynamically more stable γ-
lactone (Figure 28).9b,352,353 Subsequent methodology revealed 4-exo-trig cyclization was 
favored with strong electron with-drawing groups at the γ-position, whereas hydrogen 
substitution favored the γ-lactone.354  
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Figure 28. Modes of cyclization for β-γ-unsaturated carboxylic acids. 
 
 
1.9.2.1 Tetrahydrolipstatin. McLeod and co-workers employed this kinetic cyclization 
in a distinct and efficient approach to the frequently synthesized tran-β-lactone 
tetrahydrolipstatin.355 The β,γ-unsaturated acid was synthesized in 7 steps with Sharpless 
asymmetric dihydroxylation establishing the absolute stereochemistry of the secondary 
alcohol 338 (Scheme 1.81). The key step, bromolactonization, was originally carried out 
using conditions established by Barnett (conditions a),351 surprisingly delivering a 2:1 
mixture of cis:trans β-lactones respectively, with no detection of γ-lactone formation. 
This diastereomeric β-lactones 339 and 340 were confirmed by their characteristic 
coupling constants, which is in agreement with reported literature values.356 The high 
level of regio-control during lactonization, i.e. exclusive β-lactone formation, is believed 
to stem from the inductively withdrawing effect of the secondary alcohol, thus favoring 
opening of the brominum ion intermediate at the position β to the carboxylic acid. The 
secondary alcohol additionally seemed to dictate the diastereoselectivity, with the 
preferred trans-β-lactone being the minor diastereomer.357 The diastereoselectivity 
however was reversed employing the polor protic co-solvent methanol (conditions b), by 
   134 
reducing the stereochemical influence of the secondary alcohol’s inductive properties, 
allowing the α-alkyl chain to dominate facial selectivity. The diastereomeric mixture 
could be obtained as a 1:6 mixture of cis:trans, and was carried on as a mixture to 
radical debromination as 339 and 340 were prone to decomposition during purification 
with silica gel (purification afforded 13% of the tran-β-lactone exclusively). Crich and 
Mo’s (REF) conditions of tributyltin hydride, diphenyldiselenide, with di-tert-
butylperoxyoxalate (DBPO) as the radical initiator delivered the debrominated β-lactone  
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341 in 76% yield over the two steps. The debromination strategy beneficially funneled 
out the undesired cis-β-lactone, presumably from ‘rapid radical β-scission’ of the 
increased strain in the cis-β-lactone, or enhanced instability of it to the reaction 
conditions (previously observing only the trans product after purification). Nevertheless 
the remaining steps to tetrahydrolipstatin involved those similarly reported (supra vida), 
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esterification with Cbz-leucine, followed by hydrogenolysis and formylation all 
proceeding in good yields. 
1.9.2.1. Siastatin B and 3-C-Benzylsiastatin.  
Although the zwitterionic natural product siastain B, known for its sialidase 
inhibitory activity,358 was synthesized in 2000 by Knapp and Zhao we bear it worth 
mentioning as it was overlooked in previous reviews.359 Using tetra-n-butylammonium 
hydroxide to generate the carboxylate salt followed by treatment with bromine in 
dichloromethane, delivered the cis-β-lactone 342 in 71% yield over the two steps, 
devoid of any γ-lactone products (Scheme 1.82). The β-lactone ring was then 
immediately reduced to the 1,3-diol with protection of the primary alcohol and en route 
to siastatin B. Bromolactonization offered an alternative to traditional olefin oxidation 
methods for stereospecifically incorporating the necessary oxygen functionality.359 
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While making analogues of siastatin B Knapp and Zhao modified their approach to a 
one-pot carboxylate formation-bromolactonization procedure to give the benzyl 
substituted cis-β-lactone 347 (Scheme 1.83). Addition of the lithium salt of benzyl 
alcohol permitted esterification of the β-lactone with concomitant epoxide formation by 
displacement of the bromine with the generated secondary alkoxide. With the authors 
denoting no evidence of decarboxylation of the homobenzylic β-lactone, exemplifying 
direct conversion of the lactone to an epoxide, in a streamlined synthesis of 3-C-
benzylsiastatin.359 
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1.9.2.2. (+)-Myriocin 
  A significant advancement for the bromolactonization of unsaturated-carboxylic 
acids reported by Hasahima and Kan en route to natural products was the 
organocatalyzed desymmetrization of cyclohexadiene 349 (Scheme 1.84).360 Previously 
reporting racemic intermediate 351, in completing myriocin,361 3mol% of 
(DHQD)2PHAL was the optimal catalyst delivering gram scale quantities of tricyclic β-
lactone 350 as a single diastereomer in quantitative yield with high ee. Preliminary 
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reports by Whiteside postulate a tight ion pair of the monobromo anion with brominated 
-(DHQD)2PHAL, or associated hydrogen bonding of the protonated catalyst and 
brominium intermediate.362 This method was general to other substrates and 
experimentally facile devoid of air or moisture precautions and chromatography for 
purification. Key intermediate 351 was readily achieved following a 3-step procedure. 
The simultaneous construct of three contagious stereocenters, one of which is a chiral 
quaternary center with quantitative levels of conversion on gram scale has permitted 
additional application notably to the synthesis of sphingofungin E (not shown).363  
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1.10. Miscellaneous β-Lactone Construction Methods  
1.10.1. Fe-Mediated β-lactone Formation to Tetrahydrolipstatin and Valilactone  
The Davies group previously disclosed a powerful stereodirecting effect of chiral 
iron auxiliary [(η5-C5H5)Fe(CO)(PPh3)]364 for synthesizing intermediate 352 via a highly 
diastereoselective aldol reaction.365 Subsequently a tandem oxidative-decomplexation-
cyclization reaction of the aldol adduct 352 provided a new method for synthesizing the 
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β-lactone containing natural products tetrahydrolipstatin and valilactone.364,365 Single 
electron transfer by Br2 activated the Fe-acyl complex facilitating decomplexation with 
concomitant β-lactonization providing trans-β-lactones 353 and 354 (Scheme 1.85). The 
resultant β-lactones followed aforementioned reactions to provide the bioactive natural 
products. While iron-carbonyl complexes has been extensively documented in the 
literature for the synthesis of β-lactones366 and employed for the synthesis of other β-
lactone containing natural products104,367 we briefly present this method due to the 
limited use in synthesis during the bounds of this review. 
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1.10.2. Photoisomerization β-Lactone Formation to Inthomycin C  
The photoisomerization reaction of 2-pyrone derivatives to β-lactones has been 
reported in the literature however scarcely utilized stemming from instability, sensitivity, 
and virtually undocumented functionalization of the resultant β-lactone.368 Enticed by 
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the potential as a versatile synthetic building block Maulide and coworkers pursued 
various transformations of cyclobutene fused β-lactones initially reporting a Pd-
mediated ring opening to cis-substituted cyclobutenes.369 Subsequently they disclosed 
the serendipitous discovery of trans-halocyclobutenes via alkali halide ring opening en 
route to inthomycin C (Scheme 1.86).370 Photochemical isomerization of 357 to β-
lactone 358 proceeded in quantitative yield. Following ring-opening with LiBr, amide 
formation and 4π-electrocyclization known intermediate 360 was obtained as a single 
isomer.369a  
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1.11 Concluding Remark 
The continued isolation of natural products bearing complex scaffolds with 
embedded β-lactone moieties and potent bioactivity has prompted the application and 
exploration of β-lactones (Scheme 1.87).371,372,373,374 
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In addition, their use as specific enzyme inhibitors for a variety of biological activities 
has attracted the attention of many synthetic groups for exploiting the full potential of 
the β-lactone construct. The high degree of flexibility and plethora of documented 
transformations for direct functionalization employing this motif exhibits the emerging 
role as a valuable precursor or intermediate in natural product synthesis. 
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CHAPTER II                                                                                                                       
A PRACTICAL, DIASTEREOSELECTIVE NUCLEOPHILE CATALYZED ALDOL-
LACTONIZATION (NCAL) PROCESS∗ 
 
2.1. Nucleophile Catalyzed Aldol-Lactonization 
Our interest in β-lactone chemistry has focused on the construction of polycyclic 
fused β-lactones in the assembly of complex natural products. Employing a nucleophile-
catalyzed aldol lactonization (NCAL) process keto- or aldehyde-acids undergo 
biscyclization forming a new C-C and C-O bond. The methodology has been utilized as 
a key cyclization step for the synthesis of several natural products including 
dihyrdroplakevulin A, salinosporamide A, omphadiol, curcumanolide A and 
curcumalactone (Chapter I). Exploration of the NCAL reaction and substrate scope has 
been underway in the Romo group since the seminal publication in 2001.239c Preliminary 
reaction conditions employed Mukaiyama’s reagent and derivatives thereof along with 
nucleophilic promoter 4-PPy to form bicyclic and tricyclic β-lactones from aldehyde 
acids, keto-acids, and dione keto-acid substrates in good yields. (Eq 2.1).235c,239b,288b  
                                                
∗Reprinted with permission from “A Diastereoselective, Nucleophile-Promoted Aldol-
Lactonization of Ketoacids leading to Bicyclic-β-Lactone” by Gang Liu, Morgan E. 
Shirley, and Daniel Romo, 2012. J. Org. Chem. 77, 2496-2500, Copyright 2012 by ACS 
Publications.  
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Subsequent organocatalyzed reaction conditions, found cinchona alkaloid nucleophiles 
to be optimal in the biscyclization of aldehyde-acids for the construction of fused 
carbocyclic β-lactones and β-lactone fused tetrahydrofurans (Eq 2.2).279 While 
homobenzotetramisole (HBTM), developed by the Birman group was determined to be 
the most advantageous catalyst for desymmetrization of keto-acids.290 
CO2H
O
O
R
O
H
R
 MR (3.0 equiv), DIPEA (4.0 equiv), MeCN, 25 oC, 72 h
R = H, R' = H (51%, 86% ee)
R = H or Me
R' = H or CO2Me
N
H H OAc
N
OMe
H
R' R'
R' R'
(20 mol%), LiCl (1.0 equiv)
 TsCl (1.25 equiv), DIPEA (4.0 equiv), CH2Cl2, 23 oC, 24 h
R = Me, R' = CO2Me (71%, >98% ee)
N
N
S
(10 mol%)
(2.2)
 
The extended reaction times (up to 72 h), slow addition of the substrate (via syringe 
pump over 1-2 h), necessity to prepare Mukiayama’s reagent, required excess of the 
nucleophilic promoter (4-PPy), along with diminished yield and selectivity upon scaling 
up promoted the exploration of a more practical protocol for the NCAL. As a program 
aimed at providing rapid access to complex scaffolds en route to bioactive natural 
products, we explored ways to add greater practicality to our established NCAL process. 
 The aldol-lactonization process is proposed to involve acylammonium 
intermediate III, following transacylation of the activated acid II (Scheme 2.1). Ensuing 
deprotonation, and intramolecular aldol-lactonization provides the β-lactone. While 
ketene intermediates can be invoked for this process, the high diastereoselectivity 
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observed with β-substituted acid substrates serves as indirect evidence for the transient 
ammonium enolate leading to A1,3-strain in transition states (vide infra). 
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Analysis of our working mechanistic pathway for the NCAL process to rationalize the 
slow reaction rate revealed a possible deleterious equilibrium between the tertiary amine 
acting as a Bronsted base, and the amine employed as a Lewis base (Scheme 2.1). This is 
related to Lectka’s observations rendering the Lewis base non-nucleophilic due to its 
protonation state.98,305,375 Furthermore, reversible deprotonation (III to IV) and possibly 
to a lesser extent formation of the acyl ammonium species (II to III) could both 
significantly retard the reaction rate. 
2.2. Optimization of NCAL Conditions for Keto-Acids 
When keto-acid 2.1, derived from (R)-carvone, was subjected to previously 
reported bis-cyclization conditions (Mukaiyama’s reagent and 4-PPy) β-lactone 2.2 was 
obtained in 52% yield during a 48 h reaction time (entry 1, Table 2). Initial optimization 
aimed to use commercially available reagents; as such 4-nitrobenzenesulfonyl chloride 
and tosyl chloride were screened as alternative activating agents showing increased 
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yields (entries 2-3). With tosyl chloride proving to be superior attention was directed to 
the nucleophilic promoter. Another salient reaction parameter is the nucleophilicity of 
the Lewis base, which plays a crucial role in the kinetics of the NCAL process. 
Previously, we noted that the NCAL process with aldehyde-acids could be mediated by 
cinchona alkaloids bearing a quiniculidine-type tertiary amine In contrast, a stronger and 
more planar nucleophile, 4-pyrrolidinopyridine (4-PPy), was most effective for the bis-
cyclization of keto-acids.288b The cost of 4-PPy relative to other potential nucleophilic 
amines and the hygroscopic nature of this reagent led us to explore alternatives. The 
commodity chemical DMAP initially resulted in low yield, however the reaction was 
slow to progress as evidence by the significant amounts of recovered keto-acid after 48 
hours (entry 4). In efforts to ensure all acid was being neutralized, potassium carbonate 
was used in combination with DIPEA as a “shuttle” base.98,305,375 The increased yield 
and dramatic reduction in reaction time (entry 5-6), built off Leckta’s previously 
reported inclusion of potassium carbonate use as a phase transfer base to neutralize 
organic acid byproducts. The addition of potassium carbonate made it no longer 
necessary to use slow addition of keto-acid via syringe pump addition and promoted the 
bis-cyclization in yields comparable to those obtained with 4-PPy (entries 5 and 6). 
The NCAL of keto-acid 2.1a yielded a single diastereomer whose absolute 
stereochemistry was confirmed by X-ray analysis. This showed a trans relationship 
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Table 2. Optimization of NCAL conditions for keto-acid 2.1.  
73
entry nucleophile % yield aadditiveactivating reagent
M.R. 4-PPy --1
2
3
4
p-NO2C6H4SO2Cl 4-PPy
52
57
TsCl 4-PPy
TsCl
5 TsCl 4-PPy K2CO3
68
37 b
76 c
--
DMAPH2
a Isolated yield after chromatography. b Yield 77% based on recovered 
starting material. c Performed on 8 g scale, range 8 g to 14 g scale 71-83%
--
--
time
48 h
48 h
48 h
48 h
3 h
O
H
Me
OTsCl, DMAP, DIPEA
K2CO3, CH2Cl2
O
OH
O (dr >19:1)
2.1a 2.2a
6 TsCl DMAP K2CO3 3 h
 
 
 
between the isopropylidene moiety and the β-lactone. The high diastereoselectivity can 
be rationalized on the basis of the proposed transition-state arrangements for the aldol-
lactonization process (Scheme 2.2) Deprotonation of acylammonium II leads to an 
ammonium enolate, which can exist in two reactive conformations, III and IV. Note that 
the olefin geometry of the enolate has not been assigned but is expected to be the Z(O)-
ammonium enolate, which minimizes developing torsional strain with the ortho-
hydrogens of the pyridine ring during the deprotonation step (see structure II). In the two 
possible transition-state arrangements, the ammonium enolate can adopt III and IV. In 
the latter, which is a higher energy arrangement IV, the β-substituent (R) adopts a 
pseudoaxial position furthermore causing an unfavorable 1,3-allylic interaction. The 
absence of these unfavorable steric interactions as viewed in transition-state arrangement 
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of III leads to this conformation being the lower energy pathway and the formation of 
the anti- substituted cyclopentane V. 
Scheme 2.2 
 
 
 
 
 
 
 
 
 
2.3. Substrate Scope 
 This improved procedure renders a range of keto-acids suitable substrates for the 
bis-cyclization leading to a series of bicyclic β-lactones in useful yields (Table 3). 
To fully explore the applicability of the diastersoselctivey and generality of these 
practical conditions the corresponding β-substituted keto-acids were synthesized and 
subjected them to the NCAL process utilizing TsCl and DMAP with K2CO3 (entry 6, 
Table 3). Keto-acids bearing β- and γ-diester substutients, with respect to the carboxylic 
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acid functionality, gave moderate to good yields in short reaction times (0.5 to 2 h), 
presumably assisted by the gem-disubstituent effect. Among the monosubstituted 
substrates, β-substituted acids were found to be unique in providing high 
diastereoselectivity as previously observed.288b Keto-acid substrates with various 
substituents at this position ranging from methyl ester, siloxy, and methyl ether all gave 
the corresponding bicyclic β-lactones with high diastereoselectivity (>19:1 dr, judged by 
500 MHz 1H NMR) delivering the anti-diastereomers. With the ultimate goal of 
employing intermediate β-lactone 2.2 for natural product synthesis explored its 
compatibility with synthetically useful transformations. Os-mediated dihydroxylation, 
and cross metathesis both proved to be unfruitful for selective functionalization of the 
olefin. Oxidation of the pendant olefin with m-CPBA afforded the corresponding 
epoxide 2.8 with excellent yield (98%) and moderate diastereoselectivity (dr 4:1). In 
addition, ozonolysis of the olefin under standard conditions delivered the methyl ketone 
2.9 in 65% yield (Scheme 2.4). 
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Table 3. Practical nucleophile promoted aldol-lactonization of keto-acids mediated 
by DMAP. 
entry a keto acid !-lactone yield b
 reaction 
time (h)
CO2H
Me
O
O
O
Me
H
R R
O
O
OH
MeO2C CO2Me
O
O
OH
OTBS
O
O
Me
H
MeO2C
MeO2C
O
O
Me
H
MeO2C
MeO2C
O
O
OH
CO2Me
0.5 81
0.5 67
751
682
O
O
OH
CO2Me
CO2Me
O
O
Me
HMeO2C
O
O
Me
HTBSO
O
O
OH
OMe
O
O
Me
HMeO
O
O
OH
Me
O
O
Me
HMe
576
1
2
3
4
5
6
TsCl, DMAP
DIPEA
 CH2Cl2, K2CO3,
642
2.1b
2.1c
2.1d
2.1e
2.1f
2.1g 2.2g
2.2f
2.2e
2.2d
2.2c
2.2b
aGeneral reaction conditions: DMAP (1.5 equiv). p-TsCl (1.1 equiv), DIPEA (4.0 equiv),
K2CO3 (3.0 equiv), CH2Cl2, 23 oC. Diastereoselectivity of entries 3-6 is >19:1 as judged 
by 500 mHz 1H NMR. b Values refer to isolated yields after column chromatography.  
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Scheme 2.4 
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In summary, a practical nucleophile-promoted, aldol lactonization of keto-acids 
is described that renders this process much more amenable to scale-up as demonstrated 
by the 8 to 14 g synthesis of β-lactone 2.2. The improved procedure utilizes potassium 
carbonate as a stoichiometric, insoluble base to accelerate the reaction and further 
improvements using commercially available, inexpensive reagents provided rapid access 
to a series of bicyclic β-lactones. The high diastereoselectivity observed for β-substituted 
keto-acid substrates renders this procedure a very reliable method for the rapid 
construction of complex, substituted five-membered carbocycles. 
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CHAPTER III                                                                                                                     
β-LACTONE-BASED TOTAL SYNTHESIS OF (+)-CAULOLACTONE A 
 
3.1 Introduction 
Caulolactone A (3.3) a sesquiterpenoid from the stalk of the plant Asarum 
caulescens, a species native to Mt. Khotsu, Japan, was isolated by Iwata and co-
workers.376 There is no reported biological data for caulolactone A due to insufficient 
quantities obtained upon isolation. However, many natural products isolated from the 
same species as caulolactone A are known to display a wide array of biological 
activities, including anti-hepatotoxic activity (clearing the liver of toxins), potent 
vasorelaxant activity (widening of the blood vessels), anti-ulcer effects, anti-
inflammatory, anti-emetic, and antipyretic activity.377 
The structure of caulolactone A was determined by NMR analysis and features a 
cis-fused bicyclic core containing an α,β-unsaturated δ-lactone fused to a tetrasubstituted 
cyclopentane (Figure 29) The cyclopentane ring has three contiguous stereogenic 
centers, one of them being a quaternary carbon center. As part of a unified strategy to 
rapidly access bioactive natural products, we identified a common tetrasubstituted 
cyclopentane. This common core (as shown in blue, Figure 29) could be applied to a 
wide array of natural products including zedoarondiol,378 omphadiol,304 chinesin I,379 
cyclic lycopene deriveratives, tomoenone F, pyxidatol,380 aromadendrane, 
pycnanthquinone C,381 and (+)-4-epi-alismoxide.382 
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Figure 29. Unified approach to cyclopentane natural products. 
 
 
Our approach to caulolactone A was premised on employing β-lactone 3.2 (this 
structure was first mentioned in Chapter II and is fully characterized as structure 2.2a see 
Appendix B), accessible via a practical multi-gram (>13 g scale) NCAL process of keto-
acids, as a key intermediate to the substituted cyclopentane core. The bicyclic β-lactone 
moiety served as a versatile starting point for the synthesis of several terpenoids 
demonstrating its utility by the concise syntheses of caulolactone A and omphadiol.304 
Reporting herein the first synthesis of caulolactone A as part of a unified strategy to 
bioactive terpene and sequiterpenoids natural products. 
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3.2 Retrosynthetic Plan 
From a retrosynthetic standpoint we envisioned the final C-C bond formed via α-
alkylation of an extended enolate (3.4, Scheme 3.1), which in turn would be derived 
from esterification of 1,3-diol 3.5 with 3,3-dimethylacrylate. Subsequently intermediate 
3.5 is a reduced form of the key intermediate β-lactone 3.2. As mentioned previously the 
β-lactone was synthesized from a highly diastereoselective NCAL of keto-acid 3.6 on 
gram scale (Chapter I) with (R)-carvone serving as chiral pool to establish absolute and 
relative stereochemistry.  
Scheme 3.1 
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3.3 Route to (R)-Carvone β-Lactone 
Requiring large quantities of β-lactone 3.2 warranted exploration of robust 
economical methods for accessing known keto-acid 3.6 on gram scale,383 initial 
conditions employed Me-Cu catalyzed conjugate reduction and silylation to deliver silyl 
enol ether 3.7 as reported by Saegusa384 (Scheme 3.2). Ensuing ozonolysis in the 
presence of diazo indicator sudan red provided the desired intermediate 3.6 in relatively 
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good yields however both the sensitivity of the silyl enol ether and selectivity of 
oxidative cleavage providing highly variable yields. While an intermediate Rubottom 
oxidation and periodic acid oxidative cleavage circumvented problems with ozonolysis 
formation of the silyl enol ether was still problematic. Conjugate reduction and enolate 
trapping with TMSCl proved to be unfruitful to intermediate 3.7, delivering a mixture of 
1,2- and 1,4-reduction.385 The stability of α-hydroxy ketone 3.8 and ease of conversion 
to the desired keto-acid lead us to a Mn(II)-mediated oxidation of carvone reported by 
Magnus.386 Even though the procedure was limited to ~5 gram scale (after which 
diminished yields were observed) it was experimentally facile and negated the very 
tedious conditions to silyl enol ether 3.7.  
Scheme 3.2 
O
CuI, MeLi, HMPA,
DIBAl-H, TMSCl, NEt3
THF, -10o to -50 oC to 20 oC
OTMS
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MeOH, DMS, -78 oC
O
OH
O
O
OH
m-CPBA
CH2Cl2, 20 oC
H5IO6, Et2O, 3 h, 20o C
(88-95% Hydrosilylation, Rubottom 
[O] C-C cleavage up to 15 g)
Mn(dmp)3 (4 mol%)
 PhSiH3, O2,  0 oC to 20 oC
 O.2 M  MeOH
65% over 2 steps, 9 g
5 g scale 65 - 85%
43% to 96%, up to 15 g
Mn
O
O O
O
O
O
Mn(dpm)3 90 - 95 %
Rubottom [O]
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3.6
3.7
3.1
(R)-carvone
3.8
 
The Mn(III)-mediated oxidation and oxidative cleavage with periodic acid provided 
keto-acid 3.6 in reliable yields. Using sub stoichiometric amounts of TsCl for the NCAL 
reaction permitted isolation of intermediate 3.2 without formal purification simply a 
short passage through a silica gel plug removed the solids and polar byproducts (Scheme 
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3.3). Subsequent reduction with DIBAlH proceeded in nearly quantitative yield to 1,3-
diol 3.5.  
 
Scheme 3.3 
O O
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i-Pr2NEt (4.0 equiv)
O
Me
H O DIBAlH, CH2Cl2
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2) H5IO6, Et2O
    25 oC, 15 min.
1) Mn(dmp)3 (4 mol%)
    PhSiH3, O2 (1 atm)
    MeOH, 0 oC
(2 steps 80%)
(99%) K2CO3 (4.0 equiv)
CH2Cl2, 25 oC
OH
Me
H OH
3.1
 (R)-carvone
3.6
3.2 3.5  
3.4. Studies to Bicyclic Core 
Tosylation of the primary alcohol 3.5 proceeded well en route to intramolecular 
alkylation via dienolate 3.12 and subsequent base-induced olefin isomerization to the 
natural product (Scheme 3.4). While efforts directed towards installing the remaining 
carbons by acylation with β-dimethylacroyl chloride (3.10, R = Cl) proved challenging. 
All attempts to acylate utilizing standard coupling conditions with the acid derivative of 
3.10 (R = OH) met only failure. Extensive efforts to acylate the tertiary alcohol with the 
chloride387 or anhydride388 derivative 3.10 resulted in various elimination products or 
decomposition. 
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Owing to steric factors and the electronics of the 3,3-disubstituted acrylate 
acylation with acetic anhydride only provided possible when utilizing acetic anhydride 
as a solvent (Scheme 3.5). After obtaining the acylated tertiary alcohol 3.14 it was 
necessary to cyclize to the desired ring system. All attempts to then cyclize via tosylate 
displacement with an acetate enolate (LiHMDS, LDA, t-BuOK, etc.) resulted in 
recovery of starting material or decomposition.  
Scheme 3.5. 
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3.5. Completion of (+)-Caulolactone A 
 Alternatively Parihk-Doering oxidation296 of 3.5 and immediate Wittig 
olefination proved successful for installing the necessary carbons to form the γ-lactone 
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3.16 (Scheme 3.6). Reduction to the saturated ester was then carried out using 
magnesium, in which case some of the resulting alcohol cyclized to 3.15. Cyclization to 
the biscyclic δ-lactone could be pushed to higher conversion under reflux with PPTS. 
The final steps involved a two-step aldol condensation with acetone to yield 
caulolactone A in 10 steps and 26% overall yield.   
Scheme 3.6 
1) SO3•Py, DMSO, 
NEt3, 25 oC, 15 min
2)              , CH2Cl2, 25 oC
 8 h (88%, 2 steps)
Ph3P
MeO
O OH
Me
H
O
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1) Mg, MeOH,25 oC, 8 h
O
Me
H
O
1)LDA (3.0 equiv), THF, 2 h then
 (CH3)2O (12 equiv) 2 h, -78 oC
2) MsCl, NEt3, CH2Cl2 0 oC to 25 oC
O
Me
H
O
2) PPTS, C6H6, 80 oC, 2 h
(65%, 2 steps)
(77%, 2 steps)
3.15
3.5
3.16
3.3
caulolactone A  
This concise synthesis made use of natural product (R)-carvone for readily available 
starting material and served to establish the absolute stereochemistry of the molecule.  
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CHAPTER IV                                                                                              
DEVELOPMENT AND APPLICATION OF A NUCLEOPHILE-CATALYZED 
MICHAEL ALDOL-β-LACTONIZATION (NCMAL) PROCESS FOR PRACTICAL 
CYCLOPENTANE SYNTHESIS∗ 
4.1. Introduction 
Synthetic transformations that rapidly assemble complexity are actively being 
pursued given the importance of these processes for improvements in synthetic 
efficiency. As such organocascade reactions have emerged as some of the most powerful 
strategies to rapidly construct structural complexity389 Numerous are the conventional 
methods for constructing cyclohexanes including Robinson annulation,390 cationic 
polyene olefin cyclization,391 and the venerable Diels-Alder.392 Whereas the Pauson-
Khand reaction,393 trimethylenemethane [3+2] cycloaddition,394 photochemical olefin-
arene cycloaddition,395 and the Nazarov cyclization,396 used for cyclopentane synthesis 
suffer from the requirement for specialized substrates or have limited enantioselective 
modifications. Owing to the structural diversity and complexity of substituted 
cyclopentanes in pharmaceutical agents and bioactive natural products397 (A, Figure 30) 
                                                
∗Reprinted with permission from “Rapid Assembly of Complex Cyclopentanes 
Employing Chiral, α,β-Unsaturated Acylammonium Intermediates” by Gang Liu, 
Morgan E. Shirley, Khoi N. Van, Rae Lynn McFarlin, and  Daniel Romo, 2013. Nature 
Chem. 5, 1049-1057, Copyright 2013 by Macmillan Publishers Limited. 
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we aimed to develop a more direct and general way for forming this motif. We recently 
disclosed a nucleophile-catalyzed Michael aldol β-lactonization (NCMAL) delivering a 
diverse array of β-lactone-fused cyclopentane scaffolds (B, Figure 30) a structural motif 
found in the natural products spongiolactone, vibralactone A, and chinensin II. 
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Figure 30. Natural products accessible via NCMAL methodology. 
 
 
While our work with the NCAL has proved robust for generating cyclopentane fused β-
lactones, the requirement for tethered keto-acids often hampers the utility, as the NCAL 
precursors require several steps and can be difficult themselves to synthesize (Chapter 
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II). Prompted by our continued interest in ammonium enolate we sought to improve the 
synthetic efficiency of complex cyclopentanes by developing a tandem organocascade 
process from readily or commercially available reagents. 
  In the context of nucleophilic chiral amine catalysis 4.4-4.6 are the reported 
reactive intermediates for asymmetric bond-forming events (Scheme 4.1).285 Chiral 
acylammonium intermediate 4.4, possessing an electrophilic site has been used for 
kinetic resolution of alcohols.398 The versatile chiral ammonium enolate, 4.5 has found  
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widespread applications, notably building on Wynberg’s aldol-β-lactonization.99 While 
the most recently reported intermediate, ammonium dienolate 4.6, has been reported in 
[4+2] cycloadditions.399 Building on our previously described aldol-β-lactonization 
process (Chapter I and II) and interests in ammonium enolate chemistry we sought to 
exploit the full reaction potential of chiral α,β,-unsaturated acylammonium intermediate 
4.3 envisioning that the three disparate reactive sites could be sequentially revealed to 
induce tandem bond-forming events (Scheme 4.1) Fu reported the seminal application of 
chiral acylammonium 4.3, in a single example providing a net [3+2] cycloaddition of a 
silylated indene and acyl unsaturated acyl fluoride.400 The only other report of this 
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intermediate was by the Smith group (while we were in manuscript preparation), 
employing unsaturated, mixed anhydrides and 1,3-dicarbonyl compounds to enol 
lactones by way of a tandem Michael-enol-lactonization process.401 With only two 
reports of unsaturated chiral acylammonium 4.3 both of which overlooked the full 
potential of the latent, triple reactivity for multiple bond forming events we developed a 
novel organocascade process involving a nucleophile-catalyzed, Michael-aldol-β- 
lactonization (NCMAL) sequence that rapidly generates stereochemically complex 
cyclopentanes from commodity unsaturated acid chlorides including both fused and 
bridged cyclopentyl systems (B, Figure 30).  
 Building on our previously described aldol-β-lactonization process (Chapter I and 
II) we pioneered a catalytic, asymmetric activation of acid chlorides through use of a a 
chiral amine nucleophile (NR3*). Seeking to exploit the full reaction potential of chiral 
α,β,-unsaturated acylammonium intermediate 4.3 we envisioned three disparate reactive 
sites that could be sequentially revealed to induce tandem bond-forming events (Scheme 
4.2). Following Michael addition by an appropriate nucleophile (Nuc1), a chiral 
ammonium enolate 4.7 is revealed enabling α-substitution with a tethered electrophile 
(E) to deliver the acylammonium 4.8. While a second nucleophilic addition to the 
resulting acyl ammonium (4.8) regenerates the amine catalyst effectively stitching three 
bonds together in a tandem process. 
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The envisioned catalytic cycle for the organocascade process would be initiated by an 
intermolecular Michael of a tethered, triply-reactive reagent 4.11, such as anionic ketone 
4.10, to the α,β-unsaturated acyl ammonium intermediate 4.3. The key, chiral 
intermediate 4.3 would be derived from simple substitution of a chiral amine catalyst 
(NR3) 4.2 with an unsaturated acid chloride 4.1 (Scheme 4.3). Generation of the versatile 
ammonium enolate 12 engages with the pendant ketone in an intramolecular aldol-β-
lactonization templated by a Li(I) cation to deliver a stereoselective aldol reaction 
leading to formation of cyclopentane 4.13. Based on our previous studies, high anti 
diastereoselectivity was anticipated for β-substituted acid chlorides since this alleviates 
developing A1,3-strain during the aldol-lactonization step.  
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4.2 Condition Optimization  
 Our initial reaction conditions involved generation of the malonate anion with 
various Brønsted bases in the presence of a nucleophilic catalyst followed by slow 
addition of the acid chloride to the mixture. Use of the nucleophile alone or the strong 
Brønsted base, DBU (1,8- diazabicyclo[5.4.0]undec-7-ene) did not provide the desired 
bicyclic-β-lactone 4.14a (Table 4, entries 1, 2). While combined Lewis acid Lewis base 
conditions (DBU and LiClO4, entry 3) afforded the desired product in 68% yield, this 
was not general for all substrates, notably cyano-esters (provided less than 40% 
conversion albeit optimization). Employing LDA or LiHMDS or the ‘troublesome’ 
substrates (compounds 4.10f-i) drastically enhanced the yield. The stronger lithium 
bases lead to further improvement in yields (entries 4-6) up to 75% yield, with weakly 
coordinating counter ions (Na+ or K+) having an adverse effect (entries 7, 8).  
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Table 4. Optimization of the NCMAL process. 
 
entry catalyst % yield*base
DMAP1
2
3
4
DMAP
<5
<5
LiClO4 + DBU DMAP
LDA
5 tBuLi DMAP
68
73
75
6
7
LiHMDS DMAP
NaHMDS DMAP
75
DMAP
8
9
10
DMAP
23
<5
iPrMgCl DMAP
LiHMDS
11 LiHMDS 9-AJ†
75
84
77
12 LiHMDS -- <5
4-PPY
--
DBU
KHMDS
solvent
CH2Cl2
CH2Cl2
CH2Cl2
THF/CH2Cl2
THF/CH2Cl2
THF/CH2Cl2
THF/CH2Cl2
THF/CH2Cl2
THF/CH2Cl2
THF/CH2Cl2
THF/CH2Cl2
THF/CH2Cl2
*Refers to isolated yields. <5% yield indicates that !-lactone was not detected by TLC, 
1H NMR (500 MHz), or FT-IR.    † 9-azajulolidine (9-AJ). Initial reaction design and 
inception by Dr. Gang Liu, originally employing entry 3. Due to issues with these 
conditions for mixed EWD I moved to LDA/LiHMDsS  With the goal of a general 
approach subsequentconditio were screeed, ultimately revealing  finding LiHMDS to be 
most general for ensuing substrate variety.
O
MeO2C
MeO2C
O
Cl O
O
Me
H
MeO2C
MeO2C
+
20 mol% catalyst
4.10a (1.0 equiv.) 4.1a (2.0 equiv.) (±)-4.14a
DIPEA (2.0 equiv.)
 
 
 
After a brief screening of nucleophiles, including 9-azajulolidine, revealed 4-PPy and 
LiHMDS was an optimal combination for the NCMAL process (entries 10-11). As 
evidence for the requirement of the nucleophile, a control reaction without 4-PPY did 
not afford any β-lactone (entry 12).  
4.3 Substrate Scope 
 Exploring the generality an investigation of the Michael donors, bearing two 
electron with-drawing groups (Table 5, entries 1-9) with acryloyl chloride was 
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undertaken. The substrates were obtained in a single step by alkylation of the 
corresponding malonates with chloroacetone (Appendix A). As depicted in Table 5, a 
variety of keto diesters, diketones, and dinitriles (entries 1-5) participate in the NCMAL 
process to provide the desired cyclopentanes 4.14b-f 53-83% yields. When a β-keto 
ester or α-cyano esters were used as Michael donors (Table 5, entries 6-8), 
cyclopentanes 4.14g,h were obtained in 65-72% yields with poor diastereoselectivity (dr 
1-1.7:1) as expected, however inconsequential given that these diastereomers would 
ultimately converge to a single diastereomer following decarboxylation (vide infra). 
Introduction of an α-keto stereocenter, as in ketomalonate 4.10j, also led to a mixture of 
diastereomers 4.14j (dr 2:1) in 81% yield.  
Variation of the Michael acceptors through the study of a diverse array of 
commercially available α,β-unsaturated acid chlorides was undertaken next. Under the 
optimized NCMAL conditions, cyclopentanes were readily accessed bearing up to three 
contiguous stereocenters with excellent relative stereochemical control (Table 5, entries 
10-17) Aryl-substituted acid chlorides with varied electronic properties (entries 12-14) 
proceeded in 83-90% yields. Use of sorbic chloride (4.1g) provided a 64% yield of  
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Table 5. Scope of a racemic NCMAL process. 
 
entry % yield (dr)*Michael donor
(±)-4.14
Varying the Michael donor with acryloyl chloride 1a
O
O
Me
H
MeO2C
MeO2C
R
O
O
Me
H
MeO2C
MeO2C
Me
O
O
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Me
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MeO2C
O
O
Me
Me
MeO2C
MeO2C
Me
Varying the Michael acceptor with acetodimethyl malonate 10a*,†
15
(±)-4.14p
(±)-4.14q
(±)-4.14r
bicyclic-b-lactone
O
ClR1
R2
1 (1.3 equiv.)
entry % yield (dr)*,†,!Michael acceptor bicyclic-b-lactone
*All yields refer to isolated yields. † Diasteromeric ratio determined by 1H NMR. ‡ Relative stereochemistry verified by X-ray analysis. 
" Reaction performed by Rae Lynn McFarlin.   !Reaction  performed by Dr Gang Liu.
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 cyclopentane 4.14p with the installation of an alkene moiety on the bicyclic providing a 
robust functional handle for subsequent manipulations and diversification (4.1g, entry 
15). An α-substituted acid chloride 4.1h (entry 16) was also reactive under standard 
conditions and afforded cyclopentane 4.14q in 78% yield bearing two contiguous 
quaternary stereocenters, one of which is an all carbon quaternary center. Finally, a 
highly congested cyclopentane 4.14r was accessible with α,β-dimethyl acryloyl chloride 
4.1i (entry 17) in 60% yield as a single diastereomer. 
 In line with our previous findings of chiral isothiourea, homobenzotetramisole 
(HBTM) developed by Birman, proved to be the optimal catalyst to promote an 
enantioselective NCMAL (Table 6). Employing the aforementioned optimized 
conditions for the racemic NCMAL, HBTM uniformly delivered the cyclopentanes (+)-
4.14a, (+)-4.14c, and (+)-4.14d in 59-74% yields and 93-96% ee (Table 4, entries 1-4). 
The bis-allyl malonate ester 4.10d was of particular interest for enabling further 
functionalization or removal of an electron-withdrawing group from the cyclopentane 
adducts (+)-4.14c and (+)-4.14d through mild Pd(0)-catalyzed decarboxylative 
transformations (entry 3). The absolute configuration of β-lactone (+)-4.14a was 
confirmed by X-ray analysis of a derivative following ring opening with p- 
bromobenzylamine (Appendix A). The diketone substrate 4.10e was also well tolerated 
in the asymmetric process, leading to diketo cyclopentanes (+)-4.14e in 61% yield and 
95% ee (Table 6, entry 5). The practicality of the NCMAL process was demonstrated by 
a gram-scale reaction using dimethyl keto malonate 10a as Michael donor delivering 
(+)-4.14a with comparable results (74% yield, 93% ee, Table 6, entry 2). 
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Table 6. Catalytic, enantioselective, nucleophile catalyzed, Michael aldol-β-
lactonization. 
 
0 to 23 oC
6-24 h
(+)- or (–)-4.14
EWG
EWG
O
1.0 equiv.
LiHMDS
THF
20 mol%
(S)-HBTM
4.10 (1.0 equiv)
DIPEA (1.0 equiv.)
CH2Cl2, 0 oC
10 min
i) ii) iii)
80 (>19:1)
O
Cl
O
Cl
O
O
Me
H
MeO2C
MeO2C
Me
O
O
Me
H
MeO2C
MeO2C
Ph
O
Cl
O
O
Me
Me
MeO2C
MeO2C
O
Cl
O
O
Me
H
EWG
EWG
6
9
10!
4.1b
4.1d
4.1g
4.1h
Me
80 (>19:1)
78 (>19:1)
11
12
13
99
90
62 (>19:1)
60 (>19:1)
54 (>19:1)
80 (>19:1)
94
99
99
94
99
(+)-4.14k
(+)-4.14m
(+)-4.14m
(+)-4.14p§
(-)-4.14pò
(+)-4.14s
(+)-4.14q
N
S N Ph
4.10a (CO2Me)
4.10a 
4.10c (CO2allyl)
4.10d (CO2Bn)
4.10e (C(O)Me)
 % yield (dr)*
72(>19:1)
74(>19:1)
74(>19:1)
59(>19:1)
61(>19:1)
O
Cl O
O
Me
H
EWG
EWG
(+)-4.14a§
(+)-4.14a
(+)-4.14c
(+)-4.14d
(+)-4.14e
4.10a
4.10a
4.10c
4.10a
1†,"
2†,‡,#
3†
4†
5†
4.1a
entry
Michael
donor (EWG) acid chloride bicyclic-$-lactone % ee
97
93
95
98
95
4.10a
14
(S)-HBTM (4.2b)
O
O
Me
H
MeO2C
MeO2C
EtO2C
95 (>19:1)
90 (>19:1)
O
ClEtO2C
7†,#
8†,#
4.1c
90
89
(+)-4.14l
(-)-14.4lò
4.10a
4.10a
O
ClR1
R2
O
O
Me
R2
EWG
EWG
R1
1 (1.3 equiv.)
*All yields refer to isolated yields, enantiomeric excess was determined by chiral GC or HPLC (See
Appendix), diastereomeric ratios were determined by 1H NMR (500 MHz), and addition of acid chloride
was over a 2 h period.  Reaction times varied from 6 to 24 h (see Supplementary for reaction details). †Acid 
chlorides were added over 4 min. §Absolute stereochemistry was confirmed by X-ray analysis of (+)-14p
and a derivative of (+)-14a and others assigned by analogy. ‡Reaction was performed on gram scale. !5
mol% (S)-HBTM was employed. ò (R)-HBTM was employed as catalyst.!Reaction initially run by Dr. Gang
Liu, and replicatied by Rae Lynn McFarlin and Morgan E. Shirley. #Reaction by Rae Lynn Mcfarlin.
4.10a
4.10a
-78 to  0 oC
10 min
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To probe whether the initial Michael addition could proceed in an enantioselective 
manner, we next studied β-substituted acid chlorides. Indeed, use of (S)-HBTM with 
acid chlorides 4.1b-c and 4.1d,g gave cyclopentanes (+)-4.14k-l and (+)-4.14m,p in 89-
99% ee as single diastereomers in 62-95% yields (Table 6, entries 6-12) including those 
bearing ethyl ester and alkenyl substituents suitable for further functionalization. The 
relative and absolute stereochemistry of the alkenyl substituted cyclopentane (+)-4.14p 
was confirmed by X-ray analysis (Appendix A). When α-substituted acid chlorides were 
studied, an important difference in reaction outcomes noted under standard conditions. 
Optimization studies revealed that extending the addition time of the acid chloride once 
again led to higher conversion and enantioselectivity. A competitive, racemic 
background pathway with several acid chlorides revealed a racemic background reaction 
with varying rates owing to the unique reactivity behavior of the Michael accepters with 
the enantioselective NCMAL (Table 7). 
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Table 7. Competitive NCMAL reactions. 
 
MeO2C
MeO2C
O
O
O
Me
R2
MeO2C
MeO2C
+
20 mol% catalyst
 4.10a
(1.0 equiv.)
4.1
 (2.0 equiv.)
DIPEA (1.0 equiv)
O
ClR1
R2
R1
4.14
entry add. time eecatalyst
1
2
3
 ---
(S)-HBTM
(S)-HBTM
---
4 min
2 h
80
78
80
0
30
99
O
Cl
O
Cl
O
Cl
Me
---
4 min
2  h
10 h
(S)-HBTM
(S)-HBTM
6
7
8
9
4
5
4 min
2  h
80
93
60
80
43
72
80
81
0
80
99
95
---
(S)-HBTM
(S)-HBTM
(S)-HBTM
yield %
4.1h
4.1d
4.1b
acid chloride (4.1)
 
 
 
4.4. Applications and Derivatization  
To demonstrate the utility of the described organocascade process for ring 
annulation leading to more complex molecular architectures, a collection of polycyclic 
carbocycles with fused or bridged topology were targeted using monocyclic Michael 
donors. Cyclopentanone 4.10k was readily combined with acryloyl chloride (4.1a) to 
give the tricyclic 5,5,4-bicyclic system 4.14t as a single diastereomer in 91% yield 
(Figure 30). In contrast, cyclohexanone 4.10l afforded the corresponding tricyclic 
products 4.14u in 70% yield as a 1:1 mixture of diastereomers likely owing to the lower 
energy difference between cis- and trans-fused 5,6-bicyclic systems. Cyclohexanedione 
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4.10m also participated as a Michael donor with acryloyl chloride (4.1a) to give the 
tricyclic cyclopentane 4.14v possessing a bridged topology, albeit in 25% yield (Figure 
30). The relative stereochemistry was confirmed by single crystal X-ray analysis and the 
bridged cyclopentane in 4.14v is reminiscent of one substructure of the gibberellin 
family of terpenoids. The tetralone-derived malonate 4.10n also participated in the 
NCMAL, however the presumed intermediate β-lactone 4.15, possessing a benzylic C-O 
bond, underwent facile decarboxylation to deliver the cyclopentene 4.16. Following 
hydrogenation and Krapcho decarboxylation, the monoester 4.17 was obtained, 
demonstrating removal of an activating group in the Michael donor. Furthermore, the 
monoester 4.17 resembles a previously described steroidal intermediate (Figure 30). The 
Pd(0)-mediated decarboxylation of the allyl ester substituted cyclopentane 14i was 
explored. Mild conditions were identified that led to reductive decarboxylation of the 
mixture of diastereomeric cyclopentanes 4.14i at 77 oC which importantly left the β- 
lactone intact and converged to a single diastereomer of the cyano-substituted 
cyclopentane 4.14x. The relative stereochemistry of 4.14x was verified by X-ray 
analysis (inset, Figure 31; Appendix A). To the best of our knowledge, this is the first 
example of ester decarboxylation in the presence of a β-lactone. Extension of the 
NCMAL from ketone substrates to the corresponding aldehyde malonates too proved 
fruitful. 
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O
O
Me
H
NC
allylO2C O
O
Me
NC
(±)-4.14i
H
Pd2(dba)3-CHCl3 (9.3 mol%)
PPh3 (4.6 mol%, CH3CN
77o C, 23 h
(75%, >19:1 dr)
EtO2C
EtO2C
O
H
O
H
EtO2C
EtO2C
4.10o
(±)-4.14y 
(60%)
O
EtO2C
EtO2C
O
H
Li
O
O
H
CO2Me
CO2Me
(±)-4.14t: (91%, dr >19:1)(±)-4.10k, (n = 1)
(±)-4.10l, (n = 2)
H
EtO2C
O
H
O
OEt
Li
(±)-4.14x
4.18 4.19
12 h
H
O
MeO2C
O O
H
O
OMe
O
O
(±)-10m (±)-14v (25%, dr >19:1)
O
Me
O
CO2Me
CO2Me
O
RO
H
(±)-4.14z
CH2Cl2/THF, 23 oC
(20%, dr >19:1)
MeO2C
MeO2C
O
4.10a 
(1.0 equiv)
1.0 equiv
LiHMDS, THF
-78 to 0 oC
10 min
4.20a:R = H
4.20b: R = Ts
TsCl (2.10 equiv)
LiHMDS (2.05 equiv)
THF, 23 oC, 30 min
O CO2Me
CO2Me
(54%)
(±)-4.10n (±)-4.16
CO2Me
CO2MeO
O
H
20 mol% 4.2a
24 h
4.1a (1.3 equiv.)
20 mol% 4.2a
8 h
4.1a (1.3 equiv.)†
20 mol% 4.2a
4.1a (1.3 equiv.)
4.1a (1.3 equiv.)
20 mol% 4.2a
(2.0 equiv)
(±)-4.14u:(70%, dr 1:1)
O
O
H
CO2Me
CO2Me
H
CO2Me
CO2Me
H
(±)-4.15
1) H2, Pd/C, MeOH
2) LiCI, DMSO, 
      H2O, mW
(±)-4.17
CO2Me
H
H
4.2a (1.1 equiv.)
CO2Me
CO2Me
(70%, dr 1:1)
(dr 1.16:1)
n
1.0 equiv
LiHMDS, THF
-78 to 0 oC
10 min
† Reaction complete by Dr. Gang Liu
O
 
Figure 31. Extensions of the NCMAL process. 
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 We built our enantioselective model stemming from a report by the Smith group of 
an X-ray crystal structure of an HBTM-derived, unsaturated acylammonium salt 
supporting an interaction between the acylammonium oxygen and the sulfur atom of the 
isothiourea first proposed by Birman for these catalysts (Figure 32) The observed facial 
selectivity during the Michael addition this interaction and the half-chair conformation 
of the pyrimidine ring enforced by the planarity of the C-N-C moiety. These factors 
place the phenyl ring in a pseudoaxial orientation effectively blocking the re face of the 
unsaturated acylammonium with (S)-HBTM. The high diastereoselectivity observed 
during the aldo step derives from minimization of A1,3-strain described previously. 
 
MeO2C
MeO2C
O
NR3
O
MeMe
H Li
Cl
4.12
alleviates
A1,3-strain
MeO2C
MeO2C
NR3O
Me
Me
H
Li
Cl
O
A1,3-strain
4.12'
aldol-!-
lactonization
Michael
addition
MeO2C
MeO2C
O
MeMe
O
4.14 
(observed product)
4.14'
MeO2C
MeO2C
O
Me
Me
H
O
H
Cl
O O
MeO
OMe
Li
Me
O
H
HnO ® s
*C-S
 
Figure 32. Proposed transition state arrangements for enantioselective NCMAL. 
 
 
  The complexity-generating, nucleophile-catalyzed, Michael-aldol-β-
lactonization process described herein delivers high synthetic efficiency for complex 
cyclopentane synthesis by formation of three new bonds, up to three stereogenic centers, 
and two rings in a single operation from simple starting materials. Furthermore, the 
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simple yet powerful asymmetric activation mode of commercially available, unsaturated 
acid chlorides utilized to its full potential for the first time by reaction at all three 
positions, provides a new paradigm for the design of additional organocascade 
processes. Further explorations are currently underway discerning g the unique and 
selective nature of chiral α,β-unsaturated acyl ammoniums for multiple bond forming 
events.  
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CHAPTER V                                                                                                
CONCLUSION 
 
 A practical, diastereoselective nucleophile catalyzed aldol-lactonization (NCAL) 
process has been developed for accessing bicyclic β-lactones from keto-acid substrates 
as a C-C and C-O bond forming strategy for the assembly of complex natural products. 
Reaction rates were increased and yields improved by addition of K2CO3 as a shuttle 
base. This new and improved protocol allows for facile construction of substituted 
bicyclic β-lactones from commercially available and inexpensive acid-activating agent 
TsCl and nucleophilic promoter DMAP (Scheme 5.1), with β-substituted acids afforded 
products as a single diastereomer.  
Scheme 5.1 
O
H
Me
O
H
H
N
O
N
O
Me
H
TsCl, DMAP, DIPEA,
K2CO3, CH2Cl2
(86%, dr > 19:1)
H
H
N
O
N
O
Me
H
O
OH
O
 
 A concise synthesis of caulolactone A was reported that employs the 
aforementioned NCAL conditions for the generation of a versatile bicyclic β-lactone. 
The synthesis of caulolactone A was completed in 10 steps with a 26% overall yield void 
of protecting groups relying on a highly diastereoselective bis-cyclization with a carvone 
   175 
derived keto-acid (Scheme 5.2). The key aldol lactonization provides a tetrasubstituted 
cyclopentane core that is present in a diverse array of bioactive natural products.  
                                                  Scheme 5.2 
O
OH
O
OH
OH
Me
Ph3P
MeO
O
O
Me
H O
OH
Me
H O
OMe
O
Me
H
O
O
Me
H
O
caulolactone A
(77% 2 steps)
H
 DIBAL, CH2Cl2
 0 oC
14
single diastereomer
 TsCl, DMAP, DIPEA
K2CO3, CH2Cl2
(76-83%)
(99%)
1) SO3·Py, DMSO, 
NEt3  25 oC, 15 min
2)                     ,CH2Cl2, 25 oC
(88% 2 steps)
1) Mgo, MeOH ,25 oC, 8h
2) PPTS, C6H6, 80 oC, 2h
(65% 2 steps)
i. LDA, THF, -78 oC, 2h 
then (CH3)2CO; ii. MsCl, 
NEt3, CH2Cl2 
0 oC to 25 o
i. LDA, THF, -78 oC, 2h 
then paraformaldehyde; 
ii.  MsCl, NEt3, CH2Cl2 
0 oC to 25 oC
or
 
As our interest in β-lactones and more recently our desire for developing 
efficient methods to complex cyclopentane scaffolds, the nucleophile-catalyzed Michael-
aldol β-lactonization was disclosed. This highly efficient bonding forming process was 
used to construct two C-C bonds, one C-O bond, and two rings via an ammonium 
enolate species chemoselectively formed from chiral a-β-unsaturated acyl ammoniums 
(Scheme 5.3). Subsequent explorations revealed the potential to make polycyclic bridged 
and fused scaffolds in a single step from commodity chemicals with high levels of 
enantio- and diastereocontrol. 
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Scheme 5.3 
 
O
EWG
EWG
O
Cl O
O
Me
R2
EWG
EWG
•2 C-C bonds
•1 C-O bond
•2 rings
•2-4 stereocenters
readily available reagents
+
R1
R1
* *
**
highly functionalized and
stereochemically defined cyclopentanes
R2
 
 
Applications of this methodology and extensions to accessing natural products warrants 
itself for further explorations.  
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APPENDIX A: ABBREVIATIONS 
4-PPY 4-pyrrolidinopyridine 
AAC acyl halide-aldehyde cyclocondensation 
AcCl acetyl chloride 
AcOH acetic acid 
AcQd O-acetyl quinidine 
AcQn O-acetyl quinine 
Boc di-tert-butyl dicarbonate 
BTF trifluoromethylbenzene 
CAN ceric ammonium nitrate 
Cbz carboxybenzyl 
CDI N,N’-carbonyldiimidazole 
CGA carboxyl group activation  
CIP 2-chloro-1,3-dimethylimidazolidium hexafluorophosphate 
CITPP meso-tetra(4-Clphenyl)porphyrinato 
CSD Cambridge Structural Database 
DBPO di-tert-butylperoxyoxalate  
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC 1,3-dicyclohexylcarbodiimide 
DDQ 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DEAD diethyl azodicarboxylate 
DET diethyl tartrate 
(DHQD)2PHAL hydroquinidine 1,4-phthalazinediyl diether 
DIAD diisopropyl azodicarboxylate 
DIBAlH diisobutylaluminium hydride 
DIPEA N,N-diisopropylethylamine 
DMAP 4-(dimethylamino)pyridine 
DMDO dimethyldioxirane 
DME dimethyl ether 
DMP Dess-Martin periodinane 
DMS dimethyl sulfide 
DMSO dimethyl sulfoxide 
dr diastereomeric ratio 
DTBP 2,6-di-tert-butylpyridine 
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDCI see EDC 
ee enantiomeric excess 
Et ethyl 
EtOAc ethyl acetate 
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FDA Food and Drug Adminstration 
Fm fluorenylmethyl 
GDH-103 glucose dehydrogenase 103 
Grubbs II 2nd generation Hoveyda-Grubbs catalyst 
HATU 
 
1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b] 
pyridinium 3-oxid hexafluorophosphate 
HBTM homobenzotetranisole 
HGA hydroxy group activation 
HMPA hexamethylphosphoramide 
HOAc acetic acid 
HOAT 1-hydroxy-7-azabenzotriazole 
HOBT hydroxybenzotriazole 
HOMO highest occupied molecular orbital 
HSAB Hard Soft Acid Base 
IMes bis(1,3-(2,4,6-trimethylphenyl)imidazol-2-ylidene) 
IND investigational new drug 
KHMDS potassium bis(trimethylsilyl)amide 
LDA lithium diisopropylamide 
leu leucine  
LiHMDS lithium bis(trimethylsilyl)amide 
LUMO lowest unoccupied molecular orbital 
Lyso-PC 1-palmitoyl-sn-glycero-3-phosphatidylcholine 
MABR methylaluminum bis(4-bromo-2,6-di-t-butylphenoxide) 
mcPBA m-chloroperoxybenzoic Acid 
Me methyl 
Mes mesitylene 
MNBA 2-methyl-6-nitrobenzoic anhydride 
MO molecular orbitals 
MPLC medium pressure liquid chromatography  
MsCl methanesulfonyl chloride 
(-)-MTPACl 
 
Mosher's acid chloride or (2R)-3,3,3-Trifluoro-2-methoxy- 
2-phenylpropanoyl chloride 
Mukaiyama's 
reagent 2-chloro-1-methylpyridinium iodide 
NAD+ nicotinamide adenine dinucleotide 
NBS N-bromosuccinimide 
NCAL nucleophile catalyzed aldol-lactonization 
NHC N-heterocyclic carbene 
o-Ns   o-nitrobenzenesulfonyl 
PyBOP 
 
benzo-triazol-1-yloxytripyrrolidinophosphonium  
hexafluorophosphate  
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SEM 2-trimethylsilylethyoxymethyl 
TBAF tetra-n-butylammonium fluoride 
TBDPS  (tert-butyldiphenylsilyl) 
TBSCl tert-butyldimethylsilyl chloride 
TBSOTf tert-butyldimethylsilyl trifluoromethanesulfonate 
TEMPO (2,2,6,6-tetramethylpiperidin-1-yl)oxy 
Teoc 2-(trimethylsilyl)ethyl carbonate 
TESCl chlorotriethylsilane 
Tf triflate or trifluoromethanesulfonate 
Tf2O trifluoromethanesulfonic anhydride 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TIPS triisopropylsilyl 
TMP 2,2,6,6-tetramethylpiperidine 
TMSOTf trimethylsilyl trifluoromethanesulfonate 
TMSQd trimethylsilyl quinidine 
TMSQn trimethylsilyl quinine 
Tr trityl or triphenylmethyl 
Ts tosyl or toluenesulfonyl 
TsCl p-toluenesulfonyl chloride 
TsOH p-toluenesulfonic acid 
   216 
APPENDIX B: EXPERIMENTAL AND SPECTRAL DATA 
General Procedures: 
All non-aqueous reactions were performed under a nitrogen atmosphere in oven-
dried glassware. Dichloromethane (CH2Cl2) was dried by passing through activated 
molecular sieves or alumina (solvent purification system). Tetrahydrofuran (THF) was 
distilled over sodium and benzophenone. N’N’-Diisopropylethylamine (DIPEA) was 
distilled from potassium hydroxide prior to use. Other solvents and reagents were used 
as received from commercially available sources. Deuterated solvents were purchased 
from either Aldrich or Cambridge Isotopes and used as received. 1H NMR spectra were 
measured at 500 MHz and 300 MHz and referenced relative to residual chloroform (7.26 
ppm) or benzene (7.16 ppm) and were reported in parts per million. Coupling constants 
(J) were reported in Hertz (Hz), with multiplicity reported following usual convention: s, 
singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; ddd, doublet of doublet 
of doublets; dddd, doublet of doublet of doublet of doublets; dt, doublet of triplets; dq, 
doublet of quartets; ddq, doublet of doublet of quartets; ABq, AB quartet; m, multiplet; 
bs, broad singlet (prefix app indicates ‘apparent’). 13C NMR spectra were measured at 
125 MHz and 75 MHz and referenced relative to residual chloroform (77.23 ppm) or 
benzene (128.06 ppm) and were reported in parts per million (ppm). Flash column 
chromatography was performed with 60Å Silica Gel (230-400 mesh) as stationary phase 
using a gradient solvent system or on an automated flash chromatography system 
(EtOAc/hexanes as eluent unless indicated otherwise). High resolution mass spectra 
(ESI) were obtained through the Laboratory for Biological Mass Spectrometry (Texas 
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A&M University). Thin Layer Chromatography (TLC) was performed using glass-
backed silica gel F254 (Silicycle, 250-µm thickness). Visualization of developed plates 
was performed by fluorescence quenching or by staining with phosphomolybdic acid 
(PMA), potassium permanganate (KMnO4), p-anisaldehyde or cerium sulfate. Fourier 
Transform Infrared (FTIR) spectra were recorded as thin films on NaCl plates. Optical 
rotations were recorded on a polarimeter at 589 nm employing a 25-mm cell. High 
Performance Liquid Chromatography (HPLC) was performed using a chromatographic 
system using various chiral columns (25 cm) as noted. Gas Chromatography (GC) was 
performed on a gas chromatographic system using a chiral column as noted. X-ray 
diffraction was obtained by the X-ray Diffraction Laboratory at Texas A&M University. 
Hazard Warning. Ozonides produced from the oxidative cleavage were reduced using 
excess dimethyl sulfide. Stirring for at least 9 h at 23 °C prior to workup ensured 
complete ozonide reduction; however, an ozonide test is recommended. (S)-(+)-HBTM 
was synthesized according to the literature procedure.310b (S)-BTM was purchased from 
TCI chemicals and used as received. All unsaturated acid chlorides were purchased from 
Sigma-Aldrich and used as received without further purification. 
O
O
OH
OMe
2.1f
O
O
OH
2.S1  
3-Methoxy-6-oxoheptanoic Acid (2.S1). Ethyl 3-hydroxy-6-methylhept-6-enoate (0.90 
g, 4.8 mmol, 2.8 equiv.) was added to a round dissolved in 8 mL of CH2Cl2 along with 
0.1 g of 4 Å powdered molecular sieves and Proton Sponge (0.37 g, 1.7 mmol, 1.0 
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equiv.). The flask was then wrapped in foil, trimethyloxonium tetrafluoroborate (0.25 g, 
1.7 mmol, 1.0 equiv.) was added, the resulting mixture was stirred overnight (~8 h). 
After completion of the reaction, 1 mL of 2-propanol was added, and the reaction 
mixture was extracted with NaHCO3 (3 × 5 mL) and brine (1 × 5 mL), dried over 
Na2SO4, and concentrated by rotary evaporation. The product was of sufficient purity to 
carry on. It was redissolved in 5 mL of methanol and 1 ml of 2 M NaOH and heated to 
65 °C for 3 h. After 3 h, it was cooled to 23 °C, acidified with 1 M HCl, and diluted with 
8 mL of ethyl acetate. The organic layer was washed with brine (1 × 5 mL), dried over 
Na2SO4, and concentrated by rotary evaporation. The resulting compound, 3-methoxy-6-
methylhept-6-enoic acid, was dissolved in 9 mL of CH2Cl2 and cooled to -78 °C, at 
which point ozone was bubbled through the solution until it turned a deep blue color. 
Then oxygen was bubbled through until the color dissipated, at which time dimethyl 
sulfide (0.3 mL, 4.0 mmol, 2.5 equiv.) was added and the reaction was allowed to stir 
overnight (10 h) while warming to 23 °C. The solution was then concentrated by rotary 
evaporation and purified by flash column chromatography (SiO2, eluting with 20 to 50% 
EtOAc/hexanes) to afford keto-acid 2.1f as a pale yellow liquid (0.15 g, 43% over three 
steps): IR (thin film) 3128, 2936, 2373, 2334, 1708 cm-1; 1H NMR (500 MHz; CDCl3): δ 
3.68-3.63 (m, 1H), 3.34 (s, 3H), 2.60-2.51 (m, 3H), 2.44 (ddd, J = 15.5, 5.6, 0.9 Hz, 1H), 
2.14 (s, 3H), 1.90 (m, 1H), 1.79 (m, 1H); 13C NMR (125 MHz, CDCl3): δ 208.5, 176.3, 
76.4, 57.0, 38.9, 38.8, 30.0, 27.4; HRMS (ESI+) calcd. for C8H14O4Li (M + Li) 
181.1052, found 181.1049. 
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additive time
O
H
Me
OTsCl, DMAP, DIPEA
K2CO3, CH2Cl2
O
OH
O (dr >19:1)
2.1a 2.2a
 
(1S,2R,5R)-5-Methyl-2-(prop-1-en-2-yl)-6-oxabicyclo[3.2.0]heptan-7-one (2.2a). 
(Table 2, entry 6): To a mixture of TsCl (210 mg, 1.1 mmol. 1.1 equiv.), DMAP (183 
mg, 1.5 mmol, 1.5 equiv.), and N,N-diisopropylethylamine (0.7 mL, 4 mmol, 4.0 equiv.) 
in CH2Cl2 (2.8 mL) was added dropwise a solution of keto-acid 2.1a (184 mg, 1 mmol, 
1.0 equiv.) in CH2Cl2 (0.5 mL). The reaction mixture was stirred at ambient temperature 
(23 oC) for 10 min and then powdered anhydrous K2CO3 (414 mg, 3 mmol, 3.0 equiv.) 
was added in one portion. The reaction was stirred at room temperature for 2 h and then 
diluted with hexanes and passed through a pad of silica gel to remove solids. The 
volatiles were removed by rotavap and the residue was purified by flash column 
chromatography (SiO2, eluting with 20 to 50% EtOAc/hexanes) to afford β-lactone 2.2a 
as a colorless liquid (117 mg, 71%). [α]D23 = +33.8 (c = 1.4, CHCl3); IR (thin film) 2975, 
2937, 1818, 1643 cm-1; 1H NMR (500 MHz, CDCl3) δ 4.76 (s, 1H), 4.41 (s, 1H), 3.47 (s, 
1H), 2.84 (d, J = 7.0 Hz, 1H), 1.99-2.12 (m, 2H), 1.84-1.92 (m, 1H), 1.73 (s, 3H), 1.68 
(s, 3H); 1.62-1.67 (m, 1H), 13C NMR (125 MHz, CDCl3) δ 171.1, 145.1, 109.8, 87.9, 
63.0, 45.7, 33.7, 28.3, 22.5, 21.6; LRMS (ESI+) calcd. for C10H15O2 (M+H) 167.1072. 
Found 167.1079. 
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O
O
OH
OTBS
O
O
Me
HTBSO
2.1e 2.2e  
2-((tert-Butyldimethylsilyl)oxy)-5-methyl-6-oxabicyclo-[3.2.0]heptan-7-one (2.2e). 
β-Lactone 2.2e was prepared according to the representative procedure from keto-acid 
2.1e (75 mg, 0.27 mmol, 1.0 equiv.), p-TsCl (59 mg, 0.31 mmol, 1.1 equiv.), DMAP (49 
mg, 0.41 mmol, 1.5 equiv.), N,N-diisopropylethylamine (0.19 mL, 1.1 mmol, 4.0 equiv.) 
and K2CO3 (111 mg, 0.81 mmol, 3.0 equiv.) in CH2Cl2 (0.9 mL) after a reaction time of 
2 h. Purification by flash column chromatography (SiO2, eluting with 20 to 50% 
EtOAc/hexanes) afforded β-lactone 2.2e as a colorless liquid (47 mg, 68%). All spectral 
data were in accordance with those previously reported.288b 
O
O
OH
OMe
O
O
Me
HMeO
2.1f 2.2f  
2-Methoxy-5-methyl-6-oxabicyclo[3.2.0]heptan-7-one (2.2.f). β-Lactone 2.2f was 
prepared according to the representative procedure from keto-acid 2.1f (61 mg, 0.35 
mmol, 1.0 equiv.), TsCl (74 g, 0.39 mmol, 1.1 equiv.), DMAP (64 mg, 0.53 mmol, 1.5 
equiv.), N,N-diisopropylethylamine (0.24 mL, 1.4 mmol, 4.0 equiv.), and K2CO3 (144 
mg, 1.1 mmol, 3.1 equiv.) in CH2Cl2 (1.2 mL) after a reaction time of 2 h. Purification 
by flash column chromatography (SiO2, eluting with 20 to 50% EtOAc/hexanes) 
afforded β-lactone 2.7f as a colorless liquid (35 mg, 64 %). IR (thin film) 2998, 2945, 
1828, 1552 cm-1; 1H NMR (500 MHz, CDCl3) δ 4.01 (d, J = 3.5 Hz, 1H), 3.59 (s, 1H), 
3.30 (s, 3H), 2.11-2.21 (m, 2H), 1.86-2.06 (m, 2H), 1.75 (s, 3H), 13C NMR (125 MHz, 
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CDCl3) δ 168.6, 87.8, 81.7, 64.0, 56.5, 33.7, 30.0, 21.9; LRMS (ESI+) calcd. for 
C8H13O3 (M+H) 157.0865. Found 157.0881. 
O
O
OH
Me
O
O
Me
HMe
2.1g 2.2g  
2,5-Dimethyl-6-oxabicyclo[3.2.0]heptan-7-one (2.2.g). β-Lactone 2.2g was prepared 
according to the representative procedure from keto-acid 2.6g (84 mg, 0.53 mmol, 1.0 
equiv.), p-TsCl (112 g, 0.58 mmol, 1.1 equiv.), 4-DMAP (97 mg, 0.8 mmol, 1.5 equiv.), 
N,N-diisopropylethylamine (0.37 mL, 2.1 mmol, 3.9 equiv.), and K2CO3 (220 mg, 1.59 
mmol, 3.0 equiv.) in CH2Cl2 (1.7 mL) after a reaction time of 6 h. Purification by flash 
column chromatography (SiO2, eluting with 20 to 50% EtOAc/hexanes) afforded β-
lactone 2.2g as a colorless liquid (42.3 g, 57%): IR (thin film) 2996, 2943, 1823 cm-1; 1H 
NMR (500 MHz, CDCl3): δ 3.14 (s, 1H), 2.50-2.58 (m, 1H), 2.01-2.13 (m, 2H), 1.75-
1.85 (m, 1H), 1.72 (s, 3H), 1.62-1.68 (m, 1H), 0.97 (d, J = 7.0 Hz, 3H); 13C NMR (125 
MHz, CDCl3): δ 170.7, 87.4, 65.5, 34.2, 33.0, 30.5, 22.1, 18.6; HRMS (ESI+) calcd. for 
C8H13O2 (M + H) 141.0916, found 141.0934. 
O
Me
H O
2.2
m-CPBA
 CH2Cl2
 0 oC
(98%, dr 4:1)
O
Me
H O
2.8
O
 
(1S,2R,5R)-5-Methyl-2-(2-methyloxiran-2-yl)-6-oxabicyclo-[3.2.0]heptan-7-one 
(2.8). β-Lactone 2.2 was dissolved in CH2Cl2 (5 mL) and taken to 0 °C, Na2HPO4 (24 
mg, 1.7 mmol, 2.0 equiv.) and m-CPBA (15 mg, 0.85 mmol, 1.0 equiv.) were added, and 
the reaction was allowed to warm to 23 °C overnight (~8 h). The reaction mixture was 
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then filtered to remove excess solids and washed with an aqueous solution of saturated 
K2CO3 (2 × 5 mL) and brine (5 mL). It was then dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. Purification by flash column chromatography 
(SiO2, eluting with 10 to 40% EtOAc/hexanes) afforded an inseparable, diastereomeric 
mixture of epoxy β-lactones 2.8 (dr 4:1) as a colorless liquid (16 mg, 98%): IR (thin 
film) 2976, 2925, 1818 cm-1. Data for major diastereomer: 1H NMR (500 MHz, CDCl3): 
δ 3.43 (s, 1H), 2.66-2.60 (m, 2H), 2.51 (d, J = 4.5, 1H), 2.18-2.08 (m, 3H), 2.00-1.96 (m, 
1H), 1.72 (s, 3H), 1.71-1.65 (m, 2 H), 1.36 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 
170.8, 88.3, 66.1, 57.2, 51.8, 44.7, 35.0, 27.2, 21.7, 15.5; HRMS (ESI+) calcd for 
C10H14O3Li (M + Li) 189.1103, found 189.1111. 
O
Me
H O
2.2
O
O
Me
H O
2.9
i. O3, CH2Cl2 
-78 oC
ii. DMS, 23 oC
(65%)
 
(1S,2R,5R)-2-Acetyl-5-methyl-6-oxabicyclo[3.2.0]heptan-7-one (2.9). β-Lactone 2.2 ( 
83 mg, 0.50 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (9 mL) and taken to -78 °C, at 
which point ozone was bubbled through the solution until it turned a deep blue color. 
Then oxygen was bubbled through until the color dissipated, at which time dimethyl 
sulfide was added (2.0 mL, 2.66 mmol, XX equiv) and the reaction was allowed to stir 
overnight (~10 h) while warming to ambient temperature (23 oC). The solution was 
concentrated by rotary evaporation and purified by flash column chromatography (SiO2, 
eluting with 10 to 30% EtOAc/hexanes) to afford β-lactone 2.9 as a colorless liquid (55 
mg, 65%): [α]D19 = +50 (c = 1.5, CHCl3); IR (thin film) 2984, 2937, 1815, 1702 cm-1; 1H 
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NMR (500 MHz; CDCl3): 3.66 (s, 1H), 3.30 (d, J = 8.0 Hz, 1H), 2.24-2.20 (m, 1H), 2.20 
(s, 3H), 2.12-2.03 (m, 2H), 1.67 (s, 3H), 1.55-1.48 (m, 1H); 13C NMR (125 MHz, 
CDCl3): δ 207.3, 170.5, 88.2, 60.4, 52.0, 33.9, 28.2, 27.6, 21.4; HRMS (ESI+) calcd for 
C9H12O3Li (M + Li) 175.0946, found 175.0950. 
O
Me
H O DIBAlH, CH2Cl2
0 oC, 2 h
(99%) OH
Me
H OH
3.2 3.5  
(1R,2R,3R)-2-(Hydroxymethyl)-1-methyl-3-(prop-1-en-2-yl)cyclopentanol (3.5). To a 
solution of 3.2 (2.01 g, 12.09 mmol, 1.00 equiv.) in 121 mL of dry CH2Cl2 at 0 oC was 
added neat DIBAlH (8.62 mL, 48.37 mmol, 4.00 equiv.) dropwise. The reaction 
remained at 0 oC for 5 h at which time 12 mL of EtOAc was added dropwise followed 
by 30 mL of a saturated aqueous solution of Rochelle’s salt. The reaction was allowed to 
stir ~8 h to quench excess DIBAL. It was then diluted with 50 mL EtOAc and the 
organic extract was then washed with brine (2 x 20 mL), dried anhydrous Na2SO4 and 
concentrated under reduced pressure. Purification by flash column chromatography 
eluting 10 to 30% EtOAc/Hexanes afforded 3.5 (2.03 g, 99%) as a white crystalline 
solid. [α]D19 = -28.0 (c = 1.0, CHCl3); IR (thin film): 3347 (br s), 2988, 1643 cm-1; 1H 
NMR (500 MHz; CDCl3): δ  4.78-4.75 (m, 2H), 3.91 (dd, J = 11.3, 3.2 Hz, 1H), 3.71 
(dd, J = 11.3, 5.0 Hz, 1H), 2.87 (dt, J = 10.8, 8.8 Hz, 1H), 2.75 (br s, 1H), 2.57 (br s, 
1H), 1.98-1.90 (m, 1H), 1.78-1.72 (m, 2H), 1.70 (s, 3H), 1.59 (ddd, J = 10.9, 5.0, 3.2 Hz, 
1H), 1.54-1.49 (m, 1H), 1.40 (s, 3H); 13C (500 MHz; CDCl3): δ 147.1, 110.9, 81.8, 61.2, 
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52.8, 47.2, 41.9, 28.7, 28.2, 19.5 HRMS (ESI+) calcd. for C10H18O2 (M+Li) 177.1467. 
Found 177.1571.  
OH
Me
H OH
3.5
1) SO3•Py, DMSO, 
NEt3, 25 oC, 15 min
2)              , CH2Cl2, 25 oC
 8 h (88%, 2 steps)
Ph3P
MeO
O OH
Me
H
O
OMe
3.16  
(E)-Methyl 3-((1S,2R,5R)-2-hydroxy-2-methyl-5-(prop-1-en-2-yl)cyclopentyl)acryla- 
te (3.16): To a solution round-bottomed flask with diol 3.5 (1.13 g, 6.66 mmol, 1.00 
equiv.) was added NEt3 (7.42 mL, 52.24 mmol, 7.84 equiv.) and DMSO (16.54 mL, 
232.94 mmol, 34.98 equiv.). Then SO3-pyridine (4.24 g, 26.62 mmol, 4.00) dissolved in 
DMSO (16.54 mL, 232.94 mmol, 34.98 equiv.) was added. The reaction was stirred at 
room temperature for 15 min and then saturated aqueous NaHCO3 (35 mL) was added 
and allowed to stir for 5 min. The mixture was then extracted with EtOAc (3 x 35 mL) 
the combined organic layer was then dried with anhydrous Na2SO4 and concentrated 
under reduced pressure. The resulting solution was then dissolved in CH2Cl2 (64 mL) 
and methyl 2-(triphenylphosphoranylidene)-acetate (2.67 g, 7.99 mmol, 1.20 equiv.) was 
added and the reaction was allowed to stir overnight (~8 h) then concentrated under 
reduced pressure and purified by flash column chromatography eluting 20 to 30 % 
EtOAc/hexanes afforded 3.16 (1.31 g, 88% over two steps) as a colorless oil. [α]D19 = -
68.57 (c = 1.05, CHCl3); IR (thin film): 3467 (br s), 2963, 2360, 1723, 1650 cm-1; 1H 
NMR (500 MHz; CDCl3): δ 6.92 (dd, J = 15.8, 8.88 Hz, 1H), 5.84 (d, J = 15.8 Hz, 1H) 
4.70-4.68 (m, 2H), 3.72 (s, 3H), 2.88 (q, J = 10.0 Hz, 1H), 2.26 (dd, J = 10.9, 9.1 Hz, 
2H), 1.65 (s, 3h), 2.13-2.0 (m, 1H), 1.82 (dd, J = 8.2, 7.0 Hz, 2H), 1.65 (s, 3H), 1.61-
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1.48 (m, 2H), 1.30 (s, 3H); 13C (500 MHz; CDCl3): δ 166.8, 147.7, 146.0, 123.8, 111.0, 
81.9, 56.9, 51.7, 50.6, 40.5, 28.7, 27.3, 20.0; HRMS (ESI+) calcd. for C13H20O3 (M+Li) 
231.1572. Found 231.1660.  
OH
Me
H
O
OMe
1) Mg, MeOH,25 oC, 8 h O
Me
H
O
2) PPTS, C6H6, 80 oC, 2 h
(65%, 2 steps)
3.15
3.16
 
(4aS,5R,7aR)-7a-Methyl-5-(prop-1-en-2-yl)hexahydrocyclopenta[b]pyran-2(3H)-
one-(3.15). To a solution of methyl ester 3.16 (0.45 g, 2.0 mmol, 1.0 equiv.) in a round-
bottomed flask was added MeOH (20 mL) and Mg turnings (0.97g, 40.08 mmol, 20.0 
equiv.), which were activated by washing with a 10% aqueous solution of HCl for 2 min 
followed by through rinsing with MeOH prior to addition. The reaction was monitored 
by TLC, and after 8 h the crude reaction mixture was concentrated to remove all MeOH, 
then dissolved in EtOAc (200 mL) and filtered through a coarse fritted funnel. After 
which the mixture was concentrated under reduced pressure. To the crude mixture in 
benzene (20 mL) was added PPTS (1.01 g, 2.0 mmol, 1.0 equiv.) and allowed to stir 
under reflux conditions for 4 h. Saturated aqueous NH4Cl solution (8 mL) was added and 
the mixture was extracted with EtOAc (3 x 10 mL), and washed with brine (10 mL). The 
organic extract was dried over Na2SO4, filtered, and concentrated under reduced 
pressure. The residue was purified by flash column chromatography (silica gel, 1: 1: 1.5: 
2 (dichloromethane: pentane: hexane: diethyl ether)) to furnish 3.15 (0.25 g, 65% over 
two steps) as a colorless oil. = -24.6o (c = 1.22, CHCl3); IR (thin film): 2967, 1732, 1640 
cm1; 1H NMR (500 MHz; CDCl3): δ 4.77 (dt, J = 19.7, 1.2 Hz, 2H), 2.54-2.49 (m, 1H), 
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2.45-2.42 (m, 2H), 2.07-1.97 (m, 2H), 1.95-1.87 (m, 2H), 1.84 (dt, J = 10.5, 5.2 Hz, 1H), 
1.75-1.67 (m, 4H), 1.55-1.51 (m, 1H), 1.47 (s, 3H); 13C NMR (500 MHz; CDCl3): δ 
172.2, 145.6, 111.3, 91.4, 50.4, 44.6, 40.4, 28.2, 27.9, 26.3, 20.3, 19.7; HRMS (ESI+) 
calcd. for C12H18O2 (M+Li) 195.1385. Found 195.1393. 
O
Me
H
O
1) LiHMDS (3.0 equiv), THF, 2 h then
 (CH3)2O (12 equiv) 2 h, -78 oC
2) MsCl, NEt3, CH2Cl2 0 oC to 25 oC
O
Me
H
O
(77%, 2 steps)
3.15
3.3
caulolactone A  
(4aS,5R,7aR)-7a-Methyl-5-(prop-1-en-2-yl)-3-(propan-2ylidene)hexahydro-
cyclopenta[b]pyran-2(3H)-one-(5).To a round-bottomed flask was added a solution of 
lactone of 3.15 (143 mg g, 0.74 mmol, 1.0 equiv.) in THF (14.70 mL). The reaction was 
taken to -78 oC with a dry ice/acetone bath and allowed to react for 3 h, followed by 
addition of freshly distilled acetone stored under nitrogen over molecular sieves (0.65 
mL, 8.83 mmol, 12.0 equiv.). After an additional 3 h the reaction was quenched with a 
saturated aqueous NH4Cl solution (5 mL) and extracted with EtOAc (3 x 10 mL), then 
washed with brine (10 mL). The organic extract was dried over Na2SO4, filtered, and 
concentrated under reduced pressure. The residue was then dissolved in CH2Cl2 (7.4 
mL) and taken to 0 oC at which time NEt3 (0.82 mL, 5.88 mmol, 8.0 equiv.) was added 
followed by dropwise addition of MsCl (0.17 mL, 2.19 mmol, 3.0 equiv.). After addition 
the ice bath was removed and the reaction was warmed to reflux for 3 h. The resulting 
solution was then concentrated under reduced pressure and purified by flash column 
chromatography to afford 3.3 (132 mg, 77% over two steps) as a colorless oil. [α]D19 =  
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+48.5o (c = 0.3, MeOH); IR (thin film): 2951, 1708, 1083 cm1; 1H NMR (500 MHz; 
CDCl3): δ 4.76 (s, 1H), 4.69 (s, 1H), 2.58-2.35 (m, 3H), 2.20 (t, J = 1.51 Hz, 3H), 2.02-
1.88 (m, 3H), 1.85 (s, 3H), 1.82-1.77 (m, 1H), 1.54-1.45 (m, 1H), 1.40 (s, 3H); 13C NMR 
(500 MHz; CDCl3): δ 167.5, 151.0, 146.0, 118.4, 111.3, 89.4, 51.0, 45.7, 40.1, 27.8, 
26.0, 25.9, 23.9, 23.3, 19.7; HRMS (ESI+) calcd. for C15H22O2 (M+H) 235.1698. Found 
235.1725.  
The following except is characterization data listed from the isolation paper: 
“Colorless needles, mp 97-98 oC, C15H22O2 [α]D19 =  +170 o (c = 0.3, MeOH), IR νmax 
CCl4 1715 cm-1, UV λ max  MeOH 234 nm (ε, 16000). These data showed the presence of 
α,β-unsaturated lactone group in the molecule, and aldo CD ([θ]225 + 700, [θ]210 + 840) 
supported the presence of this group. 1H-NMR (δ CCl4 + TMS) 1.18 (tert. Methyl on a 
carbon atom bounded with the oxygenic function), 1.72, 1.81, 2.13 (three olefinic 
methyls), 4.74 (2H, s, terminal methylene).” 
Comparison of 1H NMR δ with isolation paper: As such the 5 singlets (4 methyls and 
the terminal methylene’s) were compared.  
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O
Cl+
NaH, DMF
23 oC, 21 h tBuO2C
tBuO2C
OtBuO2C
tBuO2C
4.10b4.S1 4.S2  
Di-tert-butyl 2-(2-oxopropyl)malonate (4.10b). To an oven dried, round-bottomed 
flask was added NaH 60% in mineral oil (0.49 g, 9.83 mmol, 1.25 equiv.) and 20 mL 
anhydrous DMF. The flask was then cooled to 0 oC with an ice bath and di-tert-butyl 
malonate (4.S1, 2.0 mL, 8.93 mmol, 1.00 equiv.) was added dropwise.  After 25 min, 
chloroacetone (4.S2, 1.08 mL, 13.40 mmol, 1.50 equiv.) was added dropwise and the ice 
bath removed and allowed to warm up to ambient temperature (23 oC). After 21 h the 
reaction mixture was cooled to 0 oC with an ice bath and 10 mL of sat. NH4Cl was added 
slowly. The mixture was warmed to ambient temperature (23 oC), extracted with EtOAc 
(4 x 15 mL), and the combined organic extracts were then washed with water (15 mL) 
and brine (15 mL). The organic layer was collected and dried over MgSO4, filtered, 
concentrated by rotary evaporation, and purified by flash column chromatography 
(gradient SiO2, 20 → 60% EtOAc/hexanes) to afford keto diester 4.10b (1.46 g, 60%) as 
a colorless oil: TLC (EtOAc:hexanes, 5:5 v/v): Rf = 0.80; 1H NMR (500 MHz, CDCl3): δ 
3.68 (t, J = 7.2 Hz, 1H), 2.95 (d, J = 7.2 H, 2H), 2.20 (s, 3H), 1.45 (s, 18H); 13C NMR 
(125 MHz, CDCl3): δ 205.1, 168.1(2), 81.7(2), 49.0, 42.0, 29.8, 27.8(6); IR (thin film): 
2982, 2928, 1726 cm-1; HRMS (ESI+) m/z calcd. for C14H24LiO5 [M+Li]+: 279.1784; 
found 279.1781.  
 
   229 
O
Cl+
NaH, DMF
50 oC, 12 h allylO2C
allylO2C
OallylO2C
allylO2C
4.10c4.S3 4.S2  
Diallyl 2-(2-oxopropyl)malonate (4.10c). To an oven dried, round-bottomed flask was 
added NaH 60% in mineral oil (1.16 g, 28.97 mmol, 1.06 equiv.) and then 50 mL 
anhydrous DMF followed by dropwise addition of diallyl malonate415 (4.S3, 5.00 g, 
27.14 mmol, 1.00 equiv.) at ambient temperature (23 oC). After 25 min, chloroacetone 
(4.S2, 6.55 mL, 81.41 mmol, 3.00 equiv.) was added dropwise and the reaction mixture 
was heated to 50 oC for 12 h, after which time it was allowed to cool to ambient 
temperature (23 oC) and 15 mL of sat. NH4Cl was added. The mixture was extracted 
with EtOAc (4 x 20 mL) and then washed with water (20 mL) and brine (20 mL). The 
organic layers were combined and dried over MgSO4, filtered, concentrated by rotary 
evaporation, and purified by flash column chromatography (gradient SiO2, 20 → 60% 
EtOAc/hexanes) to afford keto diester 4.10c (4.24 g, 65%) as a colorless oil: TLC 
(EtOAc:hexanes, 1:9 v/v): Rf = 0.75; 1H NMR (500 MHz, CDCl3): δ 5.93-5.86 (m, 2H), 
5.35 (q, J = 1.5 Hz, 1H), 5.31 (q, J = 1.5 Hz, 1H), 5.26 (q, J = 1.3 Hz, 1H), 5.24 (q, J = 
1.3 Hz, 1H), 4.65 (m, 2H), 4.63 (m, 2H), 3.94 (t, J = 7.1 Hz, 1H), 3.09 (d, J = 7.2 Hz, 
2H), 2.21 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 205.0, 168.7(2), 131.6(2), 119.0(2), 
66.5(2), 47.1, 42.3, 30.0; IR (thin film): 3081, 2951, 1741 cm-1; HRMS (ESI+) m/z 
calcd. for C12H16LiO5 [M+Li]+: 247.1158; found 247.1149. 
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O
Cl+
NaH, DMF
35 oC, 24 h BnO2C
BnO2C
OBnO2C
BnO2C
4.10d4.S4 4.S2  
Dibenzyl 2-(2-oxopropyl)malonate (4.10d). To an oven dried, round-bottomed flask 
containing dibenzyl malonate (4.S4, 2.50 mL, 12.0 mmol, 1.00 equiv.) in 24 mL of 
anhydrous DMF at 0 oC was slowly added NaH 60% in mineral oil (0.51 g, 12.8 mmol, 
1.07 equiv.). After 5 min at 0 oC chloroacetone (4.S2, 2.88 mL, 35.8 mmol, 3.00 equiv.) 
was added dropwise and the reaction mixture was heated at 35 oC for 24 h, after which 
time it was allowed to cool to ambient temperature (23 oC) and 15 mL of sat. NH4Cl was 
added. The mixture was extracted with EtOAc (4 x 20 mL) and then washed with water 
(20 mL) and brine (20 mL). The organic layers were combined and dried over MgSO4, 
filtered, concentrated by rotary evaporation, and purified by flash column 
chromatography (SiO2, 10 → 60% EtOAc/hexanes) to afford keto diester 4.10d (1.90 g, 
47%) as a colorless oil: TLC (EtOAc:hexanes, 3:7 v/v): Rf = 0.45; 1H NMR (500 MHz, 
CDCl3): δ 7.31-7.27 (m, 5H), 7.26-7.24 (m, 5H), 5.17 (s, 2H), 5.11 (s, 2H), 3.96 (t, J = 
7.1 Hz, 1H), 3.06 (d, J = 7.1 Hz, 2H), 2.13 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 
204.9, 168.7, 135.3, 128.7, 128.5, 128.3, 67.6, 47.1, 42.1, 29.8; IR (thin film): 1753, 
1726, 1270, 1226, 1152 cm-1; HRMS (ESI+) m/z calcd. for C20H20LiO5 [M+Li]+: 
347.1471; found 347.1476. 
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4.10e
O O
O
OMe
OMe
MeO OMe
OO O
Cl+
NaOMe, MeOH
23 oC, 21h
4.S5 4.S2  
3-Acetylhexane-2,5-dione (4.10e). In an oven dried, 250 mL round-bottomed flask was 
added acetylacetone (4.S5, 5.0 g, 49.9 mmol, 1.00 equiv.) dissolved in 100 mL of 
spectra grade benzene. DBU (7.5 mL, 50 mmol, 1.00 equiv.) was slowly added to the 
solution. Upon completion of the addition, chloroacetone (4.S2, 5.23 mL, 65.0 mmol, 
1.30 equiv.) was added dropwise and the reaction mixture was stirred for 24 h at ambient 
temperature (23 ºC). The reaction mixture was then diluted with CH2Cl2 (40 mL), 
washed with brine (50 mL), dried over Na2SO4, and concentrated by rotary evaporation. 
Flash column chromatography (SiO2, 10 → 40% EtOAc/hexanes) afforded triketone 
4.10e (2.34 g, 30%) as a yellow oil. All characterization data was in accordance with 
previously reported data for this compound.416 
(±)-4.10g
O O
O
OMeMeO
OO O
Cl+
NaOMe, MeOH
23 oC, 21h
4.S7 4.S2  
Methyl 2-acetyl-4-oxopentanoate ((±)-4.10g). An oven dried, 500 mL round-bottomed 
flask was charged with 225 mL of MeOH under a nitrogen atmosphere and then cooled 
to 0 oC with an ice bath prior to the addition of methylacetoacetone (4.S7, 10.0 mL, 92.7 
mmol, 1.0 equiv.) followed by NaOMe (5.51 g, 102 mmol, 1.10 equiv.). After 25 min at 
0 oC, chloroacetone (4.S2, 10.4 mL, 130 mmol, 1.40 equiv.) was added dropwise. After 
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the addition, the ice bath was removed and the reaction was stirred at ambient 
temperature (23 oC) for 21 h.  The reaction was again cooled to 0 oC and 100 mL of sat. 
NH4Cl was added. The reaction mixture was then extracted with EtOAc (4 x 100 mL), 
then washed with water (2 x 25 mL) and brine (1 x 50 mL). The organic layer was 
collected and dried over MgSO4, filtered, concentrated by rotary evaporation, and 
purified by flash column chromatography (SiO2, 20 → 60% EtOAc/hexanes) to afford 
diketo ester (±)-4.10g (6.86 g, 43%) as a pale yellow oil: TLC (EtOAc:hexanes, 5:5 v/v):  
Rf = 0.50; 1H NMR (500 MHz, CDCl3): δ 4.02 (dd, J = 8.3, 5.7 Hz, 1H), 3.73 (s, 3H), 
3.15 (dd, J = 18.5, 8.3 Hz, 1H), 2.95 (dd, J = 18.5, 5.6 Hz, 1H), 2.35 (s, 3H), 2.19 (s, 
3H); 13C NMR (125 MHz, CDCl3): δ 205.8, 202.3, 169.5, 53.6, 52.9, 41.8, 30.3, 29.9; IR 
(thin film): 3002, 2955, 2928, 1759. 
KI, NBu4Br, K2CO3
MeCN, 50 oC, 24h
O
MeO OMe
OO
+Cl MeO2C
MeO2C
O
Me
4.S8 4.S9 (±)-4.10j  
Dimethyl 2-(3-oxobutan-2-yl)malonate ((±)-4.10j). To a 250 mL, round-bottomed 
flask were added dimethyl malonate (4.S9, 1.81 mL, 15.84 mmol, 1.0 equiv.), 3-
chlorobutan-2-one (4.S8, 2.0 mL, 20 mmol, 1.25 equiv.), KI (0.13 g, 0.79 mmol, 0.05 
equiv.), K2CO3 (2.63 g, 19.0 mmol, 1.20 equiv.), n-Bu4NBr (0.10 g, 0.32 mmol, 0.02 
equiv.) and MeCN (25 mL). The reaction was heated to 50 oC for 12 h. Stirring was 
continued for another 12 h at ambient temperature (23 oC). After which time, the 
reaction was concentrated under reduced pressure by rotary evaporation, diluted with 20 
mL of CH2Cl2, and filtered to remove solids. The filtrate was then concentrated by rotary 
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evaporation and purified by flash column chromatography (SiO2, 20 → 60% 
EtOAc/hexanes) to afford keto diester (±)-4.10j (3.17 g, 99%) as a colorless oil. 13C 
NMR (125 MHz, CDCl3): δ 209.6, 169.1, 169.0, 54.1, 52.9, 52.8 45.9, 28.8, 14.6. All 
other characterization data was in accordance with previously reported data for this 
compound.  
K2CO3, acetone
23 oC, 18h
MeO OMe
OO
+
O CO2Me
CO2Me
O
Br
4.S10 4.S9 (±)-4.10k  
2-(2-Oxocyclopentyl)malonate ((±)-4.10k). To 2-bromocyclopentanone (4.S10, 
prepared and purified immediately prior to use,417 3.42 g, 21.0 mmol, 1.50 equiv.) was 
added dimethyl malonate (4.S9, 1.60 mL, 14.0 mmol, 1.00 equiv.), K2CO3 (2.50 g, 18.1 
mmol, 1.30 equiv.) and acetone (30 mL), which was allowed to react for 18 h at ambient 
temperature (23 oC). After which time, the reaction was concentrated under reduced 
pressure by rotary evaporation, diluted with 20 mL of CH2Cl2 and then filtered to 
remove the solids. The filtrate was then concentrated by rotary evaporation and purified 
by flash column chromatography (SiO2, 20 → 60% EtOAc/hexanes) to afford 
cyclopentanone diester (±)-4.10k as a colorless oil (720 mg, 24%)418: TLC 
(EtOAc:hexanes, 1:1 v/v): Rf = 0.53; 1H NMR (500 MHz, CDCl3): δ 3.83 (d, J = 5.7 Hz, 
1H), 3.77 (s, 3H), 3.72 (s, 3H), 2.73-2.69 (m, 1H), 2.36 (dd, J = 18.8, 8.4 Hz, 1H), 2.28-
2.20 (m, 2H), 2.12-2.08 (m, 1H), 1.90-1.78 (m, 2H); 13C NMR (125 MHz, CDCl3): δ 
217.1, 169.0, 168.4, 52.7, 52.6, 51.0, 48.6, 37.4, 26.6, 20.6; IR (thin film): 2956, 2880, 
1738 cm-1; HRMS (ESI+) m/z calcd. for C10H14LiO5 [M+Li]+: 221.1001; found 
221.1002.  
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O CO2Me
CO2Me
KI, NBu4Br, K2CO3
MeCN, 50 oC, 24h
O
MeO OMe
OO
+
Cl
4.S11 4.S9 (±)-4.10l  
Dimethyl 2-(2-oxocyclohexyl)malonate ((±)-4.10l). To a 250 mL round-bottomed flask 
were added 2-chlorocyclohexanone (4.S11, 5.0 mL, 44 mmol, 1.25 equiv.), dimethyl 
malonate (4.S9, 4.0 mL, 35 mmol, 1.0 equiv.), KI (0.30 g, 1.81 mmol), K2CO3 (5.87 g, 
42.5 mmol, 1.22 equiv.), n-Bu4NBr (0.23 g, 0.71 mmol, 0.02 equiv.) and MeCN (50 
mL). The reaction mixture was heated to 50 oC for 12 h and then stirred at ambient 
temperature (23 oC) for an additional 12 h.  The reaction was then concentrated under 
reduced pressure by rotary evaporation, diluted with 50 mL of CH2Cl2 and filtered to 
remove the solids. The filtrate was then concentrated by rotary evaporation and purified 
by flash column chromatography (SiO2, 20 → 60% EtOAc/hexanes) to afford 
cyclohexanone diester (±)-4.10l (967 mg, 12%) as a pale yellow oil: TLC 
(EtOAc:hexanes, 5:5 v/v):Rf = 0.65; 1H NMR (500 MHz, CDCl3): δ 3.58 (s, 3H), 3.57 (s, 
3H), 3.51 (d, J = 9.5 Hz, 1H), 3.07-3.01 (m, 1H), 2.29-2.26 (m, 2H), 2.00-1.96 (m, 1H), 
1.90-1.85 (m, 1H), 1.79-1.75 (m, 1H), 1.63-1.45 (m, 2H), 1.44-1.35 (m, 1H); 13C NMR 
(125 MHz, CDCl3): δ 209.9, 169.1, 169.0, 52.9, 52.8, 52.1, 50.6, 42.1, 31.4, 27.9, 25.2; 
IR (thin film): 2955, 2863, 1738, 1706 cm-1; HRMS (ESI+) m/z calcd. for C11H16LiO5 
[M+Li]+: 235.1158; found 235.1154. 
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K2CO3, acetone
40 oC, 48h
O CO2Me
CO2Me
O
MeO OMe
OO
+
Br
4.S12 4.S9 (±)-4.10n  
Dimethyl 2-(1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)malonate ((±)-4.10n). To a 50 
mL, round-bottomed flask were added dimethyl malonate (4.S9, 1.45 mL, 12.7 mmol, 
1.00 equiv.), K2CO3 (4.39 g, 31.7 mmol, 2.51 equiv.) and acetone (8 mL). The reaction 
was heated to 40 oC, then 4.S12 (4.0 g, 17.77 mmol, 1.40 equiv.) which was freshly 
prepared and used immediately without purification, was added dropwise over ~4 min 
and the reaction was maintained at 40 oC for 48 h. After 48 h, the reaction was allowed 
to cool to ambient temperature (23 oC) and EtOAc (20 mL) and water (20 mL) were 
added and the reaction was stirred for an additional 10 min. The organic layer was 
collected, washed with brine 2 x 10 mL, dried over MgSO4, filtered, concentrated by 
rotary evaporation, and purified by flash column chromatography (SiO2, 5 → 30% 
EtOAc/hexanes) to afford aromatic keto diester (±)-4.10n (1.97 g, 56%) as a 
yellow/orange solid: TLC (EtOAc:hexanes, 2:8 v/v): Rf = 0.48; 1H NMR (500 MHz, 
CDCl3): δ 8.00 (d, J = 7.9 Hz, 1H), 7.48 (td, J = 7.5, 1.3 Hz, 1H), 7.31-7.28 (m, 1H), 
7.26-7.23 (m, 1H), 4.02 (d, J = 7.1 Hz, 1H), 3.80 (s, 3H), 3.76 (s, 3H), 3.38-3.33 (m, 
1H), 3.12 (dt, J = 16.4, 8.5 Hz, 1H), 3.00 (dt, J = 16.7, 3.4 Hz, 1H), 2.20-2.15 (m, 2H); 
13C NMR (125 MHz, CDCl3): δ 196.9, 169.3, 169.0, 143.9, 133.9, 132.2, 128.9, 127.8, 
127.0, 52.9, 52.8, 52.2, 48.5, 29.6, 26.8; IR (thin film): 2952, 1735, 1676, 1270, 1217, 
1155, 764, 749 cm-1; HRMS (ESI+) m/z calcd. for C15H16LiO5 [M+Li]+: 283.1158; 
found 283.1172. 
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O3, CH2Cl2, -78 oC
then DMS, 10 h EtO2C
EtO2C
O
4.10o4.S13
EtO2C
EtO2C
 
Diethyl 2-(2-oxoethyl)malonate (4.10o). Ozone was bubbled through a 100 mL round-
bottomed flask with diethyl 2-(2-methylallyl)malonate (4.S13, 1.04 mL, 4.93 mmol, 1.00 
equiv.) and CH2Cl2 (29 mL) at -78oC until it turned a deep blue color. Then oxygen was 
bubbled through until the color dissipated at which time dimethyl sulfide (1.00 mL, 13.4 
mmol, 2.72 equiv.) was added and the reaction was allowed to stir overnight (10 h) 
while warming to ambient temperature (23 oC). The reaction mixture was concentrated 
under reduced pressure by rotary evaporation, and purified by flash column 
chromatography (SiO2, 20 → 60% EtOAc/hexanes) to afford aldehyde diester 4.10o 
(718 mg, 67%) as a colorless oil.  All characterization data was in accordance with 
previously reported data for this compound. 
Representative procedure for the racemic the nucleophile-catalyzed Michael-aldol-
β-lactonization (NMCAL) process as described for β-lactone (±)-4.14b. 
O
Cl
LiHMDS (1.0 equiv)
4-PPY(20 mol %)
DIPEA (1.0 equiv)
THF/CH2Cl2 (1:4)
6 h
+tBuO2C
tBuO2C
O4.1b
O
O
Me
H
tBuO2C
tBuO2C
(±)-4.14b4.1a  
Di-tert-butyl 5-methyl-7-oxo-6-oxabicyclo[3.2.0]heptane-3,3-dicarboxylate ((±)-
4.14b).  To an oven-dried, 25 mL round-bottomed flask equipped with a magnetic stir 
bar were added Michael donor 4.10b (88 mg, 0.32 mmol, 1.00 equiv.) and THF (1 mL).  
The mixture was cooled to -78 oC with vigorous stirring and LiHMDS (320 µL of a 1.0 
M solution in THF, 0.32 mmol, 1.00 equiv.) was added dropwise via microliter syringe 
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over ~ 4 min. After the addition, the reaction was stirred for 10 min at -78 oC and then 
warmed to 0 oC by switching the dry ice/acetone bath to an ice/water bath. Stirring was 
continued for an additional 10 min at this temperature, and then CH2Cl2 (4 mL), 4-PPY 
(80 µL of a 0.82 M solution in CH2Cl2, 0.064 mmol, 0.20 equiv.) and EtN(iPr)2 (60 µL, 
0.32 mmol, 1.00 equiv.) were added via microliter syringe, sequentially. The reaction 
was allowed to stir for an additional 10 min at 0 oC before acryloyl chloride (4.1a, 261 
µL of a 1.612 M solution in CH2Cl2, 0.42 mmol, 1.30 equiv.)  was added via microliter 
syringe dropwise over ~ 2 min. After the addition, the ice bath was removed and the 
reaction was stirred for 6 h at ambient temperature (23 oC). At this time, the reaction was 
cooled to 0 oC and silica gel (2 mL) was added and the reaction was stirred at 0 oC for 10 
min. The ice/water bath was removed and the reaction stirred at ambient temperature (23 
oC) for 20 min. The mixture was then diluted with hexanes (4.0 mL), filtered through a 
short silica gel pad (~2 mL of silica gel), and rinsed with EtOAc (3 x 4 mL). The filtrate 
was then concentrated by rotary evaporation and following 1H NMR analysis of the 
crude reaction mixture, it was purified by flash column chromatography (SiO2, 10 → 
30% EtOAc/hexanes) to afford bicyclic-β-lactone (±)-4.14b (77 mg, 73%) as colorless 
needles: m.p. 73.2 – 75.2 °C (recrystallized from hexanes: CH2Cl2 (1:1)); TLC 
(EtOAc:hexanes, 3:7 v/v): Rf = 0.66; 1H NMR (500 MHz, CDCl3): δ 3.46 (d, J = 9.0 Hz, 
1H), 2.99 (d, J = 14.1 Hz, 1H), 2.34, 2.87 (ABq, JAB = 15.4 Hz,  2H), 2.07 (dd, J = 14.1, 
9.1 Hz, 1H), 1.63 (s, 3H), 1.46 (s, 9H), 1.43 (s, 9H); 13C NMR(125 MHz, CDCl3): δ 
169.6, 169.2, 168.9, 87.0, 82.7, 82.6, 62.2, 58.8, 43.3, 34.3, 27.8(3), 27.5(3), 21.6; IR 
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(thin film): 2981, 2928, 1833, 1732 cm-1; HRMS (ESI+) m/z calcd. for C17H26LiO6 [M + 
Li]+: 333.1889; found 333.1902. 
 
O
O
Me
H
O
Oallyl
Oallyl
O
 (±)-4.14c  
Diallyl 5-methyl-7-oxo-6-oxabicyclo[3.2.0]heptane-3,3-dicarboxylate ((±)-4.14c). 
Prepared according to the representative procedure using Michael donor 4.10c (77 mg, 
0.32 mmol, 1.00 equiv.), THF (1 mL), LiHMDS (320 µL of a 1.0 M solution in THF, 
0.32 mmol, 1.00 equiv.), CH2Cl2 (4 mL), 4-PPY (80 µL of a 0.82 M solution in CH2Cl2, 
0.064 mmol, 0.20 equiv.) and N’N’-diisopropylethylamine (60 µL, 0.32 mmol, 1.00 
equiv.), and acryloyl chloride (4.1a, 261 µL of a 1.612 M solution in CH2Cl2, 0.42 
mmol, 1.30 equiv.). After addition of acryloyl chloride, the reaction was allowed to react 
for 6 h at ambient temperature (23 oC). Purification by flash column chromatography 
(SiO2, 10 → 30% EtOAc/hexanes) afforded bicyclic-β-lactone (±)-4.14c (78 mg, 83%) 
as a colorless oil: TLC (EtOAc:hexanes, 3:7 v/v): Rf = 0.45; 1H NMR (500 MHz, 
CDCl3): δ 5.92-5.80 (m, 2H), 5.34-5.22 (m, 4H), 4.69-4.57 (m, 4H), 3.54 (dd, J = 8.8, 
0.9 Hz, 1H), 3.12 (app d, J = 14.2 Hz, 1H), 3.01 (dd, J = 15.3, 0.9 Hz, 1H), 2.44 (d, J = 
15.3 Hz, 1H), 2.21 (dd, J = 14.2, 9.0 Hz, 1H) 1.7 (s, 3H); 13C NMR (125 MHz, CDCl3): 
δ170.1, 169.6, 169.0, 131.6, 131.2, 119.24, 119.22, 87.0, 77.2, 67.1, 66.8, 59.0, 43.8, 
34.7, 21.6; IR (thin film): 2362, 2339, 1824, 1729 cm-1; HRMS (ESI+) m/z calcd. for 
C15H19O6  [M + H]+  295.1182; found 295.1177. 
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O
O
Me
H
O
OBn
OBn
O
 (±)-4.14d  
Dibenzyl 5-methyl-7-oxo-6-oxabicyclo[3.2.0]heptane-3,3-dicarboxylate ((±)-4.14d). 
Prepared according to the representative procedure using Michael donor 4.10d (77 mg, 
0.23 mmol, 1.00 equiv.), THF (1 mL), LiHMDS (320 µL of a 1.0 M solution in THF, 
0.32 mmol, 1.4 equiv.), CH2Cl2 (4 mL), 4-PPY (80 µL of a 0.82 M solution in CH2Cl2, 
0.064 mmol, 0.23 equiv.) and EtN(iPr)2 (60 µL, 0.32 mmol, 1.4 equiv.), and acryloyl 
chloride (4.1a, 261 µL of a 1.612 M solution in CH2Cl2, 0.42 mmol, 1.8 equiv.). After 
addition of acryloyl chloride, the reaction was allowed to react for 6 h at ambient 
temperature (23 oC). Purification by flash column chromatography (SiO2, 10 → 50% 
EtOAc/hexanes) afforded bicyclic-β-lactone (±)-4.14d (47 mg, 53%) as a white solid: 
TLC (EtOAc:hexanes, 3:7 v/v): Rf = 0.32; 1H NMR (500 MHz, CDCl3): δ 7.23 (dt, J = 
7.3, 3.4 Hz, 6H), 7.18 (dd, J = 6.1, 3.4 Hz, 2H), 7.13 (dd, J = 6.5, 2.7 Hz, 2H), 5.12 (d, J 
= 12.2 Hz, 1H), 5.05-4.99 (m, 3H), 3.45 (d, J = 8.9 Hz, 1H), 3.07 (d, J = 14.1 Hz, 1H), 
2.36, 2.96 (ABq, JAB = 15.3 Hz, 2H), 2.12 (dd, J = 14.2, 9.0 Hz, 1H), 1.62 (s, 3H).; 13C 
NMR (125 MHz, CDCl3): δ 170.1, 169.7, 169.0, 135.2, 135.0, 128.8(2), 128.7(2), 
128.65, 128.63(2), 128.5, 128.1(2), 86.9, 68.2, 67.9, 60.9, 59.0, 43.7, 34.6, 21.6; IR (thin 
film): 1829, 1735, 1264 cm-1; HRMS (ESI+) m/z calcd. for C23H22LiO6 [M + Li]+: 
401.1576; found 401.1560. 
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O
O
Me
H
O
OMe
O
 (±)-4.14g  
Methyl 3-acetyl-5-methyl-7-oxo-6-oxabicyclo[3.2.0]heptane-3-carboxylate ((±)-
4.14g). Prepared according to the representative procedure using Michael donor 4.10g 
(55 mg, 0.32 mmol, 1.00 equiv.), THF (1 mL), LiHMDS (320 µL of a 1.0 M solution in 
THF, 0.32 mmol, 1.00 equiv.), CH2Cl2 (4 mL), 4-PPY (80 µL of a 0.82 M solution in 
CH2Cl2, 0.064 mmol, 0.20 equiv.), EtN(iPr)2 (60 µL, 0.32 mmol, 1.00 equiv.), and 
acryloyl chloride (4.1a, 261 µL of a 1.612 M solution in CH2Cl2, 0.42 mmol, 1.30 
equiv.). After addition of acryloyl chloride, the reaction was allowed to react for 8 h at 
ambient temperature (23 oC) as opposed to the standard 6 h. Purification by flash column 
chromatography (SiO2, 25 → 55% EtOAc/hexanes) afforded a mixture of diastereomers 
(~1:1) of bicyclic-β-lactone (±)-4.14g (52 mg, 72%) as a pale yellow oil: TLC 
(EtOAc:hexanes, 5:5 v/v), Rf = 0.31 and 0.28; (Note: Sufficient amounts of each 
diastereomer were isolated by flash chromatography to obtain 1H  but not 13C NMR of 
each diastereomer), Diast. with Rf = 0.31: 1H NMR (500 MHz, CDCl3): δ 3.76 (s, 3H), 
3.51 (app d, J = 8.5 Hz, 1H),  3.04 (app d, J = 14.0 Hz, 1H), 2.33, 2.87 (ABq, JAB = 15.3 
Hz, 2H), 2.18 (s, 3H), 2.04 (dd, J = 14.0, 8.9 Hz, 1H), 1.67 (s, 3H); Diast. with Rf = 0.31: 
1H NMR (500 MHz, CDCl3): δ 3.72 (s, 3H), 3.48 (app d, J = 8.5 Hz, 1H), 3.14 (app d, J 
= 14.2 Hz, 1H), 2.44, 2.93 (ABq, JAB = 15.6 Hz, 2H), 2.25 (s, 3H), 2.15 (dd, J = 14.2, 
9.1, 1H), 1.68 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 201.6, 201.5, 171.6, 171.2, 169.2, 
168.9, 87.0, 86.7, 67.8, 67.1, 59.0, 58.8, 53.5 (2), 43.0, 42.5, 33.6, 33.2, 26.9 26.5, 21.8, 
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21.7; IR (thin film):1827, 1711 cm-1; HRMS (ESI+) m/z calcd. for C11H15O5 [M+H]+: 
227.0919; found 227.0923. 
O
O
Me
H
NC
OMe
O
 (±)-4.14h  
Methyl 3-cyano-5-methyl-7-oxo-6-oxabicyclo[3.2.0]heptane-3-carboxylate ((±)-
4.14h). Prepared according to the representative procedure using known Michael donor 
4.10h419 (50 mg, 0.32 mmol, 1.00 equiv.), THF (1 mL), LiHMDS (320 µL of a 1.0 M 
solution in THF, 0.32 mmol, 1.00 equiv.), CH2Cl2 (4 mL), 4-PPY (80 µL of a 0.82 M 
solution in CH2Cl2, 0.064 mmol, 0.20 equiv.), EtN(iPr)2 (92 µL, 0.48 mmol, 1.50 
equiv.), acryloyl chloride (4.1a, 261 µL of a 1.612 M solution in CH2Cl2, 0.42 mmol, 
1.30 equiv.). After the addition of acryloyl chloride, the reaction was allowed to react at 
ambient temperature (23 oC) for 6 h. Purification by flash column chromatography 
(SiO2, 10 → 40% EtOAc/hexanes) afforded a mixture of diastereomers (1.7:1) of 
bicyclic-β-lactone (±)-4.14h (44 mg, 65%) as a yellow oil: TLC (EtOAc:hexanes, 
3.5:6.5 v/v): Rf = 0.38 and 0.12; (Note: Sufficient amounts of each diastereomer were 
separated by flash chromatography to obtain 1H  and 13C NMR for each diastereomer) 
Diast. with Rf = 0.38: 1H NMR (500 MHz, CDCl3): δ  3.89 (s, 3H), 3.74 (app d, J = 8.6 
Hz, 1H), 2.91, 2.36 (ABq, JAB =  15.2  Hz, 2H), 2.53 (dd, J = 14.4, 8.5 Hz, 1H), 2.82 
(app d, J = 14.4 Hz, 1H), 1.77 (s, 3H); 13C NMR (125 MHz; CDCl3): δ168.1, 167.7, 
118.3, 86.3, 59.4, 54.7, 47.2, 45.4, 37.0, 21.6; Diast. with Rf = 0.12: 1H NMR (500 MHz, 
CDCl3): δ  3.86 (s, 3H), 3.65 (app d, J = 9.0 Hz, 1H), 3.25 (app d, J = 14.3 Hz, 1H), 
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3.24, 2.39 (ABq, JAB = 15.1, 2H), 2.42 (dd, J = 9.1, 14.5 Hz, 1H), 1.73 (s, 3H); 13C NMR 
(125 MHz; CDCl3): δ167.6, 166.9, 118.2, 86.0, 59.2, 54.6, 46.9, 46.1, 35.5, 21.6; IR 
(thin film): 2357, 1824, 1747 cm-1; HRMS (ESI+) m/z calcd. for C10H11LiNO4 [M+Li]+: 
216.0848; found 216.0839. 
O
O
Me
H
NC
Oallyl
O
 (±)-4.14i  
Allyl 3-cyano-5-methyl-7-oxo-6-oxabicyclo[3.2.0]heptane-3-carboxylate ((±)-4.14i).  
Prepared according to the representative procedure using known Michael donor 4.10i 
(58 mg, 0.32 mmol, 1.00 equiv.), THF (1 mL), LiHMDS (320 µL of a 1.0 M solution in 
THF, 0.32 mmol, 1.00 equiv.), CH2Cl2 (4 mL), 4-PPY (80 µL of a 0.82 M solution in 
CH2Cl2, 0.064 mmol, 0.20 equiv.), EtN(iPr)2 (60 µL, 0.32 mmol, 1.00 equiv.), acryloyl 
chloride (4.1a, 261 µL of a 1.612 M solution in CH2Cl2, 0.42 mmol, 1.30 equiv.). After 
addition of acryloyl chloride, the reaction was allowed to react at ambient temperature 
(23 ºC) for 24 h. Purification by flash column chromatography (SiO2, 10 → 50% 
EtOAc/hexanes) afforded a mixture of diastereomers (1.16:1) of bicyclic-β-lactone (±)-
4.14i (41 mg, 55%) as a yellow oil: TLC (EtOAc:hexanes, 3.5:6.5 v/v): Rf = 0.39; (NMR 
data is provided for the ~1.2:1 mixture of diastereomers which were inseparable) 1H 
NMR (500 MHz, CDCl3): δ 5.97-5.89 (m, 2H), 5.44-5.38 (m, 2H), 5.35-5.32 (m, 2H), 
4.75-4.71 (m, 4H), 3.74 (d, J = 8.0 Hz, 1H), 3.63 (dd, J = 9.0, 1 Hz, 1H), 3.25 (dd, J = 
14.5, 7.5 Hz, 2H), 2.92 (dd, J = 15.0, 1.0 Hz, 1H), 2.82 (d, J = 14.5 Hz, 1H), 2.53 (dd, J 
= 14.5, 8.5 Hz, 1H), 2.45-2.40 (m, 2H), 2.38 (d, J = 2.5 Hz, 1H), 1.77 (s, 3H), 1.74 (s, 
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3H); 13C NMR (125 MHz, CDCl3): δ 167.75, 167.53, 167.28, 166.08, 130.58, 130.47, 
120.50, 120.39, 118.23, 118.20, 86.34, 86.04, 68.48, 68.23, 59.35, 59.19, 47.37, 47.12, 
46.05, 45.33, 36.92, 35.52, 21.57 (2); IR (thin film): 2937, 2246, 1822, 1745 cm-1; 
HRMS (ESI+) m/z calcd for C12H14NO4 [M+H]+: 236.0923; found 236.1220. 
O
O
Me
H
MeO2C
MeO2C
 (±)-4.14j
Me
 
Dimethyl 4,5-dimethyl-7-oxo-6-oxabicyclo[3.2.0]heptane-3,3-dicarboxylate ((±)-
4.14j). Prepared according to the representative procedure using Michael donor 4.10j 
(65 mg, 0.32 mmol, 1.00 equiv.), THF (1 mL), LiHMDS (320 µL of a 1.0 M solution in 
THF, 0.32 mmol, 1.00 equiv.), CH2Cl2 (4 mL), 4-PPY (80 µL of a 0.82 M solution in 
CH2Cl2, 0.064 mmol, 0.20 equiv.), EtN(iPr)2 (60 µL, 0.32 mmol, 1.00 equiv.), and 
acryloyl chloride (4.1a, 261 µL of a 1.612 M solution in CH2Cl2, 0.42 mmol, 1.30 
equiv.). After the addition of acryloyl chloride, the reaction was allowed to react for 12 h 
at ambient temperature (23 oC) as opposed to the standard 6 h. Purification by flash 
column chromatography (SiO2, 15 → 50% EtOAc/hexanes) afforded a mixture of 
diastereomers (2:1) of bicyclic-β-lactone (±)-4.14j (69 mg, 84%) as a pale yellow oil: 
TLC (EtOAc:hexanes, 4:6 v/v): Rf = 0.33 and 0.42; (Note: Sufficient amounts of each 
diastereomer were isolated by flash chromatography to obtain 1H but not 13C NMR of 
each diastereomer), Diast. with Rf = 0.42: 1H NMR (500 MHz; CDCl3): δ 3.72 (s, 3H), 
3.71 (s, 3H), 3.51 (dd, J = 9.1, 1.5 Hz, 1H), 3.39 (q, J = 7.6 Hz, 1H), 2.81 (dd, J = 14.7, 
1.4 Hz, 1H), 2.66 (dd, J = 14.7, 9.0 Hz, 1H), 1.59 (s, 3H), 0.90 (d, J = 7.6 Hz, 3H); 
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Diast. with Rf = 0.33: 1H NMR (500 MHz; CDCl3): δ 3.72 (s, 3H), 3.71 (s, 3H), 3.52 
(dd, J = 9.1, 0.7 Hz, 1H), 2.95 (app d, J = 14.3 Hz, 1H), 2.71 (q, J = 7.1 Hz, 1H), 2.00 
(dd, J = 14.3, 9.1 Hz, 1H), 1.60 (s, 3H), 1.19 (d, J = 7.1 Hz, 3H); 13C NMR (125 MHz; 
CDCl3): δ 171.1, 170.0, 169.9, 169.8, 169.31, 169.27, 89.12, 87.9, 65.5, 63.1, 58.4, 57.9, 
53.4, 53.23, 53.20, 52.6, 47.7, 45.8, 33.6, 31.0, 20.5, 19.6, 13.0, 9.8; IR (thin film): 2961, 
1824, 1735 cm-1; HRMS (ESI+) m/z calcd. for C12H16OLiO6 [M+Li]+: 263.1107; found 
263.1115. 
Representative procedure for the racemic nucleophile-catalyzed Michael-aldol-β-
lactonization (NMCAL) process when varying the Michael acceptors as described 
for β-lactone (±)-4.14k. 
MeO2C
MeO2C
O
O
O
Me
H
MeO2C
MeO2C
+
LiHMDS (1.0 equiv)
4-PPY (20 mol %)
DIPEA (1.0 equiv)
THF/CH2Cl2 (1:4)
4 h
Me
Me
O
Cl
4.10a 4.1b (±)-4.14k  
Dimethyl 2,5-dimethyl-7-oxo-6-oxabicyclo[3.2.0]heptane-3,3-dicarboxylate ((±)-
4.14k). To an oven-dried, 25 mL round-bottomed flask equipped with a magnetic stir bar 
was added dimethyl 2-(2-oxopropyl) malonate (4.10a, 61.0 mg, 0.32 mmol, 1.00 equiv.) 
along with THF (1 mL) and the mixture was cooled to -78 oC. With vigorous stirring, 
LiHMDS (320 µL of a 1.0 M solution in THF, 0.32 mmol, 1.00 equiv.) was added 
dropwise via microliter syringe. After complete addition, the reaction was stirred for 10 
min at -78 oC and then warmed to 0 oC by switching the dry ice/acetone bath to an 
ice/water bath. Stirring was continued for an additional 10 min at this temperature, and 
then CH2Cl2 (4 mL), 4-PPY (80 µL of a 0.82 M solution in CH2Cl2, 0.064 mmol, 0.20 
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equiv.) and EtN(iPr)2 (60 µL, 0.32 mmol, 1.00 equiv.) were added via microliter syringe, 
sequentially. The reaction was allowed to stir for an additional 10 min at 0 oC before (E)-
but-2-enoyl chloride (4.1b, 260 µL of a 1.6 M solution in CH2Cl2, 0.42 mmol, 1.30 
equiv.) was added via microliter syringe dropwise over ~2 min. After complete addition, 
the ice bath was removed and the reaction was stirred for 4 h at ambient temperature (23 
oC). The reaction was then cooled to 0 oC and silica gel (2 g) was added and stirred at 0 
oC for 10 min. Then the ice/water bath was removed and the reaction stirred at ambient 
temperature (23 oC) for 20 min. The mixture was then diluted with hexanes (4.0 mL), 
filtered through a short silica gel pad (~2 g of silica gel), and rinsed with EtOAc (3 x 4 
mL). The filtrate was then concentrated by rotary evaporation, analyzed by 1H NMR. 
Purification by flash column chromatography (SiO2, 10 → 40% EtOAc/hexanes) 
afforded a single diastereomer of bicyclic-β-lactone (±)-4.14k (77.1 mg, 94%) as a white 
solid: TLC (EtOAc:hexanes, 3:7 v/v): Rf = 0.25; 1H NMR (500 MHz, CDCl3): δ 3.71 (s, 
3H), 3.70 (s, 3H), 3.42 (app q, J = 7.5 Hz, 1H), 3.17 (app s, 1H), 2.63, 2.82 (ABq, JAB = 
16.5 Hz, 1H), 1.66 (s, 3H), 0.86 (d, J = 7.5 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ 
170.6, 168.8, 168.3, 86.0, 65.9, 64.5, 53.2, 53.0, 40.9, 39.6, 22.2, 17.0; IR (thin film): 
2996, 2927, 1835, 1735, 1730 cm-1; HRMS (ESI+) m/z calcd. for C12H17O6 [M+H]+: 
257.1025; found 257.1038. 
LiHMDS (1.0 equiv)
4-PPY (20 mol %)
DIPEA (1.0 equiv)
THF/CH2Cl2 (1:4)
4 h
MeO2C
MeO2C
O
O
O
Me
H
MeO2C
MeO2C
+
Ph
O
Cl
4.10a 4.1d (±)-4.14m  
Dimethyl 5-methyl-7-oxo-2-phenyl-6-oxabicyclo[3.2.0]heptane-3,3-dicarboxylate 
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((±)-4.14m). Prepared according to the representative procedure for (±)-4.14k, except 
that cinnamoyl chloride (4.1d, 70 mg, 0.42 mmol, 1.30 equiv.) was added as the Michael 
acceptor to afford a single diastereomer of bicyclic-β-lactone (±)-4.14m (91.6 mg, 90%) 
as a white solid: TLC (EtOAc:hexanes, 2:8 v/v): Rf = 0.15; 1H NMR (500 MHz, CDCl3): 
δ 7.27 (m, 3H), 6.95 (d, J = 7.0 Hz, 2H), 4.62 (s, 1H), 3.78 (s, 3H), 3.68 (s, 1H), 3.30 (s, 
3H), 2.90 (app s, 2H), 1.89 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 170.6, 167.9, 167.6, 
138.2, 128.7 (2), 128.0, 127.9(2), 87.3, 66.8, 65.4, 53.5, 52.63, 51.0, 41.9, 21.4; IR (thin 
film): 2967, 2935, 1829, 1732, 1728 cm-1; HRMS (ESI+) m/z calcd. for C17H19O6 
[M+H]+: 319.1182; found 319.1149. 
MeO2C
MeO2C
O
O
O
Me
H
MeO2C
MeO2C
O
Cl
+
LiHMDS (1.0 equiv)
4-PPY (20 mol %)
DIPEA (1.0 equiv)
THF/CH2Cl2 (1:4)
4 h
4.10a 4.1g (±)-4.14p  
Dimethyl 5-methyl-7-oxo-2-((E)-prop-1-en-1-yl)-6-oxabicyclo [3.2.0]heptane-3,3-
dicarboxylate ((±)-4.14p). Prepared according to the representative procedure for (±)-
4.14k, except that sorbic chloride (4.4.1g, 51.4 uL, 0.42 mmol, 1.3 equiv) was added as 
the Michael acceptor to afford a single diastereomer of bicyclic-β-lactone (±)-4.14p 
(58.0 mg, 64%) as a white solid: TLC (EtOAc:hexanes, 3:7 v/v):  Rf = 0.50; 1H NMR 
(500 MHz, CDCl3): δ 5.59 (m, 1H), 5.09 (m, 1H), 3.90 (app d, J = 10.0 Hz, 1H), 3.75 (s, 
3H), 3.63 (s, 3H), 3.33 (s, 1H), 2.65, 2.82 (ABq, JAB = 16.0 Hz,  2H), 1.71 (s, 3H), 1.64 
(dd, J = 6.5, 1.5 Hz,  3H); 13C NMR (125 MHz, CDCl3): 170.5, 168.4, 168.0, 130.0, 
126.4, 86.4, 65.3, 64.5, 53.3, 53.0, 48.6, 41.5, 22.0, 18.0; IR (thin film): 2977, 2963, 
1829, 1732, 1729 cm-1; HRMS (ESI+) m/z calcd. for C14H19O6 [M+H]+: 283.1182; found 
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283.1203.  
MeO2C
MeO2C
O
O
O
Me
Me
MeO2C
MeO2C
O
Cl
+
LiHMDS (1.0 equiv)
4-PPY (20 mol %)
DIPEA (1.0 equiv)
THF/CH2Cl2 (1:4)
4 h
4.10a 4.1h (±)-4.14q  
Dimethyl 1,5-dimethyl-7-oxo-6-oxabicyclo[3.2.0]heptane-3,3-dicarboxylate ((±)-
4.14q). Prepared according to the representative procedure for (±)-4.14k, except that 
methacryloyl chloride (4.1h, 41 µL, 0.42 mmol, 1.30 equiv.) was added as the Michael 
acceptor to afford a single diastereomer of bicyclic-β-lactone (±)-14.4q (64.1 mg, 78%) 
as a white solid: TLC (EtOAc:hexanes, 2.5:7.5 v/v): Rf = 0.45; 1H NMR (500 MHz, 
CDCl3): δ 3.73 (s, 3H), 3.71 (s, 3H), 1.85, 3.15 (ABq, JAB = 14 Hz, 2H), 2.40, 2.98 
(ABq, JAB = 15 Hz,  2H), 1.52 (s, 3H), 1.27 (s, 3H); 13C NMR (125 MHz, CDCl3): 172.4, 
170.9, 170.3, 89.3, 62.3, 58.4, 53.4, 53.2, 44.1, 42.1, 18.7, 14.1; IR (thin film): 2986, 
2937, 1829, 1739, 1725 cm-1; HRMS (ESI+) m/z calcd. for C12H17O6 [M+H]+: 257.1025; 
found 257.1058. 
MeO2C
MeO2C
O
O
O
Me
Me
MeO2C
MeO2C
O
Cl
+
LiHMDS (1.0 equiv)
4-PPY (20 mol %)
DIPEA (1.0 equiv)
THF/CH2Cl2 (1:4)
4 h
Me
4.10a 4.1i (±)-4.14r
Me
 
Dimethyl 1,2,5-trimethyl-7-oxo-6-oxabicyclo [3.2.0]heptane-3,3-dicarboxylate ((±)-
4.14r). Prepared according to the representative procedure for (±)-4.14k, except that (E)-
2-methylbut-2-enoyl chloride (4.1i, 50 mg, 0.42 mmol, 1.30 equiv.) was added as the 
Michael acceptor, to afford a single diastereomer of bicyclic-β-lactone (±)-4.14r (52 mg, 
60%) as a white solid: TLC (EtOAc:hexanes, 3:7 v/v):  Rf = 0.20; 1H NMR (500 MHz, 
CDCl3): δ 3.75 (s, 3H), 3.74 (s, 3H), 3.38 (q, J = 8.0 Hz, 1H), 2.58, 2.86 (ABq, JAB = 
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15.5 Hz, 2H), 1.52 (s, 3H), 1.21 (s, 3H), 0.78 (d, J = 8.0 Hz, 3H); 13C NMR (125 MHz, 
CDCl3): δ 173.0, 170.7, 169.2, 88.8, 64.5, 63.3, 53.3, 53.1, 42.1, 41.7, 19.2, 12.3, 11.4; 
IR (thin film): 2995, 2928, 1832, 1732, 1728 cm-1; HRMS (ESI+) m/z calcd. for 
C13H19O6 [M+H]+: 271.1182; found 271.1159. 
 
Representative procedure for the enantioselective nucleophile-catalyzed Michael-
aldol-β-lactonization (NMCAL) process as described for β-lactone (+)-4.14e. 
MeOC
MeOC
O
O
O
Me
H
MeOC
MeOC
+
O
Cl
4.10e 4.1a (+)-4.14e
LiHMDS (1.0 equiv)
(S)-HBTM (20 mol%)
DIPEA (1.0 equiv)
THF/CH2Cl2 (1:4)
6 h  
Methyl-7-oxo-6-oxabicyclo[3.2.0]heptane-3,3-diyldiethanone ((+)-4.14e). To an 
oven-dried, 25 mL round-bottomed flask equipped with a magnetic stir bar was added 
Michael donor 4.10e (49.8 mg, 0.32 mmol, 1.00 equiv.) along with THF (1 mL) and 
cooled to -78 oC. With vigorous stirring, LiHMDS (320 µL of a 1.0 M solution in THF, 
0.32 mmol, 1.00 equiv.) was added dropwise via microliter syringe over ~4 min. After 
the addition the reaction was stirred for 10 min at -78 oC and then warmed to 0 oC by 
switching the dry ice/acetone bath to an ice/water bath. Stirring was continued for an 
additional 10 min at this temperature, and then CH2Cl2 (3 mL), (S)-HBTM (17 mg, 
0.064 mmol, dissolved in 1.1 mL CH2Cl2, 0.20 equiv.) and EtN(iPr)2 (60 µL, 0.32 mmol, 
1.00 equiv.) were added via microliter syringe sequentially. The reaction was allowed to 
stir for an additional 10 min at 0 oC before acryloyl chloride (4.1a, 261 µL of a 1.612 M 
solution in CH2Cl2, 0.42 mmol, 1.30 equiv.) was added via microliter syringe dropwise 
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over 4 min (addition time varied from 4 min- 2h dependent on acid chloride employed) 
at 0 oC. After complete addition, the ice bath was removed and the reaction stirred for 6 
h (reaction time varied from 6-24 h dependent on acid chloride employed) at ambient 
temperature (23 oC). When the reaction was judged complete by TLC, the reaction was 
cooled to 0 oC and silica gel (2 g) was added and stirred at 0 oC for 10 min. Then the 
ice/water bath was removed and the reaction stirred at ambient temperature (23 oC) for 
20 min. The mixture was then diluted with hexanes (4.0 mL), filtered through a short 
silica gel pad (~2 g of silica gel), and rinsed with EtOAc (3 x 4 mL). This process 
removes polar impurities including (S)-HBTM.  The filtrate was concentrated by rotary 
evaporation, and following 1H NMR analysis of the reaction mixture, it was purified by 
flash column chromatography (SiO2, 10 → 50% EtOAc/hexanes) to afford bicyclic-β-
lactone (+)-4.14e (41.2 mg, 61%) as a white solid: [α]D
21  = +167.34 (c = 1.00, CHCl3). 
Enantiomeric excess was determined by HPLC analysis in comparison with authentic 
racemic material using a Chiralcel AD-H column: hexanes:iPrOH = 95:05, flow rate 0.5 
mL/min, λ = 210 nm: tminor = 52.0 min, tmajor = 67.4 min; 95% ee. Spectral data matched 
that reported above for the racemic compound. 
O
O
Me
H
MeO2C
MeO2C
(+)-4.14a  
(1S,5R)-Dimethyl 5-methyl-7-oxo-6-oxabicyclo[3.2.0]heptane-3,3-dicarboxylate 
((+)-4.14a). Prepared according to the representative procedure using Michael donor 
4.10a (60.0 mg, 0.32 mmol, 1.00 equiv.), THF (1 mL), LiHMDS (320 µL of a 1.0 M 
solution in THF, 0.32 mmol, 1.00 equiv.), CH2Cl2 (3 mL), (S)-HBTM (17 mg, 0.064 
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mmol, dissolved in 1.1 mL CH2Cl2, 0.20 equiv.), N’,N’-diisorpopylethylamine 60 µL, 
0.32 mmol, 1.00 equiv.), and acryloyl chloride (4.1a, 34 µL, 0.42 mmol, dissolved in 
260 µL CH2Cl2, 1.30 equiv.). After the addition of acryloyl chloride at 0oC (over ~ 4 
min), the reaction was allowed to react for 6 h at ambient temperature (23 ºC). After 1H 
NMR analysis of the reaction mixture, it was purified by flash column chromatography 
(SiO2, 20 → 50% EtOAc/hexanes) to afford bicyclic-β-lactone (+)-4.14a (55.8 mg, 72% 
yield) as a colorless oil: [α]D21 = +67.25 (c = 1.00, CHCl3). Enantiomeric excess was 
determined by chiral GC analysis in comparison with authentic racemic material; tminor = 
253.1 min, tmajor = 263.4 min; 97% ee. Spectral data matched that previously reported1 
and absolute stereochemistry was assigned by derivatization as described below. 
O
O
Me
H
MeO2C
MeO2C
(+)-4.14a
OH
O
Me
H
MeO2C
MeO2C
(+)-4.S15
N
H
Br
NH2
Br
THF, 23 oC, 40 h
 
(3R,4S)-Dimethyl4-((4-bromobenzyl)carbamoyl)-3-hydroxy-3-methylcyclo-pentane 
1,1-dicarboxylate ((+)-4.S15). To an oven-dried, 5 mL round-bottomed flask was added 
β-lactone (+)-4.14a (49 mg, 0.20 mmol, 1.00 equiv) and p-bromobenzylamine (0.10 mL, 
0.80 mmol, 4.00 equiv), in THF (2 mL). The reaction was allowed to stir at ambient 
temperature  (23 °C) for 40 h. Upon completion (as judged by TLC), the reaction was 
concentrated by rotary evaporation and purified by flash column chromatography (SiO2, 
20 → 60% EtOAc/hexanes) to afford amide (+)-4.S15 (56 mg, 65%) as a colorless 
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crystalline solid: m.p. 118–121 °C (recrystallized from CDCl3); TLC (EtOAc:hexanes, 
5:5 v/v): Rf = 0.35; [α]D19 = +8.00 (c = 1.00, CHCl3). 1H NMR (500 MHz, CDCl3): δ 
7.46 (d, J = 8.3 Hz, 2H), 7.14 (d, J = 8.3 Hz, 2H), 6.38 (brs, 1H), 4.45 (dd, J = 14.9, 5.9, 
1H), 4.41 (dd, J = 15.0, 5.9 Hz, 1H), 3.76 (s, 3H), 3.72 (s, 3H), 2.80 (app t, J = 12.7 Hz, 
1H), 2.66, 2.13 (ABq, JAB = 14.0, 2H), 2.61 (dd, J = 13.3, 7.9 Hz, 1H), 2.52 (dd, J = 
12.1, 7.9 Hz, 1H), 1.37 (s, 3H) (OH not observed); 13C NMR (125 MHz, CDCl3): δ 
173.3, 173.1, 172.7, 137.1, 132.1(2), 129.6(2), 121.8, 80.0, 58.0, 53.8, 53.4, 53.3, 48.5, 
43.0, 37.5, 25.7; IR (thin film): 3336, 2960, 2922, 1732, 1637 cm-1; HRMS (ESI+) m/z 
calcd for C18H23BrNO6 [M+H]+: 428.0709; found 428.0692. 
O
O
Me
H
O
Oallyl
Oallyl
O
 (+)-4.14c  
(1R,5S)-Diallyl 5-methyl-7-oxo-6-oxabicyclo[3.2.0]heptane-3,3-dicarboxylate ((+)-
4.14c). Prepared according to the representative procedure using Michael donor 4.10c 
(76 mg, 0.32 mmol), THF (1 mL), LiHMDS (320 µL of a 1.0 M solution in THF, 0.32 
mmol, 1.00 equiv.), CH2Cl2 (3 mL), (S)-HBTM (17 mg, 0.064 mmol, dissolved in 80 µL 
CH2Cl2, 0.20 equiv.), EtN(iPr)2 (60 µL, 0.32 mmol, 1.00 equiv.), and acryloyl chloride 
(4.1a, 34 µL, 0.42 mmol, dissolved in 260 µL CH2Cl2, 1.30 equiv.). After the addition of 
acryloyl chloride at 0 oC (over ~4 min), the reaction was allowed to stir for 6 h at 
ambient temperature (23 ºC). Purification by flash column chromatography afforded 
bicyclic-β-lactone (+)-4.14c (69 mg, 74%) as a colorless oil: [α]D19  = +39.8 (c = 0.200, 
CHCl3). Enantiomeric excess was determined by HPLC analysis in comparison with 
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authentic racemic material using a Chiralcel IA column: hexanes:iPrOH = 92:08, flow 
rate 0.5 mL/min, λ = 210 nm: tmajor = 17.3 min, tminor = 21.3 min; 95% ee. Spectral data 
matched that reported above for the racemic compound that reported above for the 
racemic compound. 
O
O
Me
H
O
OBn
OBn
O
 (+)-4.14d  
(1S,5R)-Dibenzyl 5-methyl-7-oxo-6-oxabicyclo[3.2.0]heptane-3,3-dicarboxylate ((+)-
4.14d). Prepared according to the representative procedure using Michael donor 4.10d 
(95 mg, 0.28 mmol, 1.0 equiv.), THF (1 mL), LiHMDS (256 µL of a 1.0 M solution in 
THF, 0.26 mmol, 0.93 equiv.), CH2Cl2 (3 mL), (S)-HBTM (10.4 mg, 0.033 mmol, 
dissolved in 104 µL CH2Cl2, 0.12 equiv.), EtN(iPr)2 (48 µL, 0.28 mmol, 1.0 equiv.), and 
acryloyl chloride (4.1a, 34 µL, 0.42 mmol, dissolved in 227 µL CH2Cl2, 1.5 equiv.). 
After the addition of acryloyl chloride at 0 oC (over ~4 min), the reaction was allowed to 
react for 6 h at ambient temperature (23 ºC). Purification by flash column 
chromatography afforded bicyclic-β-lactone (+)-4.14d (59 mg, 59%) as a colorless oil: 
[α]D19 = +41.3 (c = 0.36, CHCl3). Enantiomeric excess was determined by HPLC 
analysis in comparison with authentic racemic material using a Chiralcel OD-H column: 
hexanes:iPrOH = 95:05, flow rate 1.0 mL/min, λ = 210 nm: tmajor = 36.6 min, tminor = 45.6 
min; 98% ee. Spectral data matched that reported above for the racemic compound. 
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O
O
Me
H
MeO2C
MeO2C
(+)-4.14k
Me
 
(1S,2S,5R)-Dimethyl 2,5-dimethyl-7-oxo-6-oxabicyclo[3.2.0]heptane-3,3-
dicarboxylate ((+)-4.14k). Prepared according to the representative procedure using 
Michael donor 4.10a (60 mg, 0.32 mmol, 1.00 equiv.), THF (1 mL), LiHMDS (320 µL 
of a 1.0 M solution in THF, 0.32 mmol, 1.00 equiv.), CH2Cl2 (4 mL), (S)-HBTM (17 
mg, 0.064 mmol, dissolved in 1.1 mL CH2Cl2, 0.20 equiv.), EtN(iPr)2 (60 µL, 0.32 
mmol, 1.00 equiv.), and (E)-but-2-enoyl chloride (4.1b, 40 µL, 0.42 mmol, dissolved in 
2 mL CH2Cl2, 1.30 equiv.). The solution of (E)-but-2-enoyl chloride was added by 
syringe pump over 2 h at 0 oC, the reaction was allowed to stir for 16 h at ambient 
temperature (23 oC). Purification by flash column chromatography afforded a single 
diastereomer of bicyclic-β-lactone (+)-4.14k (65 mg, 80%) a colorless solid: [α]D21 = 
+116.51 (c = 1.00, CHCl3). Enantiomeric excess was determined by HPLC analysis in 
comparison with authentic racemic material using a Chiralcel OD-H column: 
hexanes:iPrOH = 90:10, flow rate 0.5 mL/min, λ = 210 nm: tmajor = 22.4 min, tminor = 29.1 
min 94% ee. Spectral data matched that reported above for the racemic compound. 
 
O
O
Me
H
MeO2C
MeO2C
Ph
 (+)-4.14m
 
(1S,2R,5R)-Dimethyl 5-methyl-7-oxo-2-phenyl-6-oxabicyclo[3.2.0]heptane-3,3-
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dicarboxylate ((+)-4.14m). Prepared according to the representative procedure using 
Michael donor 4.10a (61 mg, 0.32 mmol, 1.00 equiv.), THF (1 mL), LiHMDS (320 µL 
of a 1.0 M solution in THF, 0.32 mmol, 1.00 equiv.), CH2Cl2 (3 mL), (S)-HBTM (17 
mg, 0.064 mmol, dissolved in 400 µL CH2Cl2, 0.20 equiv.), EtN(iPr)2 (60 µL, 0.32 
mmol, 1.00 equiv.), and cinnamoyl chloride (4.1d, 67.7 mg, 0.35 mmol, dissolved in 2.6 
mL CH2Cl2, 1.10 equiv.). The solution of cinnamoyl chloride was added by syringe 
pump over 2 h at 0 oC, and then the reaction was allowed to stir for 18 h at ambient 
temperature (23 oC). Purification by flash column chromatography afforded a single 
diastereomer of bicyclic-β-lactone (+)-4.14m (82 mg, 80%) as a white solid: [α]D21 = 
+188.23 (c = 0.17, CHCl3). Enantiomeric excess was determined by HPLC analysis in 
comparison with authentic racemic material using a Chiralcel AD-H column: 
hexanes:iPrOH = 70:30, flow rate 0.5 mL/min, λ = 210 nm: tmajor = 12.0 min, tminor = 13.1  
min; 99% ee. Spectral data matched that reported above for the racemic compound. 
 
Use of a lower catalyst loading for the NCMAL (5 mol%) as described for bicyclic-
β-lactone (+)-4.14m. This reaction was run according to the procedure described above 
for (+)-4.14m with the exception that a lower catalyst loading (5 vs 20 mol%) and a 
longer total reaction time (26 h vs 20 h) were employed. Michael donor 4.10a (72 mg, 
0.38 mmol, 1.00 equiv.), THF (1 mL), LiHMDS (380 µL of a 1.0 M solution in THF, 
0.38 mmol, 1.00 equiv.), CH2Cl2 (3.6 mL), (S)-HBTM (5.1 mg, 0.019 mmol, dissolved 
in 500 µL CH2Cl2, 0.05 equiv.), EtN(iPr)2 (71 µL, 0.38 mmol, 1.00 equiv.), and 
cinnamoyl chloride (4.1d, 82 mg, 0.49 mmol, dissolved in 2.7 mL CH2Cl2, 1.30 equiv.). 
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The solution of cinnamoyl chloride was added by syringe pump over 8 h at 0 oC, and the 
reaction was allowed to stir for 18 h at ambient temperature (23 oC). Purification by 
flash column chromatography afforded a single diastereomer of bicyclic-β-lactone (+)-
4.14m (94 mg, 78%) as a white solid. Enantiomeric excess was determined by chiral 
HPLC analysis in comparison with racemic material (Chiralcel AD-H column: 
hexanes:iPrOH = 70:30, flow rate 0.5 mL/min, λ = 210 nm): tmajor = 12.0 min, tminor = 
13.1  min; 90% ee. 
O
O
Me
H
MeO2C
MeO2C
(+)-4.14p  
(1S,2S,5R)-Dimethyl-5-methyl-7-oxo-2-((E)-prop-1-en-1-yl)-6-oxabicyclo[3.2.0] 
heptane-3,3-dicarboxylate ((+)-4.14p). Prepared according to the representative 
procedure using Michael donor 4.10a (60.0 mg, 0.32 mmol, 1.00 equiv.), THF (1 mL), 
LiHMDS (320 µL of a 1.0 M solution in THF, 0.32 mmol, 1.00 equiv.), CH2Cl2 (4 mL), 
(S)-HBTM (17 mg, 0.064 mmol, dissolved in 1 mL CH2Cl2, 0.20 equiv.), EtN(iPr)2 (60 
µL, 0.32 mmol, 1.00 equiv.), and sorbic chloride (4.1g, 51.4 µL, 0.42 mmol, dissolved in 
2 mL CH2Cl2, 1.3 equiv.). The solution of sorbic chloride was added by syringe pump 
over 2 h at 0 oC, and then the reaction was allowed to stir for 16 h at ambient 
temperature (23 oC). Purification by flash column chromatography afforded a single 
diastereomer of bicyclic-β-lactone (+)-4.14p (56.0 mg, 62%) a white crystalline solid: 
m.p. 98–102 °C (recrystallized from CDCl3); [α]D23 = +140.00 (c = 1.00, CHCl3). 
Enantiomeric excess was determined by HPLC analysis in comparison with authentic 
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racemic material using a Chiralcel AD-H column: hexanes:iPrOH = 70:30, flow rate 0.5 
mL/min, λ = 210 nm: tmajor = 22.2 min, tminor = 27.1 min; 99% ee. Spectral data matched 
that reported above for the racemic compound. 
O
O
Me
H
MeO2C
MeO2C
(!)-4.14p  
(1R,2R,5S)-Dimethyl5-methyl-7-oxo-2-((E)-prop-1-en-1-yl)-6-oxabicyclo[3.2.0] 
heptane-3,3-dicarboxylate ((-)-4.14p). Prepared according to the representative 
procedure using Michael donor 4.10a (60.0 mg, 0.32 mmol, 1.00 equiv.), THF (1 mL), 
LiHMDS (320 µL of a 1.0 M solution in THF, 0.32 mmol, 1.00 equiv.), CH2Cl2 (3 mL), 
(R)-HBTM (17 mg, 0.064 mmol, dissolved in 1 mL CH2Cl2, 0.20 equiv.), EtN(iPr)2 (60 
µL, 0.32 mmol, 1.00 equiv.), and sorbic chloride (4.1g, 51.4 µL, 0.42 mmol, dissolved in 
2 mL CH2Cl2, 1.30 equiv.).  The solution of sorbic chloride was added by syringe pump 
over 2 h at 0 oC, and then the reaction was allowed to react for 21 h at room temperature 
(23 oC). Purification by flash column chromatography afforded a single diastereomer of 
bicyclic-β-lactone (-)-4.14p (54.2 mg, 60%) a colorless solid: [α]D21  = -138.00 (c = 
1.00, CHCl3). Enantiomeric excess was determined by HPLC analysis in comparison 
with authentic racemic material using a Chiralcel AD-H column: hexanes:iPrOH = 
70:30, flow rate 0.5 mL/min, λ = 210 nm: tminor = 22.2 min, tmajor = 27.2 min; 99% ee. 
Spectral data matched that reported above for the racemic compound. 
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O
O
Me
H
allylO2C
allylO2C
(+)-4.14s  
(1S,2S,5R)-Diallyl1,5-dimethyl-7-oxo-2-((E)-prop-1-en-1-yl)-6-oxabicyclo[3.2.0] 
heptane-3,3-dicarboxylate ((+)-4.14s). Prepared according to the representative 
procedure using Michael donor 4.10c (76 mg, 0.32 mmol, 1.00 equiv.), THF (1 mL), 
LiHMDS (320 µL of a 1.0 M solution in THF, 0.32 mmol, 1.00 equiv.), CH2Cl2 (3 mL), 
(S)-HBTM (17 mg, 0.064 mmol, dissolved in 1 mL CH2Cl2, 0.20 equiv.), EtN(iPr)2 (60 
µL, 0.32 mmol, 1.00 equiv.), and sorbic chloride (4.1g, 51.4 µL, 0.42 mmol, dissolved in 
2 mL CH2Cl2, 1.30 equiv.).  The solution of sorbic chloride was added by syringe pump 
over 2 h at 0 oC, and then the reaction was allowed to stir for 21 h at ambient 
temperature (23 oC). Purification by flash column chromatography afforded a single 
diastereomer of bicyclic-β-lactone (+)-4.14s (59 mg, 54%) a colorless oil: TLC 
(EtOAc:hexanes, 2:8 v/v): Rf = 0.64; [α]D23 = +76.8 (c = 0.53, CHCl3). Enantiomeric 
excess was determined by HPLC analysis in comparison with authentic racemic material 
using a Chiralcel AD-H column: hexanes:iPrOH = 95:05, flow rate 0.5 mL/min, λ = 210 
nm: tmajor = 17.7 min, tminor = 25.5 min; 94% ee. 1H NMR (500 MHz, CDCl3): δ 5.91-
5.77 (m, 2H), 5.62-5.57 (m, 1H), 5.34-5.21 (m, 4H), 5.14-5.08 (m, 1H), 4.69-4.61 (m, 
2H), 4.58-4.50 (m, 2H), 3.95 (app d, J = 10.0 Hz, 1H), 3.35 (s, 1H), 2.69, 2.87 (ABq, JAB 
= 15.7 Hz, 2H), 1.73 (s, 3H), 1.63 (dd, J = 6.5, 1.7 Hz, 3H); 13C NMR (125 MHz, 
CDCl3): δ 169.7, 168.1, 167.7, 131.5, 131.4, 130.3, 126.5, 119.3, 119.1, 86.5, 67.1, 66.7, 
65.5, 64.7, 48.7, 41.7, 22.2, 18.0; IR (thin film): 2940, 2857, 1835, 1741, 1270, 1149 cm-
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1; HRMS (ESI+) m/z calcd. for C18H22LiO6 [M+Li]+: 341.1576; found 341.1562. 
O
O
Me
Me
MeO2C
MeO2C
(+)-4.14q  
(1S,5R)-Dimethyl 1,5-dimethyl-7-oxo-6-oxabicyclo[3.2.0]heptane-3,3-dicarboxylate 
((+)-4.14q). Prepared according to the representative procedure using Michael donor 
4.10a (60.0 mg, 0.32 mmol, 1.00 equiv.), THF (1 mL), LiHMDS (320 µL of a 1.0 M 
solution in THF, 0.32 mmol, 1.00 equiv.), CH2Cl2 (3 mL), (S)-HBTM (17 mg, 0.064 
mmol, dissolved in 1 mL CH2Cl2, 0.20 equiv.), EtN(iPr)2 (60 µL, 0.32 mmol, 1.00 
equiv.), and methacryloyl chloride (4.1h, 41.0 µL, 0.42 mmol, dissolved in 2 mL 
CH2Cl2, 1.30 equiv.).  The solution of methacryloyl chloride was added by syringe pump 
over 2 h at 0 oC, and then the reaction was stirred for 18 h at ambient temperature (23 
oC). Purification by flash column chromatography afforded a single diastereomer of 
bicyclic-β-lactone (+)-4.14q (65.4 mg, 80%) as colorless solid: [α]D21  = +83.3 (c = 0.24, 
CHCl3). Enantiomeric excess was determined by HPLC analysis in comparison with 
authentic racemic material using a Chiralcel OD-H column: hexanes:iPrOH = 92:08, 
flow rate 1.0 mL/min, λ = 210 nm: tminor = 12.3 min, tmajor = 15.2 min; 99% ee. Spectral 
data matched that reported above for the racemic compound. 
(±)-4.14t(±)-14.10k
O
Cl
LiHMDS (1.0 equiv)
4-PPY(20 mol %)
DIPEA (1.0 equiv)
THF/CH2Cl2
+
O
CO2Me
CO2Me
O
O
H
CO2Me
CO2Me
4.1a  
Dimethyl 2-oxohexahydropentaleno[6a,1-b]oxete-4,4(2H)-dicarboxylate ((±)-4.14t). 
Prepared according to the representative procedure for (±)-14a, except that Michael 
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donor (±)-4.10k (68 mg, 0.32 mmol, 1.00 equiv.) was used, along with THF (1 mL), 
LiHMDS (320 µL of a 1.0 M solution in THF, 0.32 mmol, 1.00 equiv.), CH2Cl2 (4 mL), 
4-PPY (80 µL of a 0.82 M solution in CH2Cl2, 0.064 mmol, 0.20 equiv.), EtN(iPr)2 (60 
µL, 0.32 mmol, 1.00 equiv.), and acryloyl chloride (4.1a, 261 µL of a 1.612 M solution 
in CH2Cl2, 0.42 mmol, 1.30 equiv.). After addition of acryloyl chloride at 0oC (over ~4 
min), the reaction was allowed to stir for 24 h at ambient temperature (23 oC). The 
mixture was then diluted with hexanes (4.0 mL), filtered through a short silica gel pad 
(~2 g of silica gel), and rinsed with EtOAc (3 x 4 mL). The filtrate was then 
concentrated by rotary evaporation the resulting oil was of sufficient purity to warrant no 
further purification affording a single diastereomer of tricyclic-β-lactone (±)-4.14t (78 
mg, 91%): as a colorless oil: TLC (EtOAc:hexanes, 3:7 v/v): Rf = 0.43; 1H NMR (500 
MHz, CDCl3):  3.74 (s, 3H), 3.71 (s, 3H), 3.59 (dd, J = 9.0, 1.0 Hz, 1H), 3.50 (dd, J = 
11.0, 8.0 Hz, 1H), 2.83 (app d, J = 15.0, 1H), 2.65 (dd, J = 15.0, 9.0 Hz, 1H), 2.34-2.28 
(m, 1H), 2.18-2.14 (m, 1H), 1.94-1.81 (m, 2H), 1.80-1.71 (m, 1H), 1.30-1.23 (m, 1H); 
13C NMR (125 MHz, CDCl3): δ 170.4, 169.5(2), 95.7, 63.4, 59.4, 53.5, 53.2, 52.0, 31.7, 
31.5, 27.3, 23.3; IR (thin film): 2363, 2340, 1824, 1732 cm-1; HRMS (ESI+) m/z calcd. 
for C13H16O6Li [M+Li]+: 275.1107; found 275.1106. 
(±)-4.14u(±)-14.1l
O
Cl
LiHMDS (1.0 equiv)
4-PPY(20 mol %)
DIPEA (1.0 equiv)
THF/CH2Cl2
+
CO2Me
CO2Me
O
O
H
CO2Me
CO2Me
4.1a
O
 
Dimethyl 2-oxohexahydro-2H-indeno[7a,1-b]oxete-4,4(4aH)-dicarboxylate ((±)-
4.14u). Prepared according to the representative procedure for (±)-4.14a, except that 
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Michael donor (±)-4.10l (73 mg, 0.32 mmol, 1.00 equiv.), THF (1 mL), LiHMDS (320 
µL of a 1.0 M solution in THF, 0.32 mmol, 1.00 equiv.), CH2Cl2 (4 mL), 4-PPY (80 µL 
of a 0.82 M solution in CH2Cl2, 0.064 mmol, 0.20 equiv.), EtN(iPr)2 (60 µL, 0.32 mmol), 
and acryloyl chloride (4.1a, 261 µL of a 1.612 M solution in CH2Cl2, 0.42 mmol, 1.30 
equiv.). After addition of acryloyl chloride at 0oC (over ~4 min), the reaction was 
allowed to stir for 24 h at ambient temperature (23 oC).  Purification by flash column 
chromatography (SiO2, 10 → 30% EtOAc/hexanes) afforded a mixture of diastereomers 
(1:1) of bicyclic-β-lactone (±)-4.14u (60 mg, 70%) as a colorless oil: TLC 
(EtOAc:hexanes, 3:7 v/v): Rf = 0.41; (NMR data is provided for the 1:1 mixture of 
diastereomers); 1H NMR (500 MHz, CDCl3): δ 3.77-3.69 (m, 12H), 3.44 (dd, J = 11.3, 
8.9 Hz, 2H), 3.17 (dd, J = 12.9, 5.8 Hz, 1H), 3.04 (d, J = 14.0 Hz, 1H), 2.96 (d, J = 14.8 
Hz, 1H), 2.70 (dd, J = 14.8, 9.1 Hz, 1H), 2.42 (dd, J = 12.5, 3.7 Hz, 1H), 2.13-2.09 (m, 
2H), 2.05-1.87 (m, 5H), 1.79-1.72 (m, 4H), 1.67-1.51 (m, 2H), 1.40-1.11 (m, 3H), 0.92 
(m, 1H); 13C NMR (125 MHz, CDCl3): δ 171.0, 169.91, 169.86, 169.5, 169.2, 168.7, 
88.9, 88.6, 64.7, 61.1, 55.6, 55.2, 53.4, 53.3, 53.2, 52.6, 51.9, 47.6, 34.1, 32.8, 31.7, 
31.0, 26.6, 25.5, 24.4, 24.1, 23.7, 22.1; IR (thin film): 2958, 2863, 1830, 1735 cm-1; 
HRMS (ESI+) m/z calcd. for C14H18O6Li [M+Li]+: 289.1263; found 289.1277. 
LiHMDS (1.0 equiv)
4-PPY(20 mol %)
DIPEA (1.0 equiv)
THF/CH2Cl2 (1:4)
12 h
CO2Me
O CO2Me
CO2Me
CO2Me
(±)-4.16
O
Cl
+
4.1a(±)-14.1n  
Dimethyl 4,5-dihydro-2H-cyclopenta[a]naphthalene-3,3(3aH)-dicarboxylate ((±)-
4.16). Prepared according to the representative procedure using Michael donor (±)-4.10n 
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(88 mg, 0.32 mmol, 1.00 equiv.), THF (1 mL), LiHMDS (320 µL of a 1.0 M solution in 
THF, 0.32 mmol, 1.00 equiv.), CH2Cl2 (4 mL), 4-PPY (80 µL of a 0.82 M solution in 
CH2Cl2, 0.064 mmol, 0.20 equiv.), EtN(iPr)2 (60 µL, 0.32 mmol, 1.00 equiv.), and 
acryloyl chloride (4.1a, 261 µL of a 1.612 M solution in CH2Cl2, 0.42 mmol, 1.30 
equiv.). After addition of acryloyl chloride at 0oC (over ~4 min), the reaction was 
allowed to stir for 12 h at ambient temperature (23 oC). Purification by flash column 
chromatography (SiO2, 5 → 30% EtOAc/hexanes) afforded tricyclic compound (±)-4.16 
as a white solid (49 mg, 54%): TLC (EtOAc:hexanes, 3:7 v/v): Rf = 0.69; 1H NMR (500 
MHz, CDCl3): δ 7.54 (t, J = 4.5 Hz, 1H), 7.12-7.07 (m, 3H), 6.00 (dd, J = 2.6, 5.1 Hz, 
1H), 3.76 (s, 3H), 3.69-3.67 (m, 1H), 3.67 (s, 3H), 3.28 (app dt, J = 2.5, 17.4, 1H), 2.95 
(ddd, J = 4.4, 12.6, 16.8 Hz, 1H),  2.85 (ddd, J = 2.4, 4.4, 16.6 Hz, 1H), 2.78 (app dt, J = 
2.4, 17.4 Hz, 1H), 2.21-2.17 (m, 1H), 1.33 (ddd, J = 4.5, 12.7, 25.4 Hz, 1H); 13C NMR 
(125 MHz, CDCl3): δ 172.6, 171.2, 139.1, 136.6, 131.3, 129.1, 127.7, 126.3, 124.9, 
118.2, 63.2, 52.9, 52.4, 50.1, 40.7, 30.8, 26.1; IR (thin film): 1735, 1270, 1243 cm-1; 
HRMS (ESI+) m/z calcd. for C17H18LiO4 [M+Li]+: 293.1365; found 293.1375. 
CO2Me
CO2Me
(±)-4.16
1) H2, Pd/C, MeOH
2) LiCl, DMSO, H2O, µW
CO2Me
(±)-4.17  
Methyl 2,3,3a,4,5,9b-hexahydro-1H-cyclopenta[a]naphthalene-3-carboxylate ((±)-
4.17). To an oven dried, round-bottomed flask containing (±)-4.16 (39 mg, 0.14 mmol, 
1.0 equiv.) and 20% Pd/C (12.0 mg, 0.2 equiv.) was added MeOH (15 mL). The reaction 
was then purged with H2 gas, and stirred at ambient temperature (23 oC) under a H2 
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atmosphere (1 atm, balloon) for 2 h. The H2 balloon was removed and the reaction was 
filtered through celite to remove the Pd to provide a single diastereomer (~ 41 mg) and 
was of sufficient purity to carry on directly to the subsequent decarboxylation. 
 To a portion of the crude diester (2.7 mg, .0094 mmol) from the hydrogenation 
above was added DMSO (0.60 mL) and H2O (60 µL) in a microwave reaction tube. To 
this mixture was added LiCl (3.9 mg, 0.094 mmol, 10.0 equiv.) and the reaction was 
placed in a microwave reactor and heated to 180 oC for 20 min. Then NaHCO3 (4 mL) 
was added to the reaction mixture and it was extracted with Et2O (3 x 4 mL).  The 
organic layer was washed with brine (2 x 4 mL), collected and dried over MgSO4, 
filtered, concentrated by rotary evaporation, and purified by flash column 
chromatography (gradient SiO2, 0 → 15% EtOAc/hexanes) afforded a mixture of 
diastereomers (1:1) of monoester (±)-4.17 (1.5 mg, 70%) as a colorless oil: TLC 
(EtOAc:hexanes, 1:9 v/v): Rf = 0.67; (NMR data is provided for the inseparable 1:1 
mixture of diastereomers) 1H NMR (500 MHz; CDCl3):  δ 7.15-7.08 (m, 8H), 3.72 (s, 
3H), 3.71 (s, 3H), 3.27 (dd, J = 18.5, 8.4 Hz, 1H), 3.22-3.12 (m, 2H), 2.80-2.52 (m, 7H), 
2.33-2.15 (m, 4H), 2.05-1.99 (m, 1H), 1.95-1.84 (m, 4H), 1.78-1.70 (m, 1H), 1.64-1.42 
(m, 2H);13C NMR (125 MHz, CDCl3): δ 177.0, 174.8, 139.9(2), 137.1, 136.0, 129.2, 
129.1, 128.9, 128.7, 126.2, 126.1, 125.8, 125.6, 52.0, 51.7, 50.2, 49.0, 43.4, 42.2, 41.93, 
41.89, 35.2, 33.1, 29.9, 29.3, 28.9, 27.5, 24.9, 21.4; IR (thin film): 2919, 2854, 1741, 
1459, 1430, 1205, 906, 737 cm-1; HRMS (ESI+) m/z calcd. for C15H18LiO2 [M+Li]+: 
237.1467; found 237.1471. 
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O
O
Me
H
NC
Oallyl
O
 (±)-4.14i
Pd2(dba)3•CHCl3 (9.3%)
PPh3 (4.6%), CH3CN
77 to 23 oC
O
O
Me
H
NC
 (±)-4.14x  
5-Methyl-7-oxo-6-oxabicyclo[3.2.0]heptane-3-carbonitrile ((±)-4.14x). To an oven-
dried, 10 mL round-bottomed flask equipped with a magnetic stir bar was added 
Pd2(dba)3-CHCl3 (47 mg, 0.045 mmol, 0.092 equiv.), triphenylphosphine (6 mg, 0.023 
mmol, 0.047 equiv.), bicyclic-β-lactone (±)-4.14i (115 mg, 0.489 mmol, 1.00 equiv., as a 
1.16:1 mixture of diastereomers)  along with CH3CN (6 mL). After addition, the flask 
was equipped with a reflux condenser and the reaction mixture was heated to 77 °C 
using an oil bath.  With vigorous stirring the reaction remained at 77 °C for 6 h. After 
which the oil bath was removed and the reaction stirred at ambient temperature (23 °C) 
for 17 h. The mixture was then diluted with hexanes (4.0 mL), filtered through a short 
silica gel pad (~2 mL of silica gel), and rinsed with EtOAc (3 x 4 mL). The filtrate was 
concentrated by rotary evaporation and purified by flash column chromatography 
(gradient SiO2, 20 → 100% EtOAc/hexanes) afforded a single diastereomer of bicyclic-
β-lactone (±)-4.14x (55.6 mg, 75% yield) a colorless solid: m.p. 101-103 °C 
(recrystallized from CDCl3); TLC (EtOAc:hexanes, 5:5 v/v): Rf = 0.25;  1H NMR (500 
MHz, CDCl3): δ 3.64 (app d, J = 8.3 Hz, 1H), 3.35 (app t, J = 8.0 Hz, 1H), 2.66 (app d, J 
= 15.1 Hz, 1H), 2.58 (app d, J = 14.4 Hz, 1H), 2.20 (app dt, J = 14.4, 8.1 Hz,  1H), 2.00 
(dd, J = 15.1, 8.2 Hz, 1H), 1.73 (s, 3H); 13C NMR (125 MHz, CDCl3): 168.8, 120.9, 
86.9, 59.2, 40.0, 31.5, 28.2, 21.5; IR (thin film): 2360, 2339, 2235, 1807 cm-1; HRMS 
(ESI-) m/z calcd for C8H8NO2 [M - H]-: 150.0555; found 150.0562. 
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EtO2C
EtO2C
O
H O
O
H
H
EtO2C
EtO2C
O
Cl
+
LiHMDS (1.0 equiv)
4-PPY (20 mol %)
DIPEA (1.0 equiv)
THF/CH2Cl2 (1:4)
4 h
4.10o 4.1a (±)-4.14y  
Diethyl 7-oxo-6-oxabicyclo[3.2.0]heptane-3,3-dicarboxylate ((±)-4.14y). 
Prepared according to the representative procedure using Michael donor 4.10o (64.7 mg, 
0.32 mmol, 1.00 equiv.), THF (1 mL), LiHMDS (320 µL of a 1.0 M solution in THF, 
0.32 mmol, 1.00 equiv.), CH2Cl2 (4 mL), 4-PPY (80 µL, 0.064 mmol of a 0.82 M 
solution in CH2Cl2, 0.20 equiv.), EtN(iPr)2 (60 µL, 0.32 mmol, 1.00 equiv.), and acryloyl 
chloride (4.1a, 261 µL of a 1.612 M solution in CH2Cl2, 0.42 mmol, 1.30 equiv.). After 
addition of acryloyl chloride at 0oC (over ~4 min), the reaction was allowed to stir for 12 
h at ambient temperature (23 oC). Purification by flash column chromatography (SiO2, 5 
→ 30% EtOAc/hexanes) afforded bicyclic β-lactone (±)-4.14y as a colorless oil (49 mg, 
60%): TLC (EtOAc:hexanes, 3:9 v/v): Rf = 0.38; 1H NMR (500 MHz, CDCl3): δ 5.10 
(m, 1H), 4.33-4.23 (m, 4H), 4.04 (app dd, J = 9.1, 3.9 Hz, 1H), 3.23 (app d, J = 14.2 Hz, 
1H), 3.08 (app d, J = 15.6 Hz, 1H), 2.52 (dd, J = 15.6, 3.6 Hz, 1H), 2.15 (dd, J = 14.2, 
9.2 Hz, 1H), 1.35-1.30 (m, 6H); 13C NMR (125 MHz, CDCl3): δ 170.5, 170.1, 169.2, 
62.5, 60.1, 56.1, 45.1, 39.1, 34.1, 29.8, 14.1, 14.0; IR (thin film): 2925, 2854, 1838, 1735 
cm-1; HRMS (ESI+) m/z calcd. for C12H17O6 [M+H]+: 257.1025; found 257.1034. 
O
Me
O
CO2Me
CO2Me
O
RO
H
(±)-4.14z
CH2Cl2/THF, 23 oC
(20%, dr >19:1)
MeO2C
MeO2C
O
4.10a 
(1.0 equiv)
1.0 equiv
LiHMDS, THF
-78 to 0 oC
10 min
4.20a:R = H
4.20b: R = Ts
TsCl (2.10 equiv)
LiHMDS (2.05 equiv)
THF, 23 oC, 30 min
(2.0 equiv)
4.2a (1.1 equiv.)
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Dimethyl 2a-methyl-1-oxohexahydropentaleno[1,6a-b]oxete-4,4(1H)-dicarboxylate 
((±)-4.14z). To an oven-dried, 10 mL round-bottomed flask equipped with a magnetic 
stir bar were added cyclopent-1-enecarboxylic acid (4.20a, 38.6 mg, 0.344 mmol, 2.00 
equiv.) TsCl (66.1 mg, 0.347 mmol, 2.02 equiv.) and THF (1.1 mL) and the mixture was 
cooled to -78 oC. With vigorous stirring, LiHMDS (353 µL of a 1.0 M solution in THF, 
0.353 mmol, 2.05 equiv.) was added dropwise via microliter syringe. After the addition 
was complete, the reaction was allowed to react at ambient temperature (23 oC) for ~1 h. 
To an oven-dried, 25 mL round-bottomed flask equipped with a magnetic stir bar was 
added Michael donor 4.10a (32.4 mg, 0.172 mmol, 1.00 equiv.) and THF (0.55 mL) and 
the mixture was cooled to -78 oC. With vigorous stirring, LiHMDS (181 µL of a 1.0 M 
solution in THF, 0.181 mmol, 1.05 equiv.) was added dropwise via microliter syringe. 
After complete addition, the reaction was stirred for 10 min at -78 oC and then warmed 
to 0 oC by switching the dry ice/acetone bath to an ice/water bath. Stirring was continued 
for an additional 10 min at 0 oC, and then 4-PPY (4.2a, 28.0 mg, 0.189 mmol, dissolved 
in 1.7 mL CH2Cl2, 1.1 equiv) was added. The reaction was allowed to stir for an 
additional 10 min at 0 oC and then the previously prepared tosyl anhydride from 4.20a 
was added over  ~4 min at 0 oC. After the addition was complete, the reaction was stirred 
for 12 h at room temperature (23 oC). The reaction was then cooled to 0 oC and silica gel 
(2 g) was added and stirred at 0 oC for 10 min. The ice/water bath was removed and the 
reaction stirred at ambient temperature (23 oC) for 20 min. The mixture was then diluted 
with hexanes (4.0 mL), filtered through a short silica gel pad (~2 mL of silica gel), and 
the flask was rinsed with EtOAc (3 x 4 mL) with each portion passed through silica plug. 
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The filtrate was then concentrated by rotary evaporation and analyzed by 1H NMR 
which showed ~3:2 ratio of 4.10a/4.14z.  
The crude material was directly subject to NaBH4 to chemoselectively reduce 
unreacted 14.0a (which co-eluted with product). The crude reaction mixture was 
dissolved in MeOH (2.0 mL) and cooled to 0 oC, then NaBH4 (15.5 mg, 0.41 mmol, 2.38 
equiv.). After 1.5 h, the reaction was quenched with sat. NH4Cl (4 mL), and extracted 
with EtOAc (4 x 4 mL) and then washed with brine (5 mL). The organic layers were 
combined and dried over MgSO4, filtered, concentrated by rotary evaporation, and 
purified by flash column chromatography (gradient SiO2, 5 → 35% EtOAc/hexanes) to 
afford a single diastereomer (>19:1 as judged by 500 MHz NMR) of bicyclic-β-lactone 
(±)-4.14z (9.8 mg, 20%) as a white solid: TLC (EtOAc:hexanes, 3:7 v/v): Rf = 0.14; 1H 
NMR (500 MHz; CDCl3): δ  3.78 (s, 3H), 3.74 (s, 3H), 3.62 (dd, J = 11.6, 7.1 Hz, 1H), 
2.87 (d, J = 15.8 Hz, 1H), 2.64 (d, J = 15.8 Hz, 1H), 2.22 (m, 1H), 1.88-1.68 (m, 4H), 
1.53 (s, 3H), 1.14 (m, J = 7.4 Hz, 1H); 13C NMR (125 MHz; CDCl3): δ 172.7, 171.1, 
169.5, 89.7, 72.9, 61.5, 53.8, 53.4, 53.2, 41.8, 28.9, 26.3, 25.8, 20.1; IR (thin film): 2958, 
2928, 2857, 1833, 1738 cm-1; HRMS (ESI+) m/z calcd. for C14H19O6 [M+H]+: 283.1182; 
found 283.1168. 
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1H (500 MHz) spectra of substrate 2.S1 in CDCl3
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13C NMR (125 MHz) spectra of substrate 2.S1 in CDCl3
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1H (500 MHz) spectra of substrate 2.1f in CDCl3
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13C NMR (125 MHz) spectra of substrate 2.S1 in CDCl3
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1H (500 MHz) spectra of β-lactone 2.2a in CDCl3
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13C NMR (125 MHz) spectra of β-lactone 2.2a in CDCl3
O
H M
e
O
2.
2a
   273 
 
 
 
1H (500 MHz) spectra of β-lactone 2.2f in CDCl3
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13C NMR (125 MHz) spectra of β-lactone 2.2f in CDCl3
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1H (500 MHz) spectra of β-lactone 2.2g in CDCl3
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13C NMR (125 MHz) spectra of β-lactone 2.2g in CDCl3 
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1H (500 MHz) spectra of diastereomers of β-lactone 2.8 in CDCl3
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13C NMR (125 MHz) spectra of diastereomers of β-lactone 2.8 in CDCl3
O
M
e
H
O
2.
8
O
   279 
 
 
 
1H (500 MHz) spectra of β-lactone 2.9 in CDCl3
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13C NMR (125 MHz) spectra of β-lactone 2.9 in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of substrate 3.5 in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of substrate 3.17 in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of substrate 3.15 in CDCl3
O
Me
H
O
3.15 
   284 
 
 
 1H (500 MHz) and 13C NMR (125 MHz) spectra of substrate 3.3 in CDCl3
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1H (500 MHz) COSY of 3.3 in CDCl3 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of substrate 4.10b in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of substrate 4.10c in CDCl3 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of substrate 4.10d in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of substrate 4.10g in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of substrate 4.10i in CDCl3. 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of substrate 4.10j in CDCl3 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of substrate 4.10k in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of substrate 4.10l in CDCl3
O CO2Me
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1H (500 MHz) and 13C NMR (125 MHz) spectra of substrate 4.10n in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 4.14b in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 4.14c in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of amide 4.S15 in CDCl3 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 4.14d in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of diastereomers of 4.14g in CDCl3
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1H (500 MHz) spectra of each diastereomer of 4.14g in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of diastereomers of 4.14h in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of single diastereomer (higher Rf) of 
4.14h in CDCl3 
 
4.14h 
O
O
Me
H
NC
OMe
O
   297 
 
1H (500 MHz) and 13C NMR (125 MHz) spectra of single diastereomer (lower Rf) of 
4.14h in CDCl3 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactones 4.14i (dr, 1.2:1) in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactones 4.14j (dr 2:1) in CDCl3
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1H (500 MHz) spectra of the separated diastereomers of β-lactone 4.14j in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 14k in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 14m in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 4.14p in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 4.14q in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 4.14r in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 4.14s in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of tricyclic β-lactone 4.14t in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of tricyclic β-lactone 4.14u in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of cyclopentene 4.16 in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of cyclopentane 4.17 in CDCl3 
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 4.14x in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of β-lactone 4.14y in CDCl3
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1H (500 MHz) and 13C NMR (125 MHz) spectra of tricyclic β-lactone 4.14z in CDCl3 
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Figure S1. Chiral GC determination of enantiomeric excess. 
 
Determination of enantiomeric excess of β-lactone (+)-14a: 
 
Analysis of β-lactone (+)-14a: Method: CHIRALDEX-BDM GC column, 
13.85 psi, 70-160 °C oven temperature 
Temp (°C) Rate (°C/min) Hold time (min) Total time (min) 
70 0.00 2.00 2.00 
80 6.00 5.00 8.67 
94 0.05 3.00 291.67 
160 40.0 1.00 294.32 
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For 1 gram scale reaction:  
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Figure S2. Chiral HPLC determination of enantiomeric excess. 
Determination of enantiomeric excess of β-lactone (+)-4.14c: 
 
Chiral HPLC Analysis of β-lactone (+)-4.14c: Chiralcel IA column: hexanes:iPrOH = 92:08, 
flow rate 0.5 mL/min, λ = 210 nm: tmajor = 17.28 min, tminor = 21.29 min; 95% ee.  
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Determination of enantiomeric excess of β-lactone (+)-4.14d: 
 
Chiral HPLC Analysis of β-lactone (+)-4.14d: Chiralcel OD-H column: hexanes: iPrOH  = 
95:05, flow rate 1.0 mL/min, λ = 210 nm: tmajor = 36.6 min, tminor = 45.6 min,; 98% ee.  
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Determination of enantiomeric excess of β-lactone 4.14k: 
 
Chirla HPLC Analysis of (+)-β-lactone 4.14k: Chiralcel OD-H column: hexanes:iPrOH = 
90:10, flow rate  0.5 mL/min, λ = 210 nm: tminor = 29.0 min, tmajor = 22.4 min; 94% ee. 
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Determination of enantiomeric excess of β-lactone (+)-4.14m: 
Chiral HPLC Analysis of (+)-β-lactone (+)-4.14m: Chiralcel AD-H column: hexanes:iPrOH = 
70:30, flow rate 0.5 mL/min, λ = 210 nm: tmajor = 12.0 min, tminor = 13.1  min; 99% ee.  
 
Using 20 mol% HBTM 
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Using 5 mol% HBTM 
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Determination of enantiomeric excess of β-lactone (+)-4.14p: 
O
O
Me
H
MeO2C
MeO2C
(+)-4.14p  
Chiral HPLC Analysis of β-lactone (+)-4.14p: Chiralcel AD-H column: hexanes:iPrOH = 
70:30, flow rate 0.5 mL/min, λ = 210 nm: tmajor = 22.2 min, tminor = 27.0 min; 99% ee.  
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Determination of enantiomeric excess of β-lactone (-)-4.14p: 
 
Chiral HPLC Analysis of β-lactone (-)-4.14p derived from use of (R)-HBTM: Chiralcel AD-
H column: hexanes:iPrOH = 70:30, flow rate 0.5 mL/min, λ = 210 nm: tminor = 22.2 min, tmajor = 
27.2 min; 99% ee. 
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Determination of enantiomeric excess of β-lactone (+)-4.14q: 
 
Chiral HPLC Analysis of β-lactone (+)-4.14q: Chiralcel OD-H column: hexanes:iPrOH = 
92:08, flow rate 1.0 mL/min, λ = 210 nm: tminor = 12.3 min, tmajor = 15.3 min; 99% ee.  
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Determination of enantiomeric excess of β-lactone (+)-4.14s: 
 
Analysis of β-lactone (+)-4.14s: Chiralcel AD-H column: hexanes:iPrOH = 92:08, flow rate 1.0 
mL/min, λ = 210 nm: tmajor = 12.3 min, tminor = 15.3 min; 94% ee. 
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Single crystal X-ray structure (ORTEP) of amide (+)-4.S15. The crystals were grown 
from a concentrated solution of amide (+)-4.S15 in CDCl3, using a slow evaporation 
method (probability ellipsoids are shown at the 50% level). X-ray crystallographic data 
have been deposited in the Cambridge Crystallographic Data Centre database 
(http://www.ccdc.cam.ac.uk/) under accession code CCDC 927699. 
 
Crystal data and structure refinement for DRB_MS_121026_A1_306. 
Identification code  drb 
Empirical formula  C18 H22 Br N O6 
Formula weight  428.28 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2 
Unit cell dimensions a = 25.835(5) Å  = 90°. 
 b = 10.3517(19) Å  = 102.657(2)°. 
 c = 7.2252(13) Å   = 90°. 
Volume 1885.3(6) Å3 
Z 4 
Density (calculated) 1.509 Mg/m3 
Absorption coefficient 2.214 mm-1 
F(000) 880 
Crystal size 0.14 x 0.09 x 0.02 mm3 
Theta range for data collection 2.13 to 24.99°. 
Index ranges -30<=h<=30, -12<=k<=12, -8<=l<=8 
Reflections collected 8634 
Independent reflections 3250 [R(int) = 0.0389] 
Completeness to theta = 24.99° 99.5 %  
   326 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9571 and 0.7469 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3250 / 1 / 239 
Goodness-of-fit on F2 1.043 
Final R indices [I>2sigma(I)] R1 = 0.0332, wR2 = 0.0734 
R indices (all data) R1 = 0.0412, wR2 = 0.0760 
Absolute structure parameter 0.024(8) 
Largest diff. peak and hole 0.338 and -0.217 e.Å-3 
 
Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for DRB_MS_121026_A1_306.  U(eq) is defined as one third of  the trace 
of the orthogonalized Uij tensor. 
_______________________________________________________________________
_______ x y z U(eq) 
Br(1) 685(1) -33(1) 9099(1) 48(1) 
O(1) 713(1) 5887(2) 4818(3) 29(1) 
O(2) 1086(1) 7405(2) 2361(3) 27(1) 
O(3) 2953(1) 7004(3) 6603(3) 44(1) 
O(4) 3083(1) 7706(2) 3812(3) 28(1) 
O(5) 2044(1) 6847(2) 442(3) 27(1) 
O(6) 2447(1) 5245(2) 2257(3) 40(1) 
N(1) 956(1) 6502(3) 7883(4) 26(1) 
C(1) 619(1) 1805(4) 8885(5) 33(1) 
C(2) 183(1) 2324(3) 7673(5) 30(1) 
C(3) 142(1) 3657(3) 7526(4) 27(1) 
C(4) 531(1) 4459(4) 8572(5) 26(1) 
C(5) 956(1) 3896(4) 9789(5) 34(1) 
C(6) 1008(2) 2576(4) 9959(5) 36(1) 
C(7) 489(1) 5917(4) 8371(6) 29(1) 
C(8) 1032(1) 6437(3) 6107(4) 23(1) 
C(9) 1515(1) 7101(3) 5697(5) 21(1) 
C(10) 1376(1) 8053(3) 4015(4) 24(1) 
C(11) 1923(1) 8349(3) 3638(5) 24(1) 
C(12) 2217(1) 7037(3) 3886(4) 21(1) 
C(13) 1908(1) 6180(3) 5063(5) 24(1) 
C(14) 1079(2) 9251(3) 4446(5) 37(1) 
C(15) 2787(1) 7219(3) 4968(5) 24(1) 
C(16) 3644(1) 7911(4) 4675(6) 34(1) 
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C(17) 2219(1) 6402(3) 1974(5) 25(1) 
C(18) 2506(2) 4556(4) 551(5) 58(1) 
 
Single crystal X-ray structure (ORTEP) of bicyclic-β-lactone (+)-4.14p. The crystals 
were grown from a concentrated solution of amide β-lactone (+)-4.14p in CDCl3, using a 
slow evaporation method (probability ellipsoids are shown at the 50% level). X-ray 
crystallographic data have been deposited in the Cambridge Crystallographic Data 
Centre database (http://www.ccdc.cam.ac.uk/) under accession code CCDC 927698. 
 
Alert level B:THETM01_ALERT_3_B The value of sine(theta_max)/wavelength is less 
than 0.575. Calculated sin(theta_max)/wavelength = 0.5617 
 
Author Response: Data was collected on a Bruker GADDS instrument with Cu-source 
and MWPC (multiwire proportional counter) detector. Under these experimental 
conditions the maximum angle that can be collected is 120 degrees two-theta. 
 
Crystal data and structure refinement for DRB_MS_121001_G_290A. 
Identification code  drb 
Empirical formula  C14 H18 O6 
Formula weight  282.28 
Temperature  110(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 8.9133(3) Å α= 90°. 
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 b = 12.1780(5) Å β= 90°. 
 c = 12.9803(5) Å γ = 90°. 
Volume 1408.96(9) Å3 
Z 4 
Density (calculated) 1.331 Mg/m3 
Absorption coefficient 0.878 mm-1 
F(000) 600 
Crystal size 0.22 x 0.09 x 0.02 mm3 
Theta range for data collection 4.98 to 60.00°. 
Index ranges -10<=h<=10, -13<=k<=12, -14<=l<=14 
Reflections collected 28220 
Independent reflections 2069 [R(int) = 0.0521] 
Completeness to theta = 60.00° 99.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9826 and 0.8302 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2069 / 0 / 185 
Goodness-of-fit on F2 1.082 
Final R indices [I>2sigma(I)] R1 = 0.0309, wR2 = 0.0823 
R indices (all data) R1 = 0.0335, wR2 = 0.0833 
Absolute structure parameter [Hooft] -0.2(2) [-0.17(8)] 
Largest diff. peak and hole 0.354 and -0.198 e.Å-3 
 
Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for DRB_MS_121001_G_290A.  U(eq) is defined as one third of  the trace 
of the orthogonalized Uij tensor. 
 x y z U(eq) 
C(1) 9124(2) -236(2) 3096(2) 28(1) 
C(2) 9367(2) 773(2) 2425(2) 22(1) 
C(3) 10333(2) 1184(2) 3330(2) 24(1) 
C(4) 12006(3) 1254(2) 3248(2) 34(1) 
C(5) 7993(2) 1542(2) 2327(1) 21(1) 
C(6) 7898(2) 2068(1) 3429(1) 20(1) 
C(7) 9541(2) 2173(2) 3776(2) 22(1) 
C(8) 8260(2) 2364(2) 1486(2) 25(1) 
C(9) 7444(3) 2434(2) 634(2) 31(1) 
C(10) 7747(3) 3153(2) -266(2) 44(1) 
C(11) 7020(2) 1369(2) 4210(2) 21(1) 
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C(12) 5329(3) -75(2) 4489(2) 32(1) 
C(13) 7142(2) 3197(2) 3406(1) 22(1) 
C(14) 4819(2) 4115(2) 3334(2) 28(1) 
O(1) 9897(2) 159(1) 3923(1) 30(1) 
O(2) 8513(2) -1106(1) 3034(1) 34(1) 
O(3) 7127(2) 1509(1) 5125(1) 28(1) 
O(4) 6140(2) 622(1) 3771(1) 24(1) 
O(5) 7794(2) 4054(1) 3458(1) 33(1) 
O(6) 5661(1) 3095(1) 3329(1) 25(1) 
 
Single crystal X-ray structure (ORTEP) of tricyclic-β-lactone (±)-4.14t. The crystals 
were grown from a concentrated solution of β-lactone (±)-4.14t in CDCl3, using a slow 
evaporation method (probability ellipsoids are shown at the 50% level). X-ray 
crystallographic data have been deposited in the Cambridge Crystallographic Data 
Centre database (http://www.ccdc.cam.ac.uk/) under accession code CCDC 940571. 
 
 
 
Crystal data and structure refinement for DRB_MS_120913_A3_SS4BL. 
Identification code  drb 
Empirical formula  C13 H16 O6 
   330 
Formula weight  268.26 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 7.7457(16) Å  = 90°. 
 b = 12.057(3) Å  = 98.045(2)°. 
 c = 14.063(3) Å   = 90°. 
Volume 1300.4(5) Å3 
Z 4 
Density (calculated) 1.370 Mg/m3 
Absorption coefficient 0.109 mm-1 
F(000) 568 
Crystal size 0.18 x 0.17 x 0.11 mm3 
Theta range for data collection 2.23 to 27.49°. 
Index ranges -9<=h<=9, -15<=k<=15, -18<=l<=18 
Reflections collected 13565 
Independent reflections 2950 [R(int) = 0.0252] 
Completeness to theta = 27.49° 99.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9881 and 0.9806 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2950 / 0 / 174 
Goodness-of-fit on F2 1.050 
Final R indices [I>2sigma(I)] R1 = 0.0360, wR2 = 0.0952 
R indices (all data) R1 = 0.0420, wR2 = 0.1003 
Largest diff. peak and hole 0.329 and -0.174 e.Å-3 
 
Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters 
(Å2x 103) for DRB_MS_120913_A3_SS4BL.  U(eq) is defined as one third of  the 
trace of the orthogonalized Uij tensor. 
_______________________________________________________________________  
 x y z U(eq) 
_______________________________________________________________________  
C(1) 2877(2) 4445(1) 1736(1) 32(1) 
C(2) 3301(2) 4346(1) 2819(1) 25(1) 
C(3) 1821(2) 5195(1) 2823(1) 24(1) 
C(4) 2657(1) 6276(1) 3221(1) 21(1) 
C(5) 2043(2) 6336(1) 4208(1) 27(1) 
C(6) 131(2) 5990(1) 3970(1) 32(1) 
C(7) 210(2) 4989(1) 3305(1) 33(1) 
C(8) 4981(2) 4892(1) 3286(1) 24(1) 
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C(9) 4642(1) 6153(1) 3192(1) 21(1) 
C(10) 5127(2) 6620(1) 2250(1) 22(1) 
C(11) 7411(2) 6797(1) 1318(1) 41(1) 
C(12) 5673(2) 6792(1) 4024(1) 24(1) 
C(13) 6744(2) 8558(1) 4535(1) 47(1) 
O(1) 3415(2) 4100(1) 1042(1) 48(1) 
O(2) 1518(1) 5163(1) 1754(1) 32(1) 
O(3) 4187(1) 7150(1) 1671(1) 30(1) 
O(4) 6772(1) 6359(1) 2161(1) 31(1) 
O(5) 6208(1) 6396(1) 4790(1) 37(1) 
O(6) 5840(1) 7850(1) 3791(1) 34(1) 
 
Single crystal X-ray structure (ORTEP) of bicyclic-β-lactone (±)-4.14x. The crystals 
were grown from a concentrated solution of β-lactone (±)-4.14x in CDCl3, using a slow 
evaporation method (probability ellipsoids are shown at the 50% level). X-ray 
crystallographic data have been deposited in the Cambridge Crystallographic Data 
Centre database (http://www.ccdc.cam.ac.uk/) under accession code CCDC 940570. 
 
Alert level B: THETM01_ALERT_3_B The value of sine(theta_max)/wavelength is less 
than 0.575. Calculated sin(theta_max)/wavelength = 0.5617 
 
Author Response: Data was collected on a Bruker GADDS instrument with Cu-source 
and MWPC (multiwire proportional counter) detector. Under these experimental 
conditions the maximum angle that can be collected is 120 degrees two-theta. 
 
Crystal data and structure refinement for DRB_MS_130218_G_RB1. 
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Identification code  drb 
Empirical formula  C8 H9 N O2 
Formula weight  151.16 
Temperature  110(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 5.6893(5) Å  = 90°. 
 b = 10.7024(11) Å  = 95.454(6)°. 
 c = 12.4002(12) Å   = 90°. 
Volume 751.62(12) Å3 
Z 4 
Density (calculated) 1.336 Mg/m3 
Absorption coefficient 0.802 mm-1 
F(000) 320 
Crystal size 0.06 x 0.05 x 0.03 mm3 
Theta range for data collection 5.47 to 60.00°. 
Index ranges -6<=h<=6, 0<=k<=12, 0<=l<=13 
Reflections collected 1110 
Independent reflections 1110 [R(int) = 0.0000] 
Completeness to theta = 60.00° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9764 and 0.9535 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1110 / 0 / 101 
Goodness-of-fit on F2 1.013 
Final R indices [I>2sigma(I)] R1 = 0.0460, wR2 = 0.1087 
R indices (all data) R1 = 0.0600, wR2 = 0.1126 
Largest diff. peak and hole 0.226 and -0.279 e.Å-3 
 
Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 
103) for DRB_MS_130218_G_RB1.  U(eq) is defined as one third of  the trace of the 
orthogonalized Uij tensor. 
_______________________________________________________________________ 
 x y z U(eq) 
_______________________________________________________________________ 
O(1) 26(3) 3346(1) 3528(1) 20(1) 
O(2) -1888(3) 5167(2) 3834(1) 25(1) 
N(1) -2187(4) 4260(2) 910(2) 29(1) 
C(1) 2299(4) 4353(2) 1607(2) 17(1) 
C(2) 3130(4) 3186(2) 2264(2) 19(1) 
C(3) 2655(4) 3448(2) 3422(2) 18(1) 
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C(4) 2415(4) 4876(2) 3522(2) 17(1) 
C(5) 2834(4) 5426(2) 2420(2) 20(1) 
C(6) -227(4) 4286(2) 1214(2) 20(1) 
C(7) 3996(4) 2697(2) 4296(2) 24(1) 
C(8) -138(4) 4594(2) 3664(2) 19(1) 
_______________________________________________________________________ 
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